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 ABSTRACT 
 
Oxidative stress has been implicated in cardiovascular disease (CVD) including 
hypertension. We hypothesise that oxidative stress-related genes and their 
functional polymorphisms influence the risk of developing hypertension and 
coronary artery disease. Combined congenic breeding strategy and microarray 
expression profiling studies from our group previously identified rat glutathione s-
transferase mu type-1 (rGstm1) as a functional and positional candidate gene 
implicated in hypertension. In the previous studies, expression of rGstm1 was 
lower in the kidney from the hypertensive rat model, stroke-prone spontaneously 
hypertensive rat (SHRSP), compared to the normotensive Wistar Kyoto (WKY) 
and a chromosome 2 congenic strain (SP.WKYGla2c*). The rGstm1 belongs to a 
family of Gstm genes, encoding for dimeric enzymes known to detoxify oxidised 
lipids and provide secondary defence against oxidative stress. This project aims to 
characterise Gstm gene family in rat and human tissues and investigate functional 
roles of rGstm genes using pharmacological intervention studies. Association 
between functional polymorphisms in two other genes (CYBA and NOS3), 
encoding for enzymes involved in oxidative stress, and coronary artery disease 
are also investigated.  
 
I have characterised the expression profiles of the rGstm gene family in rat 
vascular and renal tissues. Five of the possible eight rGstm genes are expressed 
in thoracic aorta and kidney. Results from this thesis demonstrate reduced mRNA 
expression of several members of rGstm gene family, in vascular and renal 
tissues. Most notably, expression of vascular and renal rGstm1 mRNA and 
protein, (the latter analysed by IHC), are lower in the SHRSP compared to WKY 
and SP.WKYGla2c*. Vascular mRNA expression of rGstm2, rGstm5 and rGstm7 
were reduced in the SHRSP males compared to the WKY males and 
SP.WKYGla2c* males but not in the females. Vascular mRNA expression of rGstm3 
in SHRSP males was lower than SP.WKYGla2c* males but not WKY males, while 
SHRSP and SP.WKYGla2c* females expressed higher levels or rGstm3 than WKY 
females. There were also trends towards reduced renal mRNA expression of 
rGstm2, rGstm3, rGstm5 and rGstm7 in the SHRSP compared to WKY and 
SP.WKYGla2c*. In the carotid artery, expression of rGstm1 protein has been 
detected in all vascular cell types. In the kidney, expression of rGstm1 protein has 
 been detected widely across cortex and medulla. Renal rGstm1 expression is 
reduced in tissues from SHRSP rats compared to WKY and SP.WKYGla2c* at 5-
weeks of age suggesting that the differential gene expression is not a 
consequence of increased blood pressure (BP). This reduction in renal rGstm1 
gene expression is not compensated for by other members of the rGstm gene 
family. In addition, there is also gender-specific differential expression of several 
vascular and renal rGstm genes. 
 
The expression profile of the human GSTM (hGSTM) gene family in vascular 
tissue from varicose vein and saphenous vein have also been characterised in an 
attempt to identify the true human orthologue of rGstm1. There are five known 
members in the hGSTM gene family, all of which were expressed in vascular 
tissues. Results from characterisation of the vascular hGSTM gene family show 
that four hGSTM members are homologous to rGstm1. These four hGstm genes 
remain as potential orthologue for rGstm1. 
 
Functional roles of vascular and renal rGstm genes have been investigated using 
two pharmacological intervention studies. Olmesartan (AT1R antagonist) or 
hydralazine plus hydrochlorothiazide (direct vasodilator and diuretic) have been 
used to evaluate the oxidative stress status and gene expression of rGstm genes, 
in the reversal and prevention studies. Both drug treatments improved the BP of 
SHRSP rats in reversal study and prevented the rise in BP in the prevention study. 
Olmesartan-treated SHRSP rats demonstrated reduced superoxide (O2-) and 
hydrogen peroxide (H2O2) production in both reversal and prevention studies. 
Minor effects by both drug treatments were observed for the rGstm gene family in 
the prevention but not the reversal study. Both drug treatments did not influence 
vascular or renal rGstm1 expression in either reversal or prevention studies. 
Improvement in BP did not improve rGstm1 gene expression. The rGstm1 was not 
responsive to pharmacological interventions due to strain-dependent genetic 
abnormalities. 
 
Polymorphisms in oxidative stress related enzymes have often been associated 
with coronary artery disease (CAD). It is likely that each polymorphism imparts 
small effects that add up to alter the balance between reactive oxygen species 
(ROS) and nitric oxide (NO). Functional polymorphisms in two key enzymes 
 involved in ROS and NO balance were investigated for association with CAD and 
vascular compliance as single polymorphism and as haplotypes. The two genes 
selected were CYBA, which encodes the p22phox subunit of NADPH oxidase, and 
NOS3, which encodes for endothelial nitric oxide synthase (eNOS). The 
polymorphisms investigated were CYBA A-930G, C242T and A640G; and NOS3 
T-786C, intron 4A/4B and G894T. There was an association between CYBA A-
930G with CAD, with the A allele being recessive. There was also an association 
between NOS3 G894T with CAD, only when G allele was dominant. The T-786C 
of NOS3 was associated with small artery compliance index (C2), in both CAD and 
control groups. There were no difference in haplotype frequencies of the three 
polymorphisms in both genes between the CAD and control groups. There were 
no associations between the CYBA or NOS3 haplotypes with vascular compliance. 
 
In conclusion, this thesis provides the most detailed characterisation of the Gstm 
gene family in terms of CVD to date. It has confirmed previously identified 
reduction in rGstm1 expression in SHRSP, which could not be improved by 
antihypertensive treatment despite significant improvements in BP and oxidative 
stress levels. Despite careful human characterisation, four members of human 
GSTM gene family remain as potential orthologues for rGstm1. In addition, a 
relatively small association study identified significant association between CAD 
and polymorphisms in two key enzymes involved in NO and O2- balance. 
 CHAPTER 1:  INTRODUCTION 
 
1.1. Cardiovascular Disease 
 
According to the most recent World Health Report released in 2003, nearly 147.4 
million people in the world are burdened by cardiovascular disease based on 
estimates from 2002 alone (1). An estimated 16.7 million people died of 
cardiovascular diseases (CVD), particularly heart attacks and strokes, which 
constituted about 29.2% of death world-wide in 2002. CVD, aptly described as one 
of the world’s neglected epidemics, is a problem in industrialised countries as well 
as the poorest countries and is still a growing problem. Apart from its impact on 
morbidity and mortality, it also has an impact on social and economic 
developments. According to the British Heart Foundation (BHF) 2006 statistics on 
the website, CVD is the main cause of death in the UK having accounted for just 
over 216,000 deaths (37%) in 2004 (2). The death rate from coronary heart 
disease (CHD) has been highest in Scotland consistently for over 25 years. CVD 
cost the health care system in the UK around £14,750 million in 2003, of which 
hospital care of CVD patients accounted for 76% and 18% for costs of drugs and 
dispensing them (3). Production losses due to mortality and morbidity associated 
with CVD cost the UK over £6,200 million in 2003. In 2004, the costs of 
prescriptions for lipid lowering and antihypertensive drugs came to a total of 
£1.379 billion. Overall CVD is estimated to cost the UK economy just under £26 
billion a year. For these reasons, it is desirable to identify the mechanisms, 
including genetic factors, that leads to cardiovascular disease. 
 
CVD are diseases of the heart and circulatory system, stroke, coronary heart 
disease, heart failure, peripheral vascular disease and renal failure/end-stage 
renal disease (ESRD) (2). Hypertension, atherosclerosis and diabetes mellitus are 
risk factors, often seen in early development of CVD. The major modifiable risk 
factors of CVD are high blood pressure (BP), hypercholesterolaemia, smoking, 
lack of exercise, unhealthy diets, obesity and diabetes mellitus (2;4). Other 
modifiable risk factors include low socioeconomic status, mental ill-health, 
psychosocial stress, alcohol consumption and use of certain medication (4). While 
one can try to reduce risk factors such as these, there are also risk factors for CVD 
that cannot be changed. Non-modifiable risk factors include aging, known family 
 history of CVD, gender and ethnicity. The major CVD risk factors explain at least 
75–85% of new cases of coronary heart disease (1), and illustrate the need for 
research into risk factors such as hypertension. 
 
1.1.1. Risk Factors 
 
Hypertension, a major risk factor for many CVD and the most important risk factor 
for stroke, and its genetic components will be the main focus of this project. 
 
1.1.1.1. Hypertension 
 
Hypertension is defined clinically as systolic blood pressure (SBP) of over 
140mmHg and diastolic blood pressure (DBP) of over 90mmHg in adults aged ≥18 
(5). There are three grades of hypertension, from mild to moderate and severe 
(Table 1.1) (5).Hypertension can be primary/essential hypertension or secondary 
to other causes. Essential (idiopathic causes) hypertension (EH) refers to a lasting 
increase in BP with genetic and environmental causes. Certain hypertension 
occurs as a consequence of rare mutations that result in drastic physiological 
perturbations. These mutations will be discussed in the next section. Secondary 
hypertension is due to renal causes, such as renal artery stenosis, or adrenal 
causes, such as Conn’s disease and phaeochromocytoma. These will not be 
discussed further in this thesis.  
 
 
Table 1.1: Classification of hypertension 
 
Blood Pressure (BP) Category Systolic BP (mmHg) Diastolic BP (mmHg) 
Normal <120 <80 
High-normal 135 – 139 85 – 89 
Mild hypertension (Grade 1) 140 – 159 90 – 99 
Moderate hypertension (Grade 2) 160 – 179 100 – 109 
Severe hypertension (Grade 3) ≥180 ≥110 
 
Adapted from (5) 
 
 
 Diastolic blood pressure (DBP) increases with age until approximately 50 years of 
age while systolic blood pressure (SBP) increases with age until approximately 80 
years of age. Mean systolic blood pressure increases with age in both men and 
women, rising from 127mmHg in men aged 16-24 to 145mmHg in men aged 75 
and over, and from 119mmHg to 149mmHg in women (1). According to the 
Scottish Health Survey, 33% of Scottish men and 33% of Scottish women are 
hypertensive or are treated for hypertension (2). The prevalence of EH rises with 
age, affecting up to 60-70% of those 70-years old or more (6). The epidemiological 
relationship between SBP and DBP and risk of developing CVD is continuous but 
is only one of the important components (7). The World Health Report 2002 
estimates that around 11% of all disease burden in developed countries is caused 
by raised blood pressure, and that over 50% of CHD and almost 75% of stroke in 
developed countries is due to high SBP (8). Both epidemiological studies and 
clinical trials provide compelling evidence that antihypertensive therapy effectively 
reduce the risk of CVD. A reduction in blood pressure by an average of 12/6 
mmHg can be expected to reduce stroke by 40% and coronary heart disease 
(CHD) by 20% (9). 
 
The specific underlying mechanisms involved in the development of hypertension 
are still incompletely understood but it is a major risk factor for stroke, myocardial 
infarction, congestive heart failure and ESRD. A wide variety of physiological 
systems that have pleiotropic effects and interact in a complex manner have been 
found to influence BP (Figure 1.1) (10;11). Sodium and fluid balance, and 
vasomotor tone are important in BP regulation. Both of these mechanisms are 
affected by numerous genetic and environmental factors, controlled by hormonal, 
non-sympathetic, paracrine and intracellular feedback loops. One of the best 
examples is the renin–angiotensin system (RAS). Interactions between these 
factors change with age.  
 
RAS is well known for its regulation of blood pressure and fluid homeostasis, The 
RAS comprises a cascade of enzymatic reactions resulting in the formation of the 
main effector molecule angiotensin II (Ang II). Ang II can act either as a systemic 
hormone (endocrine) or as a locally generated factor (paracrine, autocrine) 
(12;13).  
 
  
 
 
 
 
 
Figure 1.1: Complex relationships for blood pressure regulation 
Arterial pressure can be computationally defined as the product of cardiac output and the 
total peripheral resistance. Cardiac output is determined by the complex relationships 
between extracellular fluid volume, blood volume, arterial and venous compliance and 
resistance of blood flow around the systemic circulation. The kidney is the primary 
controller of both extracellular fluid volume and arterial pressure through the pressure-
natriuresis mechanism. The total peripheral resistance is determined by the structure and 
function of the vasculature and by local autoregulatory mechanisms. Both kidney and 
vascular functions are influenced by neuroendocrine factors. Homeostatic negative 
feedback (dotted lines) also has an important role in the regulation of arterial pressure. A 
variety of sensors of arterial pressure produce signalling response outputs that feed back 
to control neuroendocrine, vascular and kidney function. Taken from Ref. (11)  
 Ang II production can be angiotensin converting enzyme (ACE)–dependent or –
independent (Figure 1.2). ACE-dependent Ang II formation is catalysed by a two-
step reaction, first to angiotensin I (Ang I) by renin and subsequently by ACE. 
ACE-independent conversion to Ang II can be from angiotensinogen directly by 
enzymes tissue plasminogen activator (tPA), cathepsin G and tonin, or from Ang I 
by chymase and cathepsin G. Ang II then binds to Ang II type 1 receptor (AT1R) or 
type 2 receptor (AT2R) located on cell membrane, mediating its physiological 
effects. A recently discovered novel ACE-related carboxypeptidase (ACE2) 
converts Ang I to angiotensin 1-9 (Ang 1-9) and subsequently to angiotensin 1-7 
(Ang 1-7), a known vasodilator (14). ACE2 expression was found to be decreased 
in three different hypertensive rat models (15) while ACE2 knock-out mice 
exhibited increased systolic blood pressure (16). AT1R has been implicated in the 
regulation of ACE2 and Ang 1-7 expression (17).  
 
The AT1R and AT2R display a heterogeneous distribution in peripheral tissues and 
brain but differ markedly in their signalling cascades and biological activities, and 
thus their role in blood pressure regulation (13). In general, AT1R expression is 
present in adult cardiovascular tissues, whereas AT2R is highly expressed during 
foetal development (18). There are two subtypes AT1a and AT1b that are 
pharmacologically indistinguishable and are thought to signal identically (19;20). 
The two subtypes are differentially expressed and regulated with AT1a being the 
predominant receptor in most organs, whereas AT1b is more abundant in the 
adrenal and pituitary glands (21). AT1R mediate vasoconstrictor responses 
whereas AT2R mediate vasodilator responses (12). Ang II binding to AT1R 
mediates vasoconstriction as well as modulating renal sodium and water 
reabsorption.  
 
1.1.1.2. Genetics of Hypertension 
 
Data generated from animal models, human twin and family studies suggested 
that inherited factors contribute to 30% of the variation in BP (22). Evidence for 
genetic influences comes from twin studies, population studies, adoptive studies 
and monogenic diseases. Twin studies documented greater concordance of blood 
pressures in monozygotic than dizygotic twins (23;24), and population studies 
show greater similarity in BP within families than between families (25). Adoption 
  
Figure 1.2: Renin-angiotensin system enzymatic cascades 
ACE = angiotensin converting enzyme; ACE2 = ACE-related carboxypeptidase; Ang = 
angiotensin; AT1R = angiotensin II type 1 receptor; AT2R = angiotensin II type 2 receptor; 
tPA = tissue plasminogen activator. Adapted from Ref. (12;216). 
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 studies demonstrate greater concordance of BP among biological siblings than 
adoptive siblings living in the same household (26). Mutations in single genes can 
have major effects on BP, accounting for the rare Mendelian forms of blood 
pressure dysregulation. Ten genes have been identified containing mutations 
resulting in hypertension and nine genes have been identified containing 
mutations resulting in hypotension (Table 1.2), mostly by altering renal salt 
handling (11;27). However, these rare alleles account for less than 1% of human 
hypertension and have not been found to be associated with essential 
hypertension. 
 
Genome-wide linkage analysis has identified over 100 hypertension–related 
quantitative trait loci (QTLs) (reviewed in (11). This suggests involvement of 
multiple loci, each imparting small effects on the trait in the general population. 
Candidate gene association studies use the statistical power of linkage analysis 
for identifying genetic variants that underlie susceptibility to hypertension. Genes 
investigated have been from the renin-angiotensin system (RAS), renal sodium 
handling system, signal transduction pathways, cholesterol metabolism pathways, 
inflammation, and oxidative stress (22). Genetic variants include single nucleotide 
polymorphism (SNP), variable number of tandem repeats (VNTR), insertion, 
deletion and duplication (28). Many genetic variants/allelic polymorphisms were 
found to be associated with primary phenotype (e.g. blood pressure), intermediate 
phenotype (e.g. arterial stiffness) and end-point phenotypes (e.g. stroke) of 
cardiovascular disease. For example, A1166C, a commonly investigated SNP in 
AT1R gene was found to be associated with essential hypertension (29), arterial 
stiffness (30) and stroke (31).  
 
Gender is a well-known genetic risk factor for hypertension. BP was shown to be 
higher in men than in women of similar ages (32) while the Y chromosome harbors 
gene(s) that contribute to BP variation in hypertensive and normotensive men (33).  
 
1.1.1.3. Environmental Factors 
 
Lifestyle choices such as smoking, heavy alcohol consumption, physical inactivity 
and diet are examples of environmental risk factors. Smoking is an independent 
cardiovascular risk factor but also through interaction with other risk factors, 
 Table 1.2: Mendelian forms of hypertension 
 
Disorder Mode of inheritance Genes Mutation and functional consequences 
Glucocorticoid-remediable 
aldosteronism  
Autosomal 
dominant 
CYP11b1 & 
CYP11b2 Ectopic expression of aldosterone synthase activity in adrenal fasciculata  
Apparent mineralocorticoid 
excess  
Autosomal 
recessive 11bHSD 
Loss-of-function mutation resulting in excess stimulation of the 
mineralocorticoid receptor (MR); hypertension mediated by increased renal 
cortical collecting tubule epithelial sodium channel (ENaC) activity  
Mutations in mineralocorticoid 
receptor  
Autosomal 
dominant NR3C2 
S810L missense mutation in the ligand-binding domain converts receptor 
antagonists (such as progesterone) to agonists; pregnancy exacerbates 
hypertension  
SCNN1B De novo missense mutation of the β-subunit of ENaC  
Liddle syndrome  Autosomal dominant SCNN1G Mutation in the γ-subunit of ENaC that deletes the cytoplasmic C terminus, resulting in excess sodium retention  
Gordon’s syndrome Autosomal dominant 
WNK1 & 
WNK4 
WNK serine–threonine kinase defects resulting in hyperkalaemia and 
hypertension 
Mutations in peroxisome 
proliferator-activated receptor-γ  
Autosomal 
dominant PPARG 
Loss-of-function mutation resulting in insulin resistance, diabetes mellitus 
and hypertension  
Hypertension with brachydactyly Autosomal dominant 
Not yet 
identified 
Complex chromosome 12p rearrangement, including deletion, insertion and 
inversion. Severe hypertension, neurovascular anomalies and death from 
stroke around 50 years of age 
Syndrome of hypertension, 
hypercholesterolaemia and 
hypomagnesaemia  
Mitochondrial 
inheritance 
Not yet 
identified 
Maternal inheritance of a homoplasmic mutation causes a cytidine 
substitution in the mitochondrial tRNA  
CYP11b1 = cytochrome P450, subfamily 11B, polypeptide 1; CYP11b2 = cytochrome P450, subfamily 11B, polypeptide 2; NR3C2 = mineralocorticoid 
receptor (aldosterone receptor); PPARG = peroxisome proliferator activated receptor-γ; SCNN1B = sodium channel non-voltage-gated 1β (epithelial); 
SCNN1G = sodium channel, non-voltage-gated 1γ; tRNA = transfer ribonucleic acid; WNK1 = lysine deficient protein kinase 1; WNK4 = lysine 
deficient protein kinase 4; 11bHSD = hydroxysteroid 11-β dehydrogenase. Adapted from Ref. (11;217;218)  
 including blood pressure (34). Smokers demonstrate significantly higher blood 
pressure than non-smokers (35). Even the effects of passive smoking are 
comparable to that of chronic active smoking (36). Studies have demonstrated 
dose-dependent impairment of endothelial function in smokers and passive 
smokers (37). 
 
Alcohol is a threshold risk factor where the risk is low when alcohol consumption is 
moderate but high with heavy alcohol consumption (38). Abstinence in heavy 
alcohol drinkers significantly reduces BP, suggesting that heavy alcohol 
consumption is a risk factor (39).  
 
Population studies show an inverse relation between physical activity and blood 
pressure levels and cardiovascular morbidity and mortality (40-42). Increased 
physical fitness has a more prominent correlation with a favorable coronary risk 
profile for women than men (43) 
 
It is well recognised that obesity is linked to hypertension from experimental 
studies showing that weight gain is associated with increase in BP (44). Clinical 
studies have shown that weight loss is effective in lowering BP in most 
hypertensive patients, and population studies showing that excess weight gain is 
one of the best predictors for development of hypertension (44). Multiple studies 
showed that most hypertensive patients are overweight providing evidence that 
obesity is a major cause of hypertension. Results from the Framingham Heart 
Study suggested that approximately 65% to 75% of the risk for hypertension can 
be directly attributed to excess weight (45). 
 
1.1.2. Current Management 
 
According to the Joint British Societies’ (JBS) guidelines on prevention of 
cardiovascular disease, the specific objective is to reduce the risk of CVD and its 
complications, including the need for percutaneous or surgical revascularisation 
procedures (coronary artery bypass grafting (CABG)), and to improve quality of life 
and life expectancy (5). Recommendations for reducing risk factors include 
change of lifestyle and therapies that reduce risk factors such as high blood 
pressure or provide cardioprotective effects. The JBS guidelines aim to emphasise 
 a total risk approach to CVD risk assessment in the asymptomatic population; and 
to define lifestyle and risk factor interventions with thresholds and targets. 
Similarly, the European guidelines on cardiovascular disease prevention in clinical 
practice published in 2004 recommended management of total cardiovascular risk 
(46). The roles of lifestyle changes such as smoking, the management of major 
cardiovascular risk factors such as diabetes and the use of different prophylactic 
drug therapies such as anti-hypercholesterolaemia in the prevention of clinical 
CVD should be addressed. 
 
There are seven classes of antihypertensive drugs used to lower blood pressure. 
They are the ACE inhibitors, Ang II receptor blockers (ARBs), α-blockers, β-
blockers, calcium channel blockers (CCBs), diuretics and direct vasodilator (47). 
ACE inhibitors (e.g. captopril) block the cleavage of Ang I to the potent 
vasoconstrictor, Ang II, by ACE. ARBs (e.g. losartan) are Ang II receptor 
antagonists that results in vasodilation. The α-adrenergic blockers (e.g. Prazosin) 
competitively block α1-adrenoceptors causing the relaxation of both arterial and 
venous smooth muscle. The β-adrenoceptor blockers can act on both β1 and β2 
receptors (e.g. propanolol) or selectively for β1 receptors (e.g. atenolol), 
decreasing cardiac output. Calcium channel blockers (e.g. nifedipine) cause 
relaxation of vascular smooth muscle, dilating mainly arterioles. Diuretics (e.g. 
hydrochlorothiazide) lower blood pressure by increasing sodium and water 
excretion, resulting in a decrease in cardiac output and renal blood flow. Direct 
vasodilators act primarily on arteries or arterioles (e.g. hydralazine) or equally on 
arterial and venous smooth muscle (e.g. sodium nitroprusside). 
 
1.2. Animal Studies 
 
Animal models have already been used extensively in the investigation of genes 
involved in BP regulation. The most commonly used species in hypertension 
research is the rat (48). There are animal models for the study of the different 
types of hypertension, including non-genetic and genetic models (49;50). Non 
genetic models such as 2-kidney 1-clip and the deoxycorticosterone acetate 
(DOCA)-salt models are used for investigating secondary hypertension, due to 
renal and endocrine causes, respectively. Genotype-driven genetic models e.g. 
transgenic animals (mostly mice) are often used to investigate the mechanisms 
 behind Mendelian hypertension. Phenotype-driven genetic models are animal 
models of heritable hypertension, such as the spontaneously hypertensive rat 
(SHR), which are used to identify underlying genes or mechanisms contributing to 
development of hypertension (49;50).  
 
Animal models of heritable hypertension offer more favourable investigative 
opportunities compared to studies in humans because of reduced genetic 
heterogeneity, controlled breeding and greater scope for interventional study (48). 
The SHR is the most commonly used model that displays hypertension as an 
inherited trait (48). Other rat strains include the stroke-prone SHR (SHRSP), the 
Dahl salt-sensitive rats, Sabra hypertensive-prone rats, Milan, Lyon, fawn-hooded 
and Prague hypertensive rats.(48;51).  
 
The SHR was obtained by inbreeding Wistar rats with persistently high systolic 
blood pressure (Figure 1.3) (52;53). The SHR blood pressure increases at 5-6 
weeks of age and then continues steadily to SBP of 180-200mmHg at 12-16 
weeks of age.(48). The SHRSP is a further developed substrain of the SHR with 
even higher levels of blood pressure and a strong preponderance to die from 
stroke (52;53). In addition to increasing BP with age, the SHR and SHRSP also 
show gender-dependent BP effects similar to human hypertension (54). Both SHR 
and SHRSP exhibited many features of hypertensive pathological characteristics 
including impaired endothelium-dependent relaxations of isolated arteries, cardiac 
hypertrophy, heart failure, and renal dysfunction (48;50). These similarities are 
also found in human essential hypertension, making them excellent models for 
studying the mechanisms involved in the development of hypertension. 
 
Genome-wide scan in rodents are commonly used to identify regions within the 
genome containing gene or genes that are linked to hypertension. At least one BP 
quantitative trait locus (QTL), has been identified on almost every chromosome in 
the rat genome (51). Following the identification of a QTL, congenic and consomic 
rat strains are developed to confirm presence of the QTL and begin narrowing 
down the implicated region (55). Congenic strains have a chromosomal segment 
transferred from a donor strain to a recipient strain background by backcrossing. 
Consomic strains have an entire chromosome transferred from a donor strain to a 
recipient strain background by backcrossing. Congenic substitution mapping is 
  
Figure 1.3: Genealogical background of the stroke-prone spontaneously 
hypertensive rat (SHRSP). 
The SHRSP strain, maintained at Glasgow University (Gla), was obtained after filial 
generation 35-36. Personal communication & Ref. (52;53) 
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 then used to reduce the chromosomal region in which the QTL resides and 
subsequently identify causal genes. The first successful example of congenic 
strategy in the identification of a causal gene is the identification of Cd36 as an 
insulin-resistance gene by Aitman et. al (56). 
 
Aitman et. al. identified QTL linkages for hypertension, hypertriglyceridaemia, 
reduced high density lipoprotein (HDL) phospholipid and metabolic defects in 
adipocytes mapped to a region on chromosome 4 in SHR x Brown Norway(BN) 
(56). The group went on to replace the region of the chromosome 4 QTL in SHR 
with the corresponding region from the BN genome. By using a combination of 
cDNA microarrays, characterisation of a congenic strain and transgenic rescue, 
Aitman et. al. identified Cd36 as a causative gene for glucose and fatty acid 
metabolism. Cd36 encodes a fatty acid receptor/transporter involved in the 
transmembrane transport of long-chain fatty acids in adipose tissue and in cardiac 
and skeletal muscle. The Cd36 gene was deleted in the SHR (56). Importance of 
this gene, however, was strain-dependent since the gene deletion in SHR is not 
observed in SHRSP (57). The congenic strain displayed lower SBP and DBP; and 
improved fructose-induced glucose intolerance, hyperinsulinemia, and 
hypertriglyceridemia (57). Overexpression of Cd36 gene improved glucose 
tolerance, insulin-stimulated glucose incorporation into muscle glycogen, and 
serum fatty-acid levels (58). 
 
Similarly, previous work in our laboratory identified two blood pressure QTLs 
mapping to a region on rat chromosome 2 (59), which have been implicated in 
several other crosses (60). To confirm the chromosome 2 QTL, our group 
generated a panel of congenic strains by speed congenic strategy (Figure 1.4) 
One of the congenic strain (SP.WKYGla2c*) as depicted in Figure 1.5 contains a 
single introgressed region from WKY into SHRSP, which encompasses one of the 
two chromosome 2 QTLs. SP.WKYGla2c* strain has significantly lower blood 
pressure than the SHRSP but higher than the WKY (Figure 1.6), suggesting that 
the genes within this QTL region affect blood pressure homeostasis (61). QTL 
within the same region has been confirmed in different congenic strains by 
introgressing the relevant region from Milan normotensive or WKY into the Dahl 
salt-sensitive (62-64).  
 
  
Figure 1.4: Marker-assisted “speed” congenic strategy 
Congenic strain construction, illustrating the difference between the traditional and 
marker-assisted speed congenic approach. The arrows indicate the backcross at which 
background heterozygosity is theoretically the same. Decreasing shades of grey to white 
represent the serial dilution of the donor genome in the genetic background. D = donor 
strain alleles, R = recipient strain alleles, B = backcross, F1 = first filial generation; QTL = 
quantitaive trait locus 
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Figure 1.5: Chromosome 2 congenic strain SP.WKYGla2c*  
The congenic strain contains a 22-cM segment, encompassing a quantitative trait locus 
(QTL), transferred from WKY (donor strain; blue) to the genetic background of SHRSP 
(recipient strain; orange) between the markers D2Wox9 and D2Mgh12. The congenic 
strain described is the SP.WKYGla2 (D2Wox9 – D2Mgh12) and is abbreviated to 
SP.WKYGla2c* for simplicity, and 2c* in figures. The rGstm family gene locus is 
encompassed within the congenic region, under the quantitative trait locus (QTL). AMPD2 
= adenosine monophosphate deaminase 2; EPS8L3 = epidermal growth factor receptor 
pathway substrate 8-like protein 3. Adapted from (61). 
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Figure 1.6: Daytime and night-time average systolic (A) and diastolic (B) blood 
pressure. 
The systolic and diastolic blood pressures, measured by radiotelemetry over a 3-week 
period, for WKY, SHRSP and congenic strain SP.WKYGla2c* (n=8-11 per group) D = day, 
N = night. Taken from Ref. (61) 
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 Microarray analysis of gene expression in kidney homogenates from 16-week old 
rats showed reduction in glutathione s-transferase mu type-1 (rGstm1) expression 
by about 4-fold in SHRSP compared to WKY and SP.WKYGla2c* (61). A similar 
microarray study by Okuda et. al. of kidneys from 10-week old SHR and WKY also 
showed down-regulation of rGstm1 (65) (please note that in this study, the gene 
was mis-named as GSTM4). Another microarray study by Okuda et. al. in seven 
different rat strains also identified rGstm1 (please note that the gene was mis-
named as Gstm2) as differentially expressed (66). Subsequent Western blot 
analysis in our laboratory confirmed differential expression of rGstm1 protein in 
SHRSP, WKY and SP.WKYGla2c* (67). These results suggest that rGstm1 is a 
positional and functional candidate gene for blood pressure regulation.  
 
1.3. Oxidative Stress in Cardiovascular Disease 
 
1.3.1. Nitric Oxide 
 
Nitric oxide (NO) first identified as endothelium-derived relaxing factor (EDRF), is 
responsible for vasorelaxation by its effect on the vascular smooth muscle cells 
(VSMCs) (68). The release of paracrine vasodilators from endothelial cells is a 
critical determinant of vascular tone and an integral regulatory mechanism 
involved in maintenance of local blood flow and systemic blood pressure (69). 
Endothelium-dependent agonists, including acetylcholine (ACh) and bradykinin, 
stimulate endothelial cells to release NO, prostacyclin (PGI2) and endothelial-
derived hyperpolarisation factor (EDHF) (70). The relative contribution of each 
mediator to endothelial-dependent dilation is inversely related to vessel calibre, 
with NO- and PGI2-mediated responses predominating in large conduit vessels 
while EDHF is more prominent in peripheral resistance vessels. As NO has a half-
life of only 3.8 to 6.2 seconds and is released upon synthesis, vascular NO levels 
are mainly regulated through alterations in expression and activity of constitutive 
endothelial nitric oxide synthase (eNOS) (71).  
 
Major physiologic stimulus of vascular NO production is blood-flow induced shear 
stress on endothelial cells (72). NO is produced by nitric oxide synthases (NOSs) 
by conversion of L-arginine to L-citrulline and NO (Figure 1.7) (73). Established 
mechanisms of NO action include vasodilation, inhibition of platelet aggregation, 
  
Figure 1.7: Schematic diagram to illustrate NO intracellular signalling processes 
across the vascular wall. 
BH4 = tetrahydrobiopterin; cGMP = cyclic guanosine monophosphate; ECM = extracellular 
matrix; eNOS = endothelial nitric oxide synthase; GMP = guanosine monophosphate; 
GTP = guanosine triphosphate; NO = nitric oxide; O2- = superoxide anion; PDE = 
phosphodiesterases; PKG = cGMP-dependent protein kinase; VSMC = vascular smooth 
muscle cell 
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 leucocyte adhesion, and smooth muscle proliferation and antioxidative effects. 
Vasodilation is the best documented activity of NO in the cardiovascular system. 
NO mediates vasodilation through activation of cyclic guanosine monophosphate 
(cGMP)-dependent protein kinases (PKG I and PKG II) mainly via PKG I (74;75). 
The activity of cGMP is terminated by rapid conversion to GMP which is catalysed 
by various phosphodiesterases (PDE), specifically PDE5 (73). The vasodilation 
effect of NO can also be independent of PKG I activation (76). Platelets have the 
ability to aggregate and form a haemostatic plug but this effect must be carefully 
balanced against the necessity to maintain the fluid state of the blood and to avoid 
thrombosis (73). Atherosclerotic changes are often followed by hyperactivity 
associated with thrombosis, myocardial infarction and stroke. NO-induced 
inhibition of platelet aggregation is mainly through activation of PKG I. Increased 
leucocyte adhesion is a major step in the pathogenesis of atherosclerosis and NO 
is an important endogenous mediator which inhibits leucocyte adhesion. The 
mechanism of the anti-adhesive action of NO most likely involves anti-oxidative 
effects (73). Proliferation of smooth muscle cells plays a key role in narrowing the 
lumen of blood vessels in CAD and disappearance of contractile activity. NO also 
has been shown to inhibit smooth muscle proliferation. Vascular oxidative stress 
contributes to pathophysiology of cardiovascular diseases. The antioxidative 
effects of NO are in part mediated by inducing expression of ferritin, haem 
oxygenase-1 and extracellular superoxide dismutase (ecSOD), the activities of 
which decrease superoxide levels and formation of highly reactive radical 
peroxynitrite in the vascular wall (73).  
 
1.3.2. Endothelial dysfunction 
 
Endothelial dysfunction describes impaired endothelium-dependent vasorelaxation 
caused by a loss of NO bioactivity in the vessel wall (77;78), as a consequence of 
decreased NO bioavailability. Evidence includes blunting of forearm vasodilator 
response to mental tasks following NO synthesis inhibition with N-monomethyl-L-
arginine (L-NMMA) (79;80), a reduction in NO activity in both primary and 
secondary hypertension (81;82), and even in normotensive offspring of 
hypertensive parents (83). Basal NO production, as measured by plasma nitrate 
levels, was shown to be lower in patients with essential hypertension (84). Racial 
difference has been found to influence NO-dependent vasodilator response (85). 
 Altered endothelium-dependent vascular relaxation has been shown in all animal 
models of cardiovascular disease (48). Anti-oxidant vitamins have been shown to 
enhance endothelium-dependent vasodilation in experimental models (86;87) but 
not in large human studies (88;89). There has been accumulating evidence in 
animal models and humans that endothelial dysfunction and decreased NO 
bioavailability may contribute to hypercholesterolaemia, diabetes and hypertension 
(90). Overexpression of eNOS by gene transfer in animal studies and substrate L-
arginine supplementation in human studies have been shown to improve 
endothelium-dependent relaxation (91-94), further supporting the importance of 
NO in endothelial function. 
 
1.3.3. Reactive Oxygen Species 
 
Many cells that comprise the vasculature generate reactive oxygen species (ROS) 
(Figure 1.8). Reactive oxygen species (ROS) include free radicals, such as 
superoxide anion (O2-), hydroxyl radical (OH-), nitric oxide (NO), lipid radicals 
(LOO-), which possess unpaired electrons or molecules that possess oxidising 
effects, such as hydrogen peroxide (H2O2), hypochlorous acid (HOCl) and 
peroxynitrite (ONOO-) (77). ROS regulate cellular signalling systems in both 
VSMCs and/or endothelial cells (78;95;96). ROS production induced by agonists 
has been shown in VSMCs, endothelial cells and adventitial fibroblasts. ROS 
mediate cell responses to agonist by activation of specific signalling cascades, 
through redox-sensitive proteins. These include tyrosine kinase receptors such as 
platelet-derived growth factor receptor (PDGF-R), epidermal growth factor receptor 
(EGF-R) and G-coupled receptor agonists such as phenylephrine and thrombin. 
H2O2 has been shown to activate several mitogen-activated protein kinases 
(MAPKs), a family of serine/threonine kinases that control cellular responses to 
growth, apoptosis and stress signals. ROS have also been shown to be necessary 
for VSMCs survival and even apoptosis (97). O2- appears to induce cell growth 
while H2O2 appears to lead to cell death in in vitro studies. Similarly, in endothelial 
cells, ROS appear to be required for survival as well as apoptosis (78). ROS 
generation by different sources can suppress endothelial cell death or promote 
endothelial cell apoptosis.  
 
 The vascular superoxide level is determined by the balance between its rate of 
formation by various oxidases, auto-oxidation processes and its rate of removal 
and reaction with various molecules (96). Vascular tissue contains multiple 
oxidases whose activity and expression appear to be highly regulated, thus the 
tight control of ROS metabolism. Superoxide dismutase (SOD) dismutate O2- at a 
rate of 2.4 x 109 mol.L-1.s-1 to the more stable hydrogen peroxide (H2O2), which is 
then converted to water by catalase of glutathione peroxidase (GPx) (78;95;98). 
Since NO reacts with O2- forming ONOO- at a rate of 6.7 x 10-9 mol.L-1.s-1, it 
becomes an important scavenger of O2- (77). Additionally, anti-oxidants such as 
ascorbate scavenge superoxide but many of these substances may not be present 
at sufficient levels (96). Finally, the expression of ROS-producing enzymes can be 
altered by hormones such as angiotensin II (Ang II) or cytokines such as tumour 
necrosis factor (TNF) -α and interleukin (IL) -1β (95)  
 
1.3.4. Oxidative stress 
 
Oxidative stress occurs when ROS and its derivatives are produced excessively, 
outstripping endogenous anti-oxidant defence mechanisms (Figure 1.8) (77). The 
imbalance between NO and ROS results in reduced NO bioavailability, leading to 
endothelial dysfunction, which is the basis of many other vascular diseases. 
Endothelial dysfunction and oxidative stress are common features in human and 
rat hypertension (48). Reduction of NO bioavailability in the endothelium, can be 
the result of decreased NO production or increased ROS production (77). 
Decreased NO production might be a consequence of reduced expression of 
eNOS (99), lack of substrate or cofactor (100-102), or alterations of cellular 
signalling resulting in the eNOS not being activated (103). Increased O2- 
production can be due to increased expression or activity of O2--producing 
enzymes, shear stress or excess stimulation (77). Even eNOS, in the absence of 
sufficient key co-factor tetrahydrobiopterin (BH4), produce O2- and H2O2 instead 
(Figure 1.7) (104;105). 
 
Overproduction of the first reactive oxygen radical O2-, can lead to a radical chain 
reaction generating more ROS (Figure 1.8). Due to its rapid reaction with NO, O2- 
can consume NO rapidly, thus decreased NO bioavailability, and prevents its 
interaction with the signalling mechanisms normally regulated by NO, leading to 
  
Figure 1.8: The roles of oxidative stress enzymes in maintaining the balance 
between O2- and NO.  
BH4 = tetrahydrobiopterin; eNOS = endothelial nitric oxide synthase; H2O = water; H2O2 = 
hydrogen peroxide; GPx = glutathione peroxidase; GSH = glutathione; GSSG = oxidised 
glutathione; GSTs = glutathione s-transferases; LO- or LOO- = lipid radicals; NAD(P)H = 
nicotinamide adenine dinucleotide (phosphate); NO = nitric oxide; O2 = molecular oxygen; 
O2- = superoxide anion; ONOO- = peroxynitrite; ROS = reactive oxygen species; SOD = 
superoxide dismutase; VSMC = vascular smooth muscle cell. Adapted from Ref. (77)  
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 endothelial dysfunction. Agonists-induced activation of vascular NAD(P)H 
oxidases produce H2O2 in large quantities, which in turn amplifies its own 
production, resulting in compensatory or detrimental consequences (106). H2O2 
either mediates endothelium-dependent vasodilatation in hypertension when NO is 
substantially reduced as a compensatory mechanism, or may be involved in 
VSMC proliferation and hypertrophy over long period of time. At least five different 
mechanisms are implicated in self-propagation of H2O2 in vascular cells.  
 
One of the most important ROS is ONOO-, the by-product of NO and O2-. It is a 
highly reactive radical, strong oxidant and it is more stable than either NO or O2- 
(96;107). ONOO- activates signalling-like mechanisms such as (a) inactivation of 
mitochondrial electron transport and respiration, (b) increased potency of O2- as 
inhibitor of mitochondrial respiration, (c) stimulation of cyclooxygenase production 
of prostaglandin (PG) H2, a prothrombotic vasoconstrictor, (d) inhibition of PGI2 
synthase, (e) the potential to convert production of endothelium-derived PGI2, an 
antithrombotic vasodilator to PGH2. ONOO- has been shown to irreversibly inhibit 
protein tyrosine phosphatases, thus disrupting balance maintained between 
cellular kinase and phosphatase activity. Inhibition of anti-oxidant enzymes GPx, 
catalase and manganese (Mn) SOD by ONOO- probably affect redox control 
mechanisms, promoting O2- generation leading to decreased anti-oxidant defence, 
which is likely to promote activation of apoptosis. 
 
ROS are implicated in oxidation of biological macromolecules, such as DNA, 
protein, carbohydrates and lipids (Figure 1.8). ROS oxidation of lipid can lead to 
production of other lipid radical chain reactions, whereby oxidised fatty acids 
generates fatty acid peroxyl radicals, which attack adjacent fatty acid side chains 
(77). Lipid radicals accumulate in cell membrane causing leakage of plasmolemma 
and dysfunction of membrane-bound receptors. In addition, the end-products of 
lipid peroxidation have cytotoxic and mutagenic effects. The effects of ROS vary 
depending on the oxidative stress levels and the cell types involved (108). A 
number of enzymes play important roles in the maintaining the balance between 
the levels of O2- and NO including eNOS 
 
 1.3.5. Endothelial Nitric Oxide Synthase 
 
Nitric oxide synthases (NOSs) are haem containing oxido-reductases that convert 
L-arginine to NO and by-product L-citrulline in the presence of nicotinamide 
adenine dinucleotide phosphate (NADPH) and O2 (109-113). Each NOS 
polypeptide is comprised of an N-terminal oxygenase domain and a C-terminal 
reductase domain (Figure 1.9) (110;112;113). The core region of NOS oxygenase 
domain binds haem, BH4 and L-arginine as well as forming the active site where 
NO synthesis takes place. The C-terminal reductase domain binds flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), and NADPH. During 
NO synthesis the reductase flavins acquire electrons from NADPH and transfer 
them to the haem iron, which permits it to bind and activate O2- and catalyse NO 
synthesis. 
 
There are three distinct enzyme isoforms (Table 1.3), which are neuronal NOS 
(nNOS), inducible NOS (iNOS) in phagocytic cells and eNOS (109-113). All three 
NOSs expression have been detected in other cell types, in addition to the 
suggestion from its name (111). The gene encoding for nNOS is NOS1, located on 
chromosome 12q24; iNOS, encoded by NOS2 on chromosome 17q11-12; and 
eNOS encoded by NOS3 on chromosome 7q35-36 (109;113). Both nNOS and 
eNOS are constitutively expressed while iNOS expression is typically synthesised 
in response to inflammatory mediators (109-113). NO is usually produced by 
eNOS in the vasculature, but can also be produced by iNOS in pathological states 
by macrophages. In the cardiovascular system, eNOS is a major player in the 
control of endothelial function and therefore will be the focus of subsequent 
discussion. 
 
eNOS was first purified and its corresponding cDNA cloned from endothelial cells 
but was subsequently found to be expressed in other cells of the cardiovascular 
system (111). NOS3 containing 26 exons spanning approximately 21kb of 
genomic DNA encodes for a 135kDa polypeptide (109). No alternative splice 
variants have been characterised but a number of allelic variants have been 
associated with cardiovascular disease. The gene expression of NOS3 is 
regulated at transcriptional and post-transcriptional level (109;111;113). 
Transcriptional regulation includes allelic variant in the promoter with binding sites 
  
Figure 1.9: Schematic diagram of a functionally active dimeric NOS 
Arg = L-arginine; BH4 = tetrahydrobiopterin; CAM = calmodulin; FAD = flavin adenine 
dinucleotide; FMN = flavin mononucleotide; (Fe) = haem; NADPH = nicotinamide adenine 
dinucleotide phosphate. Taken from Ref. (112) 
 
 
Figure 1.10: Regulation of NAD(P)H oxidase ROS production by rac1 
NAD(P)H oxidase consists of 5 subunits, 3 cytoplasmic subunits (p67phox, p47phox and 
p40phox), and 2 membrane subunits (Nox and p22phox), which are also known as 
cytochromeb558 (Cytb558). NAD(P)H oxidase production of O2- is regulated by rac1 protein. 
ECM = extracellular matrix; NAD(P)+ = oxidised nicotinamide adenine dinucleotide 
(phosphate) ; NAD(P)H = reduced nicotinamide adenine dinucleotide (phosphate). 
Adapted from Ref. (127) 
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Table 1.3: Properties of nitric oxide synthases (NOSs) 
 
Gene Enzyme Monomeric size (Molecular weight) 
Human chromosomal 
location 
Rat chromosomal 
location 
Principal tissue distribution 
under basal conditions 
NOS1 nNOS 
1439 a.a. 
(161kDa) 12q24.2–q24.31 12q16 
Neurons  
Skeletal muscle  
Macula densa segment  
Bronchial and tracheal 
epithelium 
NOS2 iNOS 
1153 a.a. 
(131kDa) 17q11.2–q12 10q25 
Bronchial airway, epithelium, 
alveolar, macrophages 
Ileum  
Uterus  
Platelets 
NOS3 eNOS 
1203 a.a 
(133kDa). 
7q35–q36 4q11 
Endothelium  
Hippocampal CA1 neurons  
Cardiac myocytes  
 
The monomeric size and molecular weight of the enzymes are represented by the human proteins. a.a. = amino acid; NOS = nitric oxide synthase; 
nNOS = neuronal NOS; iNOS – inducible NOS; eNOS = endothelial NOS; kDA = kiloDalton. 
Adapted from Ref. (109;113) 
 for transcription factors such as Sp1, activator proteins 1 and 2 elements (AP1, 
AP2), a nuclear factor-1 element (NF-1), and regulatory sequences for stimuli such 
as sterol regulatory element (SRE), partial oestrogen responsive elements (ERE), 
a cyclic AMP response element (CRE) and a putative shear stress response 
element (SSRE) (111;114). Lysophosphotidylcholine is the most potent activator of 
eNOS mRNA expression, in a dose- and time- dependent manner (115), while 
oxidised low density lipoproteins (oxLDL) decrease eNOS mRNA, probably 
involving mRNA stabilisation (116). Transforming growth factor (TGF)-β increase 
eNOS mRNA, protein and activity (117) while TNF-α does the opposite (118). 
Oestrogen and other hormones have also been found to influence the expression 
of eNOS (114).  
 
Covalent modifications of eNOS by palmitoylation, myristoylation, phosphorylation 
and acetylation have been reported (112;113). These modifications might 
influence the activity of the enzyme. eNOS is able to synthesise NO in response to 
increased calcium ions (Ca2+), and in some cases, to shear stress (Figure 1.7) 
(110;112). Functionally active eNOS is made of homodimeric subunits (Figure 1.9) 
and dimer stability may also regulate eNOS activity. Interactions of eNOS and 
other proteins, such as caveolins, calmodulin and heat shock protein (HSP)-90 
have been shown to alter the activity of eNOS. Activity of eNOS is also regulated 
by a feedback inhibition through binding of NO to haem in a reversible manner. 
One of the most important factors regulating activity of eNOS is physiological 
concentration of BH4, an essential redox cofactor permanently bound to eNOS. 
BH4 stabilises the dimeric form of eNOS and directly increases production of NO 
(119). Insufficient BH4 can result in uncoupling of the electron transfer from 
NADPH to L-arginine by eNOS, which produces O2- instead (Figure 1.7) (100). 
Low concentrations of ONOO- can oxidise BH4 at physiological conditions (120). 
Consequently low levels of BH4 can mediate eNOS-dependent ONOO- formation. 
BH4 also inhibits O2- production by eNOS and xanthine oxidase in a dose-
dependent manner (119). 
 
1.3.6. Reactive Oxygen Species: Sources and Stimuli 
 
It is now established that sources of ROS are mitochondrial respiration, 
arachidonic acid pathway enzymes (e.g. lipoxygenase and cyclooxygenase), 
 cytochrome p450s, xanthine oxidase, nicotinamide dinucleotide / nicotinamide 
dinucleotide phosphate (NAD(P)H) oxidase, NOS, peroxidase and haemoproteins 
(77). In cardiovascular research, NAD(P)H oxidase, xanthine oxidase and NOS 
are the enzymes studied most extensively because they have been proven to 
contribute to development of hypertension.  
 
1.3.6.1. NAD(P)H oxidase 
 
All cell types found in the vessel wall are equipped with NAD(P)H oxidases, which 
are active under basal physiological conditions, participate in redox-sensitive 
mechanisms that control both vascular function and adaptive gene expression 
responses (96). The majority of available data show the use of nicotinamide 
dinucleotide (NADH) but there is also evidence of the utilisation of the 
nicotinamide dinucleotide phosphate (NADPH) as a substrate for O2- production. 
The NAD(P)H oxidase has been confirmed to be the predominant O2- producing 
enzyme and the major source of O2- in vascular tissues (77). Studies in animal 
models have shown that NAD(P)H oxidase generation of O2- is greater in vascular 
tissues from hypertensive strains and tend to be higher in older animals (121). 
Endothelium from male rats also produced higher NAD(P)H oxidase-dependent 
O2- than from female rats in aorta and microvessels (122;123). 
 
The membrane-associated NAD(P)H oxidase enzyme consists of 5 subunits, 3 
cytoplasmic subunits and 2 membrane subunits (124-127). The membrane 
components are p22phox and Nox more commonly know as cytochrome b558 
(Cytb558) or flavohaemoprotein while the cytoplasmic components consist of 
p40phox, p47phox and p67phox (Figure 1.10). Vascular NAD(P)H oxidases are similar 
in structure to the neutrophil NAD(P)H oxidase, but produce less O2- for a longer 
period (98). Activation of NAD(P)H oxidase requires guanosine triphosphate (GTP) 
binding protein rac1, through interaction of rac1 with p67phox subunit. Rac1 is a 
21kDa protein, which regulates the production of O2- by NAD(P)H oxidase and is 
required for the assembly of the NAD(P)H oxidase subunits. ROS generated by a 
rac1-regulated oxidase, such as NAD(P)H oxidase is crucial in suppressing 
endothelial cell death while ROS produced independently of rac1 promote 
endothelial cell apoptosis (78).  
 
 O2- production in aorta of adult SHR was associated with upregulation of p22phox 
mRNA, with evidence pointing to VSMCs as potential source (128) Luciferase 
activity of VSMCs from SHRs was higher than WKY, preferring NADH to NADPH 
as substrate. The p22phox subunit is an essential component of the vascular 
NAD(P)H oxidase. This is further confirmed by decreased O2- production following 
inhibition of p22phox mRNA expression by stable transfection of antisense cDNA 
into VSMCs (125). 
 
1.3.6.2. Other Sources of O2- 
 
Other sources include xanthine oxidase, myeloperoxidase, cyclooxygenase, 
lipoxygenase, mitochondrial respiration, cytochrome p450 isoenzymes, haem 
oxygenase, and glucose oxidase (77;129). 
 
Xanthine oxidase generates O2- and H2O2 by catalysing oxidation of hypoxanthine 
and xanthine to uric acid during purine metabolism (129;130). Under 
pathophysiological conditions, it is another major source of vascular oxidative 
stress. Xanthine oxidase is not only expressed in vascular cells but also circulates 
in the plasma and binds to endothelial cell extracellular matrix. 
 
During inflammation, neutrophils and monocytes are activated and can be a major 
source of reactive oxygen species (129). For example, activated neutrophils and 
monocytes secrete myeloperoxidase, a haemoprotein that localises in and around 
endothelial cells after leukocyte degranulation. This enzyme uses H2O2 peroxide to 
produce HOCl. Myeloperoxidase can also oxidise tyrosine and nitrite (NO2-) to 
form tyrosyl radicals and nitrogen dioxide radicals, respectively. These reactions 
lead to formation of reactive nitrogen species and protein nitration, for example, 
nitrotyrosine formation. 
 
1.3.6.3. Angiotensin II and Other Stimuli 
 
Ang II is, perhaps, the most widely investigated and potent stimulus for the 
production of ROS in vascular cells. Ang II can increase O2- in cultured VSMCs 
from rats (131;132) as well as human arteries and veins (133), mediated through 
NAD(P)H oxidase. Ang II stimulation of AT1R in the vascular wall leads to 
 activation of NAD(P)H oxidase in vascular cells (134). This is due to the assembly 
of enzyme subunits and the upregulation of expression of oxidase subunits and 
rac1 (135-140). Other enzymes also contribute to Ang II–induced oxidative stress 
in the vasculature. Modulation of AT1R expression levels by various agonists 
influences Ang II-induced ROS production in vascular cells. 
 
Several growth factors such as platelet-derived growth factor (PDGF) (141), 
epidermal growth factor (EGF) (142) and thrombin (143) lead to increased ROS. 
The pro-inflammatory cytokines such as IL-1 (144) and TNF-α (144;145) activate 
NAD(P)H oxidase and xanthine oxidase in vascular cells. During endotoxaemia, 
lipopolysaccharides induce oxidative stress by enhancing xanthine oxidase and 
NAD(P)H oxidase expression and activity (146). ROS and their oxidised by-
products such as H2O2, lipid peroxides and oxidised low density lipoprotein 
(oxLDL) have been shown to activate NAD(P)H oxidase O2- production in vascular 
smooth muscle cells and fibroblasts (147-150). Mechanical stimuli such as shear 
stress have been shown to increase endothelial cells O2- production in a manner 
requiring both NAD(P)H oxidase and xanthine oxidase (151;152). 
 
1.4. Anti-oxidant Enzymes – 1st Line of Defence 
 
There are several anti-oxidant enzymes that help to balance the levels of nitric 
oxide and reactive oxygen species by converting ROS into less harmful 
compounds. Superoxide dismutase (SOD) and catalase provide the first line of 
defence, while glutathione peroxidase (GPx) and glutathione s-transferase (GSTs) 
provide the second line of defence (Figure 1.8) (153-155). 
 
1.4.1. Superoxide Dismutase 
 
Superoxide dismutases (SODs) are the first and most important line of anti-oxidant 
enzyme defence, particularly against O2- (153;156). SODs catalyse the conversion 
of two O2- and two hydrogen ions to H2O2 and molecular O2 at a diffusion-limited 
rate (153). Vascular tissue contains three isoforms of SOD which accelerate the 
dismutation of superoxide into H2O2 and O2- (Table 1.4) (157). The first isoform is 
cytosolic copper zinc (Cu/Zn)–SOD encoded by SOD1, which is thought to lower 
O2- levels from the nanomolar to picomolar concentration range. Mitochondria 
  
 
 
 
Table 1.4: Properties of superoxide dismutases (SODs) 
 
Gene Enzyme Monomeric size (Molecular weight) 
Human chromosomal 
location 
Rat chromosomal 
location 
Cellular localisation 
under basal conditions 
SOD1 Cu/Zn–SOD 
154 a.a. 
(17kDa) 
21q22.11 11q11 Cytosol 
SOD2 Mn–SOD 
222 a.a. 
(26.6kDa) 
6q25.3 1q21 Mitochondria 
SOD3 ecSOD 
240 a.a. 
(26kDa) 
4p15.3–p15.1 14q11 Extracellular matrix 
 
The monomeric size and predicted molecular weight of the enzymes are represented by the human proteins. a.a. = amino acid; SOD = superoxide 
dismutase; Cu/Zn–SOD = copper/zinc SOD; Mn–SOD = manganese SOD; ecSOD = extracellular SOD; kDA = kiloDalton. 
 
 contain a second isoform, manganese (Mn)–SOD encoded by SOD2, and lastly, 
arterial smooth muscle cells are the principal source of the extracellular isoform of 
the Cu/Zn–SOD enzyme in the vascular wall, commonly known as extracellular 
SOD (ecSOD) encoded by SOD3. Although the enzymes are related, the genes 
are localised on different chromosomes, with human SOD1 on chromosome 
21q22, SOD2 on 6q25 and SOD3 on 4p-q21 (157). 
 
Cu/Zn–SOD and ecSOD have copper (Cu) and zinc (Zn) in their catalytic centre 
while Mn–SOD has manganese as a cofactor (156). Cytosolic Cu/Zn-SOD 
functions as a homodimer, Mn–SOD as homotetrameric enzyme while ecSOD is 
made up of homotetrameric glycoproteins with a high affinity for heparin sulphate. 
The importance of SODs as anti-oxidant enzymes was shown by gene transfer 
experiments where overexpression of the SODs reduced oxidation of low density 
lipoprotein (LDL) in endothelial cells (158-160), improved endothelial function 
(161) and provided protection against myocardial infarction (157). Gene 
expression levels of SODs can be upregulated by mechanical, chemical and 
biological stimuli or downregulated in certain pathophysiological conditions 
(153;156;157). In addition, Mn–SOD expression is also regulated at post-
transcriptional level by a RNA-binding protein (162). 
 
1.4.2. Catalase 
 
Catalase is a homotetrameric haemin-enzyme containing four ferriprotoporphyrin 
groups (153;156). Catalase is an intracellular anti-oxidant enzyme, mainly located 
in cellular peroxisomes and to some extent in the cytosol. It catalyses the 
heterolytic decomposition of two H2O2 molecules to water and O2. Catalase 
contains 4 tightly bound NADPH molecules, which function to prevent the 
accumulation of an inactive Fe(IV) form of the enzyme (163-165). Catalase is one 
of the most efficient enzymes with the capability to deal with H2O2 in the millimolar 
range of concentration (166). Catalase prevents the accumulation of H2O2 in 
peroxisomes, without which, the cells would undergo immediate cell death. 
 
A rare inherited autosomal recessive disease in the human catalase gene is 
located on chromosome 11p13 and results in catalase deficiency in Hungarian 
families associated with increased cardiovascular risk (154). A variant in the 
 promoter region of catalase gene was found to be associated with essential 
hypertension. These human studies support the importance of catalase as an anti-
oxidative enzyme. However, studies in animals and humans have only provided 
evidence for moderate protection by catalase against oxidative stress (167). ROS 
production was reduced by gene transfer of both SOD and catalase but the 
relative contribution of each gene is still not clear (168). A number of transcription 
factors are involved in the regulation of catalase gene expression in a tissue-
specific manner (169;170). Catalase itself is also involved in the regulation of 
cyclooxygenase gene expression in rat aortic smooth muscle cells (171). 
 
1.5. Anti-oxidant Enzymes – 2nd Line of defence 
 
Interaction of ROS with macromolecules does occur, generating highly reactive 
products that are capable of damaging DNA, protein and lipid (172). Extended 
chain reaction from these secondary oxidation products can result in degradation 
of cellular components and ultimate death of the cell so there is a need to detoxify 
these secondary oxidation products. Secondary line of protection is provided by 
enzymes such as glutathione peroxidase (GPx), glutathione s-transferase (GSTs), 
aldo-keto reductase and aldehyde dehydrogenase. 
 
1.5.1. Glutathione 
 
Glutathione (GSH) is a small molecular weight organic donor molecule used by a 
number detoxifying enzymes, namely GPx and GSTs. Since its discovery in 1920s 
biochemical and functional studies in parallel with developments in protein 
biochemistry and enzymology has placed glutathione in the centre of drug and 
foreign substance detoxification and multi-drug resistance (173). Functional roles 
of glutathione can include anti-oxidant defence mechanisms as well as metabolic 
and regulatory functions (Figure 1.11) (173). The anti-oxidant function of 
glutathione is probably due to the unique redox chemistry of the cysteinyl–thiol of 
the molecule (155;173). 
 
Glutathione is the principal intracellular non-protein thiol, present in concentrations 
up to 10mM in cells (174). Concentrations of glutathione in various cells are 
relatively constant in physiological conditions but intracellular concentrations can 
  
Figure 1.11: Functional roles of glutathione 
Adapted from Ref. (173) 
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 be affected in various pathologies (155;173). Plasma glutathione arises largely 
from the liver. Glutathione exists in reduced form and is a tri-peptide γ-Glu-CysH-
Gly synthesised in a two-step reaction (174). L-glutamate and L-cysteine is first 
catalysed by γ-glutamyl-cysteine synthase (GCS), in the presence of adenosine 
triphosphate (ATP) and magnesium ion (Mg2+), to form L-γ-glutamyl-L-cysteine in a 
rate-limiting step. L-γ-glutamyl-L-cysteine and glycine is then catalysed by 
glutathione synthase (GS), in the presence of ATP and Mg2+, to form glutathione. 
Less than 0.2% of total glutathione occurs in oxidised form as glutathione 
disulphide (GSSG), which is potentially highly cytotoxic. This form is reduced by 
glutathione reductase in the presence of NADPH. The [GSH]:[GSSG] ratio, often 
used as an indicator  of the cellular redox state, is the major redox couple that 
determines the antioxidative capacity of cells (173). Its value can, however, be 
affected by other redox couples including NADPH/NADP+ and 
thioredoxinred/thioredoxinox. Metabolites detoxified via glutathione conjugation are 
eliminated from cells by energy-dependent efflux pumps such as glutathione s-
conjugate transporter, which is also known as multidrug resistance-associated 
protein (MRP). 
 
1.5.2. Glutathione Peroxidases 
 
GPxs plays a role in both first line of defence, by reducing H2O2 to water and 
second line of defence, by reducing organic peroxides such as lipid hydroperoxide 
to water and lipid alcohol, via conjugation of glutathione, forming GSSG (175;176). 
There are four known GPxs which contain selenocysteine at the active site and at 
least two other proteins with over 40% sequence identity to cytosolic GPx that do 
not contain selenocysteine (175). GPx1 and GPx2 are homotetrameric proteins, 
GPx3 is a homotetrameric glycoprotein while GPx4 is a monomeric enzyme (175). 
Cytosolic or cellular GPx (GPx1 or GSHPx-1), encoded by GPx1 on chromosome 
3p21.3, can metabolise H2O2 and a variety of organic peroxides, including 
cholesterol and long-chain fatty acid peroxides. The fatty acid metabolism by 
GPx1 requires phospholipase A2 activity as well. GPx2 found mainly in the 
epithelium of gastrointestinal tract (GSHPx-GI), encoded on chromosome 14q24.1 
has similar activities to GPx1. GPx3, encoded on chromosome 5q23, was first 
purified from plasma, thus GSHPx-P. GPx3 mRNA was later found to be 
expressed predominantly in kidney, particularly the proximal tubular epithelial 
 cells. GPx4, encoded on chromosome 19p13.3, can react with phospholipid 
hydroperoxide (PHGPx) 
 
GPx1 knockout mice show increased susceptibility to ROS-induced oxidative 
stress (177) while induction of GPx1 has been shown to protect endothelial cells 
against oxidative stress (178), and transgenic GPx1 expression improved 
endothelial dysfunction (179). GPx1 is also important for modulation of ROS and 
consequently transcription factor activation (175). Cellular and tissue location of 
the GPxs are critical for their biological functions. The unusual distribution of GPx2 
suggests a specific function in metabolising ingested lipid hydroperoxides. 
Regulation of GPx2, unlike GPx1, is less restricted by selenium deficiency. GPx3 
also has activity against phospholipid hydroperoxides. GPx4 is responsible for 
protection of membranes against oxidative damage and also control of cell 
function. Although GPxs are important, there are also non-selenocysteine 
enzymes that have peroxidase activity, most notably the GSTs. 
 
1.5.3. Glutathione S-Transferases 
 
The soluble dimeric glutathione s-transferases (GSTs) are major phase II 
detoxification enzymes, with the ability to conjugate xenobiotics and reactive 
oxygen species using donor molecule glutathione (155;180-184). There are two 
distinct families encoding proteins with GSTs activities, the first consists of 
cytosolic proteins and the second consists of membrane-bound proteins 
(185;186). The cytosolic proteins are the bona fide GSTs, having both GSTs_N 
and GSTs_C domains (186) while the membrane-bound enzymes are not part of 
the GSTs gene superfamily. In the human, the GSTs gene family comprises 16 
genes in six classes – one pi (π) gene (GSTP1) on chromosome 11q13, five mu 
(μ) genes (GSTM1-GSTM5) on chromosome 1p13.3, five alpha (α) genes 
(GSTA1-GSTA5) on chromosome 6p12, two omega (ω/Ω) genes (GSTO1, 
GSTO2) on chromosome 10q25, one zeta (ζ) gene (GSTZ1) on chromosome 
14q24 and two theta (θ) genes (GSTT1, GSTT2) on chromosome 22q11.  
 
GSTs are dimeric proteins, each subunit about 26kDa, formed only from subunits 
within the same class (181). GSTs are 2-domain structures made of structurally 
conserved nucleophilic glutathione binding sites (G-sites) and the diverse 
 hydrophobic binding sites (H-sites) that determines the substrate specificities 
(184). The G–sites are largely made up through interactions with N-terminal 
residues while the H–sites involve C-terminal residues and other parts of the 
protein. Substrates are electrophilic compounds that are able to react with the thiol 
moiety of glutathione (181). GSTs catalyse binding of a large variety of 
electrophiles to sulphydryl group of glutathione, generally resulting in less harmful, 
more water-soluble molecules (155). Expression of GSTs seems to be under 
control of responsive elements such as glucocorticoid response element (GRE), 
xenobiotics response element (XRE) or antioxidant response element (ARE) 
(182;187). The major role of GSTs is detoxification of α,β-unsaturated carbonyls, 
epoxides, hydroperoxides and electrophilic metabolites of xenobiotics (155). 
Particular isoenzymes are extremely efficient at conjugating glutathione with 4-
hydroxynonenal aldehyde formed from lipid peroxidation of polyunsaturated fatty 
acids. Certain GSTs can catalyse conjugation of glutathione with cholesterol α-
oxide, a mutagenic compound generated during oxidation of membranes. Some 
GSTs exhibit selenium -independent peroxidase, isomerase and thiol transferase 
activity (184). While some GSTs are active with phospholipid hydroperoxides, 
many are active with free fatty acid hydroperoxides  (155). Generally, the 
reductase activity of GSTs can arrest lipid peroxidation. In DNA, thymines are 
likely targets of free radical damage as they have the highest electron affinity and 
will form thymine hydroperoxides (155). Certain GSTs conjugate glutathione with 
adenine and thymine propenals, which are reactive purine and pyrimidine bases 
formed during oxidative damage to DNA. Although the biological significance of 
GSTs’ ability to reduce DNA hydroperoxides is not clear, GSTs in rat liver appear 
to translocate to the nucleus during periods of drug-induced oxidative stress. In 
addition to their role in catalysing the conjugation of electrophilic substrates to 
glutathione, these enzymes also carry out a range of other functions. These 
include removal of ROS, regeneration of S-thiolated proteins, catalysis of 
conjugations of endogenous ligands and catalysis of reactions in metabolic 
pathways not associated with detoxification (187). GSTs represent a second line 
of defence against highly toxic spectrum of substances produced by ROS-
mediated reactions due to their broad substrate specificity.  
 
SODs are the most studied anti-oxidant enzymes, with catalase and GPx also 
increasingly becoming a focus of several studies. The role of GSTs as protectors 
 of cardiovascular system is beginning to emerge. Most of the studies on GSTs 
have been in cancer research. However, the rat Gstm1 was identified to be 
differentially expressed in the genetic models of hypertension (61;65;66). The 
following sections will discuss the GSTM gene family in greater detail. 
 
1.5.3.1. Nomenclature of Glutathione S-Transferase μ Genes 
 
The current nomenclature used for the GSTs was standardised in 1992 (188). 
GSTM1 null is referred to as GSTM1*0. As the current study does not look at the 
different alleles of each GSTsμ isoenzymes, GSTM1*A or GSTM1*B are referred 
to as only GSTM1 without differentiating between the two alleles of GSTM1. 
Likewise, GSTM3 is used instead of GSTM3*A or GSTM3*B. For the isoforms 
without known alleles such as GSTM2-2, GSTM2 is used instead of GSTM2-2. 
However, it should be noted that in the literature pre-dating the standardised 
nomenclature, GSTM1, GSTM2 and GSTM5 were previously referred to as GST1, 
GST4 and GST5 respectively. Likewise, the rat Gstm genes were and are still 
referred to as the Yb genes, with Gstm1, Gstm2, Gstm3 and Gstm4 corresponding 
to Yb1, Yb2, Yb3 and Yb4, respectively. Subsequently, more rat Gstm genes have 
been identified and are named as Gstm rather than Yb. With the confusion of GST 
nomenclature in the literature as well as discovery of new GSTs, there is a 
continuous effort to update the nomenclature of human soluble GSTs by 
researchers around the world (189). 
 
To avoid any confusion, for this thesis, a prefix ‘r’ followed by Gstm (capital ‘G’, 
lower case ‘stm’) i.e. rGstm, is used to describe the rat Gstm isoform. A prefix ‘h’ 
followed by GSTM (all capital letters) i.e. hGSTM, is used to describe human 
GSTM isoform. The hGSTM1 null allele will be described as hGSTM1*0. When 
referring to genes, italics is used. When referring to the gene family in either rat of 
human, rGstm and hGSTM will be used, respectively. When referring to either rat 
or human version of gene or protein, GSTM is used instead. A rat Gstm gene 
described as similar to GSTM7-7 in the NCBI database will be referred to as 
rGstm7. A predicted rat Gstm gene described as Gstm6_predicted in the NCBI 
database will be referred to as rGstm6a. A second predicted gene described as 
similar to Gstm6 protein will be referred to as rGstm6b. As the enzyme isoforms 
 are not studied as dimeric proteins but as individual subunits, the proteins will be 
referred to as GSTM1 and so on. 
 
1.5.3.2. Glutathione S-Transferase μ Class 
 
There are five members in the GSTM class in human and possibly eight in the rat. 
Each GSTM gene consists of 8 exons and 7 introns. The sequences of these 
genes and their encoded amino acid sequences are highly homologous, 
suggesting gene duplication in the evolution of the GSTM genes.  
 
The 155kb cluster of rat Gstm locus is located to chromosome 2q34, in the order 
of M7-M1-M2-M4-M6b-M3-M6a, followed by M5 in an inverted orientation (Figure 
1.12A). It should be noted that rGstm6a, rGstm6b and rGstm7 have only been 
identified and named within the past two years. There are no published studies 
involving these three genes to-date. There is extensive literature on the 
biochemistry of rat GSTs as well as their roles as phase II detoxification enzymes. 
With the recent identification of new GST classes and members of the earlier 
known classes, results from literature, pre-dating the late 1990s and probably the 
early 2000s, should be interpreted with caution. The rGstm1 has been identified as 
a positional and functional candidate gene for hypertension by our group (61). 
There are also data on differential expression of this gene in other hypertensive rat 
strains as compared to normotensive reference strains (65;66) but there have 
been very few follow up studies until now. 
 
Similarly the 85kb cluster of human GSTM locus is situated on chromosome 
1p13.3 (190;191), in the order M4-M2-M1-M5 followed by M3 in an inverted 
orientation (Figure 1.12A) (192). The hGSTM3 gene is most distantly related to 
others and the hGSTM3 subunit is also structurally distinct from the other GSTM 
with 4 residue extensions at N–terminus and 3 residue extensions at C–terminus 
(193). Early work on hGSTM shows that in the hGSTM1 gene alone, reported 
polymorphisms include a single base change giving rise to the functionally 
identical hGSTM1*A and hGSTM1*B alleles (194); a duplication of the hGSTM1 
gene (195); and deletion of the hGSTM1 gene resulting in the hGSTM1 null allele 
(hGSTM1*0) (Figure 1.12B) (196;197). Numerous studies have demonstrated 
weak associations between the hGSTM1*0 polymorphism with an increased risk to 
  
Figure 1.12: Organisation of the glutathione s-transferase mu genes in human and 
rat 
(A) Synteny between rat Gstm gene cluster on chromosome 2 and human GSTM gene 
cluster on chromosome 1. The names in brackets are the alternate names for the 
respective genes in earlier literature. AMPD2, adenosine monophosphate deaminase 2; 
EPS8L3, epidermal growth factor receptor pathway substrate 8-like protein 3; GSTs, 
glutathione S-transferase;  
(B) Organisation hGSTM genes in individuals missing hGSTM1 gene.  
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 various epoxide induced cancers (198;199). The hGSTM1*0 polymorphism has 
also been associated with increased cardiovascular risk (200-203). An alternative 
non-functional splice variant of hGSTM1 also exists. A polymorphism in the 
hGSTM3 gene consisting of two alleles, hGSTM3*A and hGSTM3*B, is 
distinguished by a three base pair deletion in intron 6 (204). The hGSTM3*B has 
been associated with altered expression levels of hGSTM3-3 and, in linkage with 
the hGSTM1*A allele, has been shown to reduce the risk of developing epoxide 
induced cancers (204;205). In hGSTM4, two alternatively spliced, non-functional 
transcripts have been identified (206). A recent study described many more 
polymorphisms in the hGSTM genes (207) but in this thesis, the polymorphisms in 
the hGSTM genes are not the main focus.  
 
There are no readily available isoform-specific antibodies against each of the 
GSTM isoforms, and probably due to unavailable substrate specificities between 
the GST classes, and isoform within a GST class, most studies measured GST 
expression and activities as a class rather than as individual isoforms (208-212). 
Any known enzyme activities previously attributed to any one rGstm isoform might 
also include the activities of the recently identified rGstm members. When the 
activities of the isoforms were measured, it is often not all the isoforms of a GST 
class that were investigated (213-215). When such studies were done, the results 
showed that the substrates specificities were not mutually exclusive; but rather the 
different isoforms have different affinities for the same substrates.  
 AIMS 
 
We hypothesise that oxidative stress-related genes and their functional 
polymorphisms influence the risk of developing hypertension and thus coronary 
artery disease. Previous gene expression profiling combined with congenic 
strategies identified rGstm1 as a positional and functional candidate gene for 
blood pressure regulation (61;219). However, rGstm1 is one of eight members of 
the rGstm family of genes that actively provide a second line of defence against 
oxidative stress. We hypothesise that the Gstm gene family are important anti-
oxidant enzymes that help to regulate the balance of ROS and NO in the kidney as 
well as vasculature. There is also no consensus of which human GSTM is a true 
orthologue of rat Gstm1. It will be of interest to find the human orthologue of 
rGstm1, to determine if there is also differential expression of hGSTM genes and 
proteins in human vasculature. As CVD are polymorphic diseases, there is also a 
need to determine if the reduced renal rGstm1 expression in SHRSP is a 
secondary effect of increased blood pressure or play a primary functional role in 
pathogenesis of hypertension. Human GSTM1*0 polymorphisms and 
polymorphisms in oxidative stress related enzymes are often associated with CVD. 
It if likely that each polymorphism impart small effects that add up to regulate the 
balance of ROS and NO. 
 
The aims of this study are : 
(1) To characterise the vascular and renal expression of the rat Gstm genes as 
well as human GSTM genes in vascular tissues.  
(2) To investigate the functional role of rGstm genes in the major sites of action 
for blood pressure regulation – vessel and kidney – different classes of 
antihypertensive drug treatments will be used to evaluate the oxidative stress 
status and gene expression of rGstm genes.  
(3) To establish if functional polymorphisms in two key enzymes involved in ROS 
and NO balance are associated with CAD as single polymorphism and as 
haplotypes. 
 
 CHAPTER 2:  MATERIALS & METHODS 
 
The details for all the equipments, chemicals, reagents and consumables used in 
this study are listed in Appendix B. 
 
2.1. Animal Strains 
 
The animal strains used in this thesis are WKYGla, SHRSPGla and a chromosome 2 
congenic strain (SP.WKYGla2c*). All animals were housed under controlled 
environmental conditions, where the temperature was maintained at 21°C, 12 hour 
light/dark cycles were from 7am to 7pm and the rats were fed standard rat chow 
(rat and mouse No.1 maintenance diet, Special Diet Services) and water provided 
ad libitum. The offspring were weaned after 3 weeks of age when they were 
sexed, ear-tagged (National Band and Tag Co.) and caged (maximum 3 animals 
per cage) according to sibling group and sex. 
 
Work with experimental animals was in accordance with the Animals Scientific 
Procedures Act 1986 under the project license held by Prof. A.F. Dominiczak. 
Inbred colonies of the SHRSP and WKY strains have been maintained in Glasgow 
by brother-sister mating since 1991, when 6 males and 7 females of each strain 
were given as a gift by Dr. D.F. Bohr from the Department of Physiology at the 
University of Michigan, USA. These colonies originated from National Institutes of 
Health, Bethesda, USA and were subsequently maintained as inbred colonies for 
over 15 years at the University of Michigan (219). Maintenance of the integrity of 
the colonies as well as the hypertensive and normotensive phenotypes was 
undertaken by selection of SHRSP adult breeders with blood pressures 170-190 
mmHg (males) and 140-170 mmHg (females), and WKY adult breeders of 120-
140 mmHg (males) and 100-130 mmHg (females). Routine microsatellite 
screening was used to confirm homozygosity of all loci within a group of animals 
from each strain, selected at random.  
 
2.1.1. Congenic breeding strategy 
 
The congenic SP.WKYGla2c* strain was produced and published by the group 
using a marker-assisted “speed” congenic strategy (Figure 1.4), prior to the 
 beginning of this project (219). The congenic strain used in the present study 
contains a 22-cM segment transferred from WKY (donor strain) to the genetic 
background of SHRSP (recipient strain). The nomenclature of the strains consists 
of the first abbreviation belonging to the recipient strain and the second to the 
donor: Gla denotes that strains originate from the Glasgow colonies, and the 
number 2 refers to rat chromosome 2. Thus, the congenic strain described is the 
SP.WKYGla2 (D2Wox9-D2Mgh12) and is abbreviated to SP.WKYGla2c* for 
simplicity (Figure 1.5). Five backcrosses were required to produce the congenic 
strain with no detectable heterozygosity of background markers. The 
SP.WKYGla2c* strain incorporated only the lower blood pressure QTL on rat 
chromosome 2. 
 
Genomic DNA was isolated from a 4-mm tip from the tail of congenic animals and 
genotyping as described previously. Genotyping was performed by polymerase 
chain reaction (PCR) amplification of microsatellite markers, and the genotypic 
results obtained were mapped relative to each other using the MAPMAKER/ EXP 
3.0 computer package with an error-detection procedure (220). A genetic linkage 
map of rat chromosome 2 was constructed, consisting of 74 microsatellite markers 
(polymorphic between the WKY and SHRSP strains) by genotyping F2 animals. 
Genetic distances were calculated with the Haldane mapping function. PCR was 
performed using the rat genome T55 radiation hybrid (RH) panel obtained from 
Research Genetics. Of the 74 markers scored, 55 were accurately positioned on 
the RH map of rat chromosome 2. The markers covered a distance of 1224 
centiRays and were all placed with a logarithm of odds ratio (LOD) 10, which 
equates to 1010 odds for linkage. Scored consensus data were submitted to the 
RHMAPPER program (http://rgd.mcw.edu/RHMAPSERVER/).  
 
2.1.2. Blood Pressure Measurement by Tail-Cuff Plethysmography  
 
Systolic blood pressure was measured by tail-cuff plethysmography in conscious, 
restrained animals as previously described (221). Rats were placed in a 37°C 
incubation chamber for 15-20min to allow vasodilation, wrapped in a cloth for 
restrain purposes, and an inflatable cuff placed on their tail along with a 
piezoceramic transducer (Hartmann & Braun type 2) for pulse direction. The 
pressure in the cuff could be controlled in 1mmHg steps over a 300mmHg range 
 and the resulting pulsation detected by the transducer was amplified and filtered 
before being displayed on computer using IBM compatible software. This signal 
was visualised as a function of pressure and an estimation of the systolic pressure 
was marked. A minimum of six readings were taken for each rat per sitting and the 
average was taken for the systolic blood pressure value for that animal.  
 
2.2. Rat Tissues 
 
Rat tissues freshly removed form rats under deep terminal anaesthesia 
(halothane), for total RNA and protein extraction, were immediately snapped 
frozen in liquid nitrogen. 
 
2.2.1. Preparation of Rat Tissues for Cryosections 
 
A small cup was made using aluminium foil over the base of a Bijoux container 
and filled with optimal cutting temperature (O.C.T.) compound. Vascular tissues 
(e.g. carotid arteries, aorta) were cleaned of the surrounding connective tissues, 
slowly inserted into the compound, kept upright and placed on top of dry ice to 
freeze the specimens in the O.C.T. compound. Sterile pipette tips were used to 
hold the vessel upright when necessary. The frozen tissue blocks were then kept 
at -70°C until required. Transverse cross-section of a kidney from the each rat was 
cut and the kidney was then embedded (cut surface facing the bottom of the well) 
in the O.C.T compound. 6-10μm thick sections were cut using the Thermo cryostat 
and thaw-mounted on RNase-free silanised slides. The slides were then kept at -
70°C until required. 
 
2.2.2. Preparation of Rat Tissues for Paraffin Sections 
 
The tissues were rinsed with PBS to remove excess blood and the connective 
tissue surrounding vascular tissues were removed. The tissues were then fixed in 
10% formalin solution overnight or 1hr for carotid arteries (CA) at room 
temperature (RT), after which the formalin solution was replaced with PBS. The 
fixed samples were later embedded into paraffin blocks by trained technical staff in 
the laboratory. Paraffin sections of 6μm thickness were cut and baked onto 
silanised slides at 60°C for 3hr followed by 40°C overnight. Both the paraffin 
 blocks and paraffin sections were then kept at RT in appropriate boxes. For 
kidney, transverse cross-sections were used. 
 
2.2.2.1. Silanisation of Microscope Slides 
 
The microscope slides were first placed in racks and immersed in a trough of 
distilled water (dH2O) containing 0.1% diethylpyrocarbonate (DEPC) to deactivate 
RNases in fume cupboard for 1hr at RT. Excess water were drained and the racks 
were then wrapped in foil and autoclaved. The autoclaved slides were then coated 
in freshly prepared 2% solution of 3-aminopropyltriethoxysilane (APES) in dry 
acetone for 5s, in a fume hood. The slides were then rinsed once in dry acetone 
for 5s and twice in DEPC- treated dH2O (DEPC-dH2O) for 5min each. The slides 
were then wrapped in foil, sealed and dried overnight at 42°C and stored until 
required. Slides used for immunohistochemistry (IHC) did not require treatment 
with DEPC-dH2O or be wrapped in foil. 
 
2.3. Human Tissues 
 
2.3.1. Vascular Tissues from Clinical Patients 
 
The study was approved by the local ethics committee, and all of the patients gave 
written informed consent. Freshly collected saphenous veins (SVs) and internal 
mammary arteries (IMAs), from patients undergoing CABG operation were 
collected in sterile saline solution by the surgical team at Western Infirmary, and 
control veins (VVs), from patients undergoing varicosed vein removal, by the 
surgical team at the Gartnavel Hospital in Glasgow. 
 
2.3.2. Handling of Vascular Tissues 
 
Vessels were trimmed of connective tissues and transferred into Bijoux containers 
containing RNAlater® solution. Any sections of control veins that were varicosed 
were discarded. The samples were kept at -20°C until further use.  
 
 2.3.3. Preparation of Vascular Tissues for Cryosections 
 
When sufficient tissues was available, cryosections of human internal mammary 
arteries, saphenous veins and varicose veins were prepared as described in 
section 2.2.1. 
 
2.3.4. Preparation of Vascular Tissues for Paraffin Sections 
 
Paraffin sections were prepared as described in section 2.2.2. 
 
2.4. General Molecular Biology 
 
The water used in molecular biology work is distilled water (dH2O) that has been 
autoclaved, and are referred to as sterile dH2O (sdH2O). Any experiments 
involving RNA used autoclaved DEPC-treated dH2O (DEPC-dH2O). All plasticware 
or glassware used for RNA work were pre-soaked in 0.1% DEPC water for at least 
2hr at RT (in fume hood) and then autoclaved. Glassware used for in situ 
hybridisation (ISH) in Edinburgh was baked at 180°C for at least 8hrs. Filtered 
RNase-free tips were used in all RNA work. 
 
2.4.1. DNA Extraction 
 
Approximately 0.5cm of human vessels were minced briefly with sterile blades and 
placed into Eppendorf tubes containing 500μl of DNA extraction solution 
containing a final concentration of 50mM of Tris pH 8.0, 100mM EDTA pH 8.0, 
100mM NaCl, 1% SDS and 0.5mg/ml Proteinase K. The samples were incubated 
at 55°C overnight. The entire solution was transferred to a pre-spun Eppendorf 
Phase Lock Gel heavy (PLG-H) tube and 500μl of phenol:chloroform:isoamyl 
alcohol (25:24:1) was added and mixed by gentle inversion. The tubes were 
centrifuged at 14,000rpm for 5min. The aqueous phase was transferred to a fresh 
pre-spun PLG-H tube, 500μl of chloroform:isoamyl alcohol added and mixed by 
gentle inversion. The tubes were centrifuged at 14,000rpm for 5min and the 
aqueous phase transferred to a fresh Eppendorf tubes. 100μl pf 10M ammonium 
acetate (NH4OAc) and 500μl of ice cold 100% ethanol were added and mixed 
gently. The tubes were then centrifuged 10,000rpm for 2min. The ethanol was 
 decanted with care taken to avoid disrupting the DNA pellet. 500μl of ice cold 70% 
ethanol was added to the pellet, mixed gently and the tubes centrifuged at 
10,000rpm for 2min. The ethanol was again decanted with care and excess 
ethanol drained onto a clean paper towel. The samples were air-dried in a rack at 
4°C for 15min to remove residual ethanol. The DNA pellet was dissolved in 100μl 
of sdH2O and quantified. The DNA was diluted to a working concentration of 
5ng/μl.  
 
2.4.2. DNA Purification 
 
If the concentrations of the extracted samples were too diluted or contaminated 
with lipids, the samples were purified and reconstituted in smaller volume of 1X 
Tris/EDTA (TE) buffer (10mM Tris, 5mM ethylenediaminetetraacetic acid (EDTA)). 
40μl of 3M sodium acetate (NaOAc) was added to the DNA sample and the total 
volume was made up to 400μl with 1X TE buffer. 800μl of ice-cold 100% ethanol 
was added to the sample. The sample was then incubated at –20°C overnight. 
The sample was then centrifuged at 14,000 rpm for 2min and the supernatant 
discarded carefully without disturbing the DNA pellet. 1ml of 70% ethanol was 
added to the pellet and mixed gently. The sample was then centrifuged at 
14,000rpm for 2min and the supernatant discarded carefully without disturbing the 
DNA pellet. The pellet was then air-dried at 4°C and re-suspended in 1X TE. The 
concentration of the sample was then re-quantified. 
 
2.4.3. Nucleic Acid Quantitation 
 
The RNA samples were quantified using RiboGreen™ RNA Quantitation Reagent 
and Kit while DNA samples were quantified using PicoGreen™ dsDNA 
Quantitation Kit according to the manufacturer’s instructions. The plate was read 
using the Wallac 1420 Victor machine.  
 
The samples for real-time RT-PCR were quantified with a method that is 
technologically more advanced, less time-consuming and requires less sample. 
1μl of the RNA/DNA samples was quantified using the NanoDrop ND-1000 
spectrophotometer and the programme ND-1000 v3.1.0 
 
 2.4.4. Polymerase Chain Reaction (PCR) 
 
The genes of interest were amplified by polymerase chain reaction (PCR) set up in 
a PCR plate with 2μl of template cDNA, 1.5mM MgCl2, 1X Mg-free buffer (10mM 
TrisHCl pH 9, 25mM KCl and 0.1% Triton-X-100), 1μl 10mM forward primers, 1μl 
10mM reverse primers, 3.2μl 1.25mM dNTPs, 0.2μl Taq DNA polymerase (5U/ml) 
and made up with sdH2O to a final volume of 20μl. The PCR reactions were run on 
the Peltier Thermal Cycler (PTC-225). 5μl of the PCR reactions were then 
electrophoresed with 1μl of 6X loading dye in a 2% agarose gel at 100V for 1hr, 
alongside 100bp DNA ladder. 
 
2.4.5. Restriction Fragment Length Polymorphism (RFLP) 
 
The PCR products of the genes of interest were digested with restriction enzymes 
(RE) at the appropriate temperature for 2hr. A typical reaction was set up with 15μl 
PCR products, 1u/μl RE and 1X RE buffer and made up to 20μl with sdH2O. The 
digested reactions were then run in a 2% agarose gel at 100V for 1hr, alongside 
the 100bp DNA ladder. For fragments between 10 – 150bp, the digested reactions 
were run in 3.5% Metaphor agarose gel, alongside pUC18 Msp I digest DNA 
ladder. 
 
2.4.6. Sequencing 
 
For PCR products of longer than 200bp, the products were cleaned using the 
Nucleofast 96 PCR plate according to the manufacturer’s instructions. The 
cleaned PCR products were then re-solubilised in 50µl of sdH2O. For PCR 
products 200bp or shorter, the products were cleaned using the microCLEAN 
reagent according to the manufacturer’s instructions. Pellets of PCR products 
were then re-solubilised in 15μl of sdH2O. 5µl of cleaned PCR products were 
electrophoresed in a 1.5% agarose gel to check for the efficacy of the cleaning 
procedure.  
 
Two sequencing reactions were set up for each sample, each containing a final 
concentration of 3.2µM of forward or reverse primer, 0.5µl of Big Dye® Terminator 
 v3.1 Cycle sequencing kit, 0.875X sequencing buffer, 4-8µl of cleaned PCR 
product and sdH2O to a final volume of 20µl. The reactions were sequenced at 
96°C for 45s, 50°C for 25s and 60°C for 4min for 25 cycles. The sequencing 
reactions were cleaned using the genCLEAN DYE Terminator Removal plate 
according to the manufacturer’s instructions. 7µl of the cleaned sequencing 
reaction were mixed with 10µl of formamide in a bar-coded plate and analysed on 
the Applied Biosystems 3730 DNA analyser and Seqscape v2.5 software.  
 
2.5. mRNA Expression 
 
The following two methods were used for total RNA extraction. The second 
method was used later on in the project due to improvement of technology, which 
gives better quality than the first method. 
 
2.5.1. Total RNA Extraction 
 
2.5.1.1. Total RNA Extraction using RNA Bee 
 
Frozen tissue samples (0.5cm to 1cm) were homogenised completely in 2ml of 
ice-cold RNA Bee in a Bijoux container using a Polytron. 200μl of chloroform was 
added to the samples and mixed by brief vortexing. The homogenates of each 
sample were transferred into 2 labelled pre-spun 1.5ml PLG-H tubes and placed 
on ice for 5min. The PLG-H tubes were centrifuged at 12,000rpm at 4°C for 15min 
in a pre-cooled centrifuge. The top aqueous layers of both PLG-H tubes were 
transferred into 1 labelled 2ml Eppendorf tube. An equal volume of isopropanol 
(~1ml) were added to the samples and mixed by brief vortexing. The samples 
were centrifuged at 12,000rpm at 4°C for 15min. The supernatants were removed 
carefully without disturbing the pellet. 1ml of 70% ethanol in DEPC-dH2O was 
added to the samples and vortexed briefly. The tubes were centrifuged at 
10,000rpm at 4°C for 10min. The supernatants were removed carefully and the 
RNA pellets were air-dried at 4°C, covered with a clean paper towel. The pellets 
were then re-suspended in 100μl of DEPC-dH2O. The RNA samples were then 
quantified as described in section 2.4.3. and 1μl of the sample was diluted to a 
final concentration of 100-500ng/μl and integrity of the extracted RNA checked on 
the Agilent at MBSU, University of Glasgow. 
 2.5.1.2. Total RNA Extraction using Qiagen RNeasy Kits 
 
The total RNA from samples was extracted using Qiagen RNeasy kits accordingly 
to the manufacturer’s recommended instructions for fibrous tissues (Appendix C of 
RNeasy Handbooks) with the following exceptions. The columns were left to stand 
at RT for 5min instead of 1min to elute the clean total RNA. The first eluate was 
pipetted back onto the membrane in the columns and left to stand for another 
1min. The resulting eluate was then quantified as described in section 2.4.3., 1μl 
of each samples was diluted to a final concentration of 100-500ng/μl and integrity 
of the extracted RNA checked on the Agilent. 
 
2.5.2. DNase Treatment of Extracted Total RNA 
 
The following two methods were used for DNase treatment of total RNA. The 
second method was used in later experiments due to improvement of technology, 
which gives better retrieval of total RNA or equivalent quality. 
 
2.5.2.1. DNase Treatment using RQ1 DNase 
 
The RNA samples extracted were treated using RQ1 RNase-free DNase before 
further experiments. For each RNA samples, a reaction were set up with 1X RQ1 
buffer, total RNA and RQ1 DNase (1u/μl) to a concentration of 1u/μg RNA and 
DEPC-dH2O to a final volume of 100μl if necessary. The samples were incubated 
at 37°C for 1hr. 100μl of phenol were added to the samples, vortexed for 15s and 
centrifuged at 14,000rpm at 4°C for 5min. The top layer were transferred to a new 
Eppendorf tube, 100μl of phenol:chloroform (1:1) were added to the samples, 
vortexed for 15s and centrifuged at 14,000rpm at 4°C for 5min. The top layer were 
transferred to another new Eppendorf tube, 100μl of chloroform were added to the 
samples, vortexed for 15s and centrifuged at 14,000rpm at 4°C for 5min. To each 
sample, 10μl of 3M NaOAc and 300μl of ice-cold 100% ethanol were added and 
placed in –20°C overnight. On the following day, the samples were centrifuged at 
14,000rpm at 4°C for 5min and the supernatant discarded. 300μl of 70% ethanol in 
DEPC-dH2O was added to the samples, vortexed briefly and centrifuged at 
14,000rpm at 4°C for 5min. The supernatants were removed carefully and the 
 RNA pellets were air-dried at 4°C, covered with a clean paper towel. The pellets 
were then re-suspended in appropriate volume of DEPC-dH2O, depending on the 
amount of starting total RNA used for the treatment. 
 
2.5.2.2. DNase Treatment using DNA-free™ kit 
 
Alternatively, extracted total RNA was treated with DNase using the DNA-free™ kit 
from Ambion. RNA aliquot of up to 50μg or 44μl was transferred to RNase-free 
tube containing 5μl of 10X buffer and 1μl of DNase I and incubated at 37°C for 20-
30min. After incubation, 5μl of inactivation reagent was added to the tubes and left 
at RT for 2min and centrifuged at 12,000rpm for 2min at 4°C. The supernatant 
containing the cleaned total RNA was then transferred into new tubes. The RNA 
samples were then re-quantified, 1ug aliquoted into fresh tubes for reverse 
transcription reaction and the remaining samples stored at –70°C. 
 
2.5.3. Reverse Transcription (RT) – PCR 
 
All RT-PCR experiments were carried out in a two-step protocol. The Reverse 
Transcription system from Promega was used to obtain cDNA from commercial 
and patients' total RNA samples. 1 μg of DNase-treated total RNA for each sample 
was incubated at 70°C for 10min, spun briefly and placed on ice for 5min. The 
RNA samples were reverse transcribed to cDNA in a 20μl reaction containing a 
final concentration of 5mM of MgCl2, 1X RT buffer, 1mM of dNTP mixture, 1u/μl of 
RNasin, 15u of AMV reverse transcriptase and 0.5μg of random primers. A few 
selected samples were used for negative control cDNA reactions without AMV 
reverse transcriptase. The reverse transcription reactions were carried out at 42°C 
for 1hr. The reactions were stopped by incubating the samples at 99°C for 5min 
and then placed on ice for 5min. The samples were diluted to a final volume of 
100μl. When not used immediately, the samples were stored at –20°C.  
 
The genes of interest were amplified by PCR, using specific primers as described 
in section 2.4.4. The PCR products of the genes of interest obtained were cleaned 
and sequenced as described in section 2.4.6., to confirm the identity of the 
amplicons. 
 
 2.5.4. Real-time RT-PCR 
 
Initial experiments was performed using the first method (Lightcycler) but due to 
limited number of samples that could be done in each experimental run, later 
experiments (which contained much larger sample size) were performed using the 
second method (Taqman).  
 
2.5.4.1. Real-time RT-PCR using Lightcycler™ 
 
Real-time RT-PCR quantitation of the samples was carried out in a two-step RT-
PCR assay. The reactions were prepared using the LightCycler™ DNA Master 
SYBR Green I kit. Each reaction consists of 2μl of cDNA sample, 2μl of SYBR 
master mix, 4mM MgCl2, 0.5μM sense primer, 0.5μM antisense primer in a 20μl 
reaction. The real-time RT-PCR reaction was carried out at 95°C for 60sec, 35 
cycles of 95°C for 3sec, annealing temperature for 15sec, 72°C for 10sec and 
80°C-83°C for signal acquisition, continuous acquisition of signal during melting 
curves of samples from 99°C to 40°C. The melting curves were used to assess the 
quality of each run. A standard curve of purified RT-PCR products was included in 
each assay for the calculation of absolute number of template copies. The gene of 
interest was expressed as a percentage of β-actin.  
 
An optimisation RT-PCR and an efficiency assay was performed for each gene 
prior to real-time RT-PCR experiments. The optimisation PCR was set up in 
duplicates, with each reaction capillary set up and carried out as described above, 
with the exception of annealing temperature of 50°C to 65°C. The efficiency assay 
involved setting up seven serial dilutions of a random sample and the dilutions 
were plotted against the crossing points. The results were acceptable is the 
calculated r is >0.9.  
 
2.5.4.2. Real-time RT-PCR using Taqman 
 
Relative real-time RT-PCR quantitation of the samples was carried out in a two-
step RT-PCR assay using the Taqman Gene Expression Assays from Applied 
Biosystems in a multiplex reaction (if the gene of interest and β-actin reacts with 
the same efficiency). Each reaction consists of 2.5μl of Taqman Universal PCR 
 Master Mix, 1X VIC-labelled β-actin probe, 1X FAM-labelled probe for genes of 
interest and 2μl of cDNA in a final volume of 5μl, in barcoded 384-well plate. For 
genes of interest that do not run with the same efficiency as β-actin, the gene of 
interest was run in a singleplex reaction within the same plate as β-actin. The ∆∆Ct 
comparative method was used for the relative quantitation of gene expression, 
normalised to β-actin according to manufacturer’s instructions (ABI PRISM 7700 
Sequence Detection System User Bulletin #2) 
 
An efficiency assay was performed for each gene of interest in various tissues 
prior to real-time RT-PCR experiments. A serial dilution of a random sample was 
set up in singleplex or multiplex reactions as described above. The slope as 
calculated according to manufacturer’s instructions (ABI PRISM 7700 Sequence 
Detection System User Bulletin #2) was considered to be valid if the absolute 
value was < 0.1. 
 
2.5.5. Establishment of RT-PCR Product Identity 
 
The RT-PCR product identities were confirmed using RFLP (as described in 
section 2.4.5.) and/or direct sequencing (section 2.4.6.). The digested fragments 
were electrophoresed in 2.5% agarose at 100V for 1hr 20min. 
 
2.6. mRNA Localisation 
 
2.6.1. Preparation of Cryosections 
 
The frozen sections were cut to 6-10μm thickness and thaw-mounted on RNase-
free silanised slides. The slides were then kept at –70°C until required. 
 
2.6.2. In Situ Hybridisation using 35S-riboprobes 
 
The majority of ISH experiments were carried out in the Department of Molecular 
Genetics, in Western General Hospital in Edinburgh. The last batch of slides were 
dipped at the Yoshitomi Research Institute of Neuroscience Glasgow (YRING) 
with help from Dr Susan Cochran. 
 
 2.6.2.1. Preparation of Riboprobes 
 
The templates used for generating the RNA probes were obtained by two PCR 
reactions. The first PCR amplified the gene of interest from several cDNA samples 
in a 20μl PCR reaction containing a final concentration of 1.5mM MgCl2, 1X buffer, 
1X Q-solution, 0.2mM dNTPs, 0.5μM of each primer, 0.01u/μl of Qiagen HotStar 
Taq polymerase and 2μl of cDNA for hGSTM and rGstm; or 1μl of cDNA for 
ACTA2. The PCR reaction was set at 95°C for 15min followed by 35 cycles of 
95°C for 1min, 62°C for 90 sec, 72°C for 2min, followed by 72°C for 10min and 
finally 60°C for 20min. The PCR products were then cleaned and sequenced to 
check the specificity of the PCR reaction. The specific cleaned PCR products were 
pooled.  
 
A second nested PCR was performed on the first cleaned PCR products using 
primers with integrated binding sites for T3 and T7 RNA polymerase. The nested 
PCR consists of a 20μl PCR reaction containing a final concentration of 1.5mM 
MgCl2, 1X buffer, 1X Q-solution, 0.2mM dNTPs, 0.5μM of each primer, 0.01u/μl of 
Qiagen HotStar Taq polymerase and 2μl of 1/100 dilution of the pooled 1st PCR. 
The PCR reaction was set at 95°C for 15min followed by 4 cycles of 95°C for 
1min, 62°C for 90 sec, 72°C for 2min, followed by 29 cycles of 95°C for 1min, 72°C 
for 2min, and finally 72°C for 10min and 60°C for 20min. The nested PCR 
reactions were checked by electrophoresis in 1% agarose gel, cleaned as 
described in section 2.4.6. and quantified as described in section 2.4.3. If required 
the samples were concentrated by incubating at 50°C for 10-20min.  
 
Two reaction mixtures were prepared for each probe, containing a final 
concentration of 0.9X Transcription buffer, 8.9mM of dithiothreitol (freshly 
prepared), 5.3U of RNasin, 0.3mM rNTPs (ATP, CTP and GTP), 1.85mBeq 35S-
UTP, 5U of T3 RNA polymerase for sense probes or T7 RNA polymerase for 
antisense probes and at least 200ng of PCR template. The reactions were 
incubated at 37°C for 90min, after which 1μl of RNase-free DNase was added to 
each reaction, mixed gently and incubated at 37°C for 10min. The probes were 
then purified through Nick™ columns in 400μl of 1X TE buffer, pH 8.0. The amount 
of radioactive-labelled probe was quantified by counting 1μl of purified probe in 
 1ml of scintillation fluid in a beta-counter. The probes were then frozen at -20°C 
until required. The probes were never kept for more than 1 month before use in 
experiments. 
 
2.6.2.2. Pre treatment of Tissue  
 
The frozen sections were removed from the freezer and fixed immediately in a 
fume hood, in freshly prepared cold 4% paraformaldehyde in 0.1M phosphate 
buffer for 10min, washed in PBS for 5min twice. This was followed by acetylation 
of positively-charged amino groups in 0.1M triethanolamine containing 0.25% of 
acetic anhydride (added prior to transfer of slides, mixed by agitating rack in 
solution) for 10min. The slides were then washed in PBS for 3min and dehydrated 
in 70% ethanol for 2min, 80% ethanol for 2min and 95% ethanol for 2min. Each 
solution was changed after 2 racks, except for triethanolamine which was replaced 
after each rack of slides. The slides were allowed to dry briefly before pre-
hybridisation. 
 
2.6.2.3. Prehybridisation 
 
The sections on each slide were covered with 200μl of prehybridisation buffer 
containing 1:1 (RNase-free deionised formamide: 2X prehybridisation buffer) and 
any bubbles were removed. The slides were then incubated in a humid box lined 
with two pieces of Whatman 3M filter paper soaked in box buffer (4X SSC, 50% 
deionised formamide) at 50°C for 3hr. 
 
2.6.2.4. Hybridisation 
 
Hybridisation solution containing 50% RNase-free deionised formamide and 
probes of 107 counts/ml were prepared for each probe and 2X hybridisation buffer 
was used to make up to the final volume of the hybridisation mix required for each 
probe. The hybridisation solution were mixed well and incubated at 75°C for 10min 
and cooled on ice for 10min. Next, 10μl of 1M dithiothreitol was added for every ml 
of hybridisation mix, mixed well and placed on ice. The prehybridisation buffer was 
drained from the slides onto tissue (2-3 slides at a time to avoid excess drying of 
slides). Lens tissues were used to wipe around the sections to remove excess 
 prehybridisation buffer (one slide at a time). 200μl of the appropriate hybridisation 
mix was then added to each slide (remove any bubbles), covering the sections 
and returned to humid box. Care was taken to ensure each humid box has 
sufficient box buffer (damp but not soaking). The boxes were sealed with 
autoclave tape and incubated at 50°C for 14-16hr. 
 
2.6.2.5. RNase Treatment and Washes 
 
The hybridisation mix was drained onto the filter paper in the box and slides were 
transferred into slide racks and washed in 2X SSC for 5min thrice. The slides were 
kept in the last wash before the RNase buffer was added. RNase buffer was 
prepared by adding 3μl of 10μg/ml RNase A per ml of RNase box buffer (0.5M 
NaCl, 0.01M Tris pH 7.5 and 1mM EDTA). The slides (2-3 at a time) were drained 
onto tissues and excess SSC was wiped off using lens tissue and 200μl of RNase 
buffer was added to the slides, covering the sections (remove any bubbles). The 
slides were then placed in the RNase humid boxes lined with one piece of 
Whatman 3M filter paper soaked in RNase box buffer. The slides were then 
incubated at 37°C for 1hr.  
 
The washes were carried out in Omnibaid in situ wash system. The slides were 
drained onto tissues as before, transferred to slide racks and placed into the first 
wash sleeve, containing 2X SSC, at RT for 1hr. The second wash was carried out 
in 0.1X SSC at 60°C for 1hr. For the third wash, the sleeve containing 0.1X SSC 
was pre-heated to 60°C. The slide rack was transferred from the second wash to 
the third wash, agitated up and down a few times and the third wash sleeve was 
removed and let stand in ambient rack for 1hr. The slides were then dehydrated by 
passing through 50% ethanol in ammonium acetate for 2min, 70% ethanol in 
ammonium acetate for 2min and 95% ethanol in ammonium acetate for 2min. The 
slides were then air-dried in the fume hood. When dried, the slides were placed 
against Kodak BioMax MR film in cassette. 
 
2.6.2.6. Slide Dipping 
 
While the experiments were carried out in Edinburgh, the slides were dipped by 
Dr. Michelle O’Reilly. The nuclear emulsion used was the Kodak NTB2. A Falcon 
 tube of dH2O and about 20ml of emulsion (sufficient for ~50 slides) in another 
Falcon tube were warmed in a 42°C water bath for 20min in the darkroom, 
alongside an empty slide mailer. The emulsion volume is measured briefly and an 
equivalent amount of the pre-warmed dH2O is added to the emulsion and mixed 
gently by rocking back and forth. The emulsion mixture was then poured into the 
pre-warmed slide mailer and left for about 20min in the water bath or until the 
bubbles dispersed. Each slide was then dipped evenly, inserted into alternate slide 
spaces of a black plastic rack on its side with the tissue side facing up and left to 
dry for 3-4hr. The slide box was then wrapped in tin foil and black bag, taped up, 
labelled and placed in the fridge for exposure (~5 times the length of time they 
were exposed to film for). When the dipped slides were ready for developing, the 
slide box was removed from the fridge and allowed to come to RT. The slides 
were brought through troughs of developer for 4min, water for 10sec, fixer for 5min 
and water for 5min, all solutions at 15°C. The slides were then left to dry for 1hr. 
Each trough of solutions was used for only two racks.  
 
For experiments where the slides were dipped in Glasgow, the slides were dipped 
in Ilford K5 nuclear emulsion (under the Kodak 6B/Ilford 905 filter). A Falcon tube 
of 0.5% glycerol in dH2O and the dipping chamber were pre-warmed in a 45°C 
water bath in the darkroom. About 20ml of emulsion was measured into another 
Falcon tube, the glycerol solution added to the emulsion and mixed well. The tube 
was then wrapped in aluminium foil and placed back in the water bath for 15-
30min. The emulsion mix was then filtered through damp muslin via a filter funnel 
into the pre-warmed dipping chamber. The slides were dipped evenly and left to 
dry in slide tray for 2-3hr. The slides were then stored in a slide box with silica gel, 
sealed, labelled and kept in fridge for exposure. For development, the slide boxes 
were taken out of the fridge and warmed to RT. The slides were transferred to a 
slide rack and brought through troughs of developer (D19) for 10min with 
occasional agitation, dH2O for 30sec with continuous agitation, fixer (30% sodium 
thiosulphate made up fresh on day of use) for 5min with occasional agitation and 
dH2O for 30min under continuous stream of running water. The developer and the 
first wash were changed after each rack of slides. 
 
The dipped slides were observed with dark field microscopy using equipment in 
either laboratory. The exposed films were scanned using Microtek Phantom 336 
 CX and the pictures obtained and adjusted using Adobe Photoshop 7.0 software. 
Adjustments include brightness and cropping of scanned pictures. 
 
2.6.2.7. Haematoxylin and Eosin Counter Stain 
 
The dipped and developed slides were counterstained with Mayer’s haematoxylin 
for 1min, washed with dH2O for 20sec and the nuclei blue colour development was 
done by bringing the sections through 0.03% ammonium hydroxide for 1min. The 
slides were washed in dH2O for 1min, followed by 70% ethanol for 1min and the 
cytoplasm was then stained with Eosin (solution Y) for 1min. The slides were then 
brought through 95% ethanol for 1min twice, 100% ethanol twice and Histoclear 
for 1min twice. The slides were dripped dry and cover slip-mounted with 
Histomount. The emulsion on the back of the slides was scrapped off with a 
scalpel blade before analysing the slides microscopically. 
 
The slides were viewed with bright field microscopy on the Olympus BX40 
microscope and pictures obtained using the Hitachi HV-C20A 3-CCD colour 
camera and Image Pro Plus version 5 software. The Adobe Photoshop 7.0 
software was used for subsequent adjustments, such as brightness and cropping. 
 
2.7. Protein Expression 
 
2.7.1. Protein Extraction 
 
Protein from tissues were extracted using the Ripa lysis buffer (150mM NaCl, 
0.05% Nonidet P-40 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 5mM EDTA, 
20mM TrisHCl pH 7.5). On the day of use, for every 10 ml of lysis buffer used, a 
tablet of Roche complete EDTA-free protease inhibitors cocktail was added. The 
samples were homogenised in the Ripa buffer (900μl of Ripa buffer for up to 0.3g 
tissue). The homogenates were made up to 1% NP-40 (add 100μl of 10% NP-40 
for every 900μl of Ripa buffer), vortexed hard and placed on ice for 5min. The 
samples were centrifuged at 14,000rpm for 10min at 4°C and the supernatant 
containing the proteins were transferred to new tubes and kept on ice. 5μl of the 
supernatant was removed for determining the protein concentration while the rest 
of the protein samples were stored at -70°C until needed.  
  
2.7.2. Protein Quantitation 
 
The protein concentrations were determined using Pierce BCA (bicinchoninic acid) 
protein assay kit, according to the manufacturer’s instructions. The bovine serum 
albumin (BSA) standard was diluted in 10X dilution of appropriate buffer while the 
samples were diluted 10X before quantitation. 
 
2.7.3. Dot blot 
 
1μl of recombinant protein samples diluted in PBS was spotted onto nitrocellulose 
membrane at the centre of appropriately labelled-grids (drawn with pencil). The 
protein spots were applied little by little to minimize the area that the solution 
penetrates. When the spots have dried, the membrane was blocked with 5% milk 
in PBS for 1hr at RT. The membrane was then incubated with primary antibody 
diluted in 5% milk/PBS for 1hr at RT. The membrane was then washed three times 
with PBS for 5min each. The membrane was then incubated with horse radish 
peroxidase (HRP)-conjugated secondary antibody diluted in 5% milk/PBS for 
30min at RT and washed three times with PBS for 5min each. The protein spots 
were detected with Amersham ECL detection system according to the 
manufacturer’s instructions and the signals developed on Hyperfilm. 
 
2.8. Protein Localisation 
 
The microscope slides were silanised as described in section 2.2.2.1., with the 
exception that the slides need not be soaked in DEPC-containing water, wrapped 
in foil and autoclaved. 
 
2.8.1. Immunohistochemistry (IHC)  
 
Total protein concentration of antisera and normal serum were determined as 
described in section 2.7.2. Dilutions of antisera and normal serum were made to 
contain equivalent amount of total protein. For antisera and antibodies without 
recommended dilution for IHC, serial dilutions of both antisera and negative 
controls were performed to determine the best dilution to use for IHC. 
 2.8.1.1. Pre-treatment of Sections 
 
Frozen sections were air dried for 1hr at RT, fixed in acetone for 10min, air dried 
for 10min and washed in PBS for 5min addition of blocking serum. The paraffin 
sections were deparaffinised and hydrated by bringing the slides through 
Histoclear for 7min twice, 100% ethanol for 7min, 95% ethanol for 7min, 70% 
ethanol for 7min and dH2O for 7min. Endogenous peroxidase activity was first 
quenched by incubating the slides in 0.3% H2O2 in methanol for 30min and 
washed in dH2O for 10min twice.  
 
2.8.1.2. Antigen Retrieval 
 
Antigen retrieval was performed when detection of cell surface antigen was 
required. A glass coplin jar or Pyrex glass beaker containing 0.01M citrate buffer 
pH 6.0 was heated to 95°C in a waterbath. The slides from previous step were 
then place into the coplin jar and incubated at 95°C for 15min. The slides were 
then washed with dH2O for 10min twice. 
 
2.8.1.3. Primary Antibody 
 
The sections were then blocked with 0.01% normal serum of the animal the 
secondary antibody was raised in (diluted in PBS) for 1hr, in humidified trays at 
RT. The blocking serum was drained off and the primary antibody or antisera at 
appropriate dilutions; or negative control immunoglobulins (Igs) or negative control 
serum in blocking solution was then added and incubated overnight in humidified 
trays. The sections were washed in PBS for 5min thrice.  
 
2.8.1.4. Secondary Antibody for IHC 
 
For primary antibodies or antisera raised in either rabbit or mouse, the Vectastain 
Elite ABC Universal kit was used. Biotinylated secondary antibody in 0.02% 
blocking serum/PBS was added and incubated for 30min in humidified trays. The 
sections were washed in PBS for 5min thrice. The Vectastain ABC reagent, pre-
incubated for 30min at RT, was added, incubated for 30min in humidified trays and 
washed in PBS for 5min thrice. For primary antibodies raised in other animals, 
 appropriate HRP-conjugated secondary antibody in 0.02% blocking serum/PBS 
was added and incubated for 1hr at RT. The sections were washed in PBS for 
5min thrice.  
 
2.8.1.5. Enzymatic Colour Development 
 
The Vector Lab DAB (3,3’-diaminobenzidine) substrate kit was used for colour 
development. The substrate (DAB) reagent was added, incubated for 5min in 
humidified trays and washed in dH2O for 5min. The sections were then 
counterstained with Harris’s modified haematoxylin and washed in running cold 
tap water for 5min for “blue” staining the nucleus. The sections were finally 
dehydrated by bringing the slides through 70% ethanol for 10min, 95% ethanol for 
10min, 100% ethanol for 10min and Histoclear for 10min twice. The slides were 
then cover slip-mounted with Histomount.  
 
2.8.2. Multiple Antigen IHC 
 
Sections were pre-treated as described in section 2.8.1.1. and antigen retrieval 
step was undertaken when required as described in section 2.8.1.2. 
 
2.8.2.1. First Antigen IHC 
 
The sections were blocked, primary antibody/antisera or the negative controls 
were added as described in section 2.8.1.3. Secondary antibodies were added as 
described in section 2.8.1.4. The Vector Lab DAB substrate kit was used for colour 
development. The substrate (DAB-Nickel) reagent was added, incubated for 5min 
in humidified trays and washed in dH2O for 5min. 
 
2.8.2.2. Second Antigen IHC 
 
Immediately following section 2.8.2.1, the sections were blocked and primary 
antibody/antisera or the negative controls added as described in section 2.8.1.3. 
Secondary antibodies were added as described in section 2.8.1.4. The Vector Lab 
DAB substrate kit was used for colour development. The substrate (DAB) reagent 
was added, incubated for 5min in humidified trays and washed in dH2O for 5min. 
 The sections were then counterstained, dehydrated and mounted as described in 
section 2.8.1.5. 
 
The slides were viewed with bright field microscopy on the Olympus BX40 
microscope and pictures obtained using the Hitachi HV-C20A 3-CCD colour 
camera and Image Pro Plus v5 software. The Adobe Photoshop 7.0 Professional 
software was used for subsequent adjustments, such as brightness and cropping. 
Changes to brightness settings were made only after the appropriate negative 
control pictures were added to the figures. 
 
 CHAPTER 3:  EXPRESSION AND LOCALISATION OF RAT AND HUMAN 
GLUTATHIONE S-TRANSFERASE μ ISOFORMS 
 
3.1. Introduction 
 
Previously, gene expression profiling combined with congenic strain construction 
by our group identified rGstm1 as a positional and functional candidate gene for 
blood pressure regulation (61;67). In these studies, expression of renal rGstm1 
was significantly reduced in SHRSP compared to WKY and a chromosome 2 
congenic strain (SP.WKYGla2c*). The rGstm1 gene is one of possibly eight 
members of a closely related family of genes that lie on an important pathway of 
endogenous cellular defences against oxidative stress induced damage of 
macromolecules. Even though renal rGstm1 was identified as differentially 
expressed in the microarray expression profiling, not all of the other rGstm genes 
were represented on the microarray chip. As the rGstm gene family locus falls 
within the introgressed chromosome 2 congenic region (as defined on page 16 
and Figure 1.5), it is possible that the expressions of the other members of the 
rGstm gene family may also be reduced in the SHRSP kidney. However, the 
contribution of the other members of the rGstm gene family is as yet unknown. 
Vascular oxidative stress is also an important contributary factor in development of 
essential hypertension. Thus, it is of interest whether rGstm gene expression is 
also reduced in vascular tissues. 
 
SHRSP is an excellent model of human essential hypertension, showing many 
characteristics in common with the human disease. Therefore identification of 
defective oxidative stress defence mechanisms in the rat may be directly 
applicable to human hypertension. Furthermore, new genes identified in animal 
studies, such as rGstm1, provide potentially new targets for pharmacogenomic 
therapy. At present, there is uncertainty as to which hGSTM is the true orthologue 
of rGstm1. While there are possibly eight members in the rGstm gene family, there 
are only five known members in the hGSTM gene family. The rGstm5 and 
hGSTM3 are the only known true orthologues leaving the remainder four hGSTM 
genes as homologues of rGstm1. It is likely that one of the hGSTM isoforms is a 
true orthologue or plays a similar functional role as rGstm1. 
 
 The aims of this study were (1) to characterise the expression profile of the rGstm 
gene family in the vascular and renal tissues; and (2) to characterise the 
expression profile of the hGSTM gene family in vascular tissue in an attempt to 
identify the true human orthologue of rGstm1. 
 
3.2. Materials & Methods 
 
The details for all the equipment, chemicals, reagents and consumables used in 
this study are listed in Appendix B. 
 
3.2.1. Animal Strains 
 
Baseline characteristics were investigated in both male and female, 16-week-old 
SHRSP, WKY, and SP.WKYGla2c* congenic strains (n=3-6). Systolic blood 
pressure was measured using tail-cuff plethysmography within 1 week of sacrifice 
as described in section 2.1.2. Thoracic aorta, carotid artery, heart, liver, kidney 
and brain taken from rats sacrificed under deep terminal anaesthesia were 
snapped frozen in liquid nitrogen and stored at -70°C for further experiments. The 
effect of age was investigated using RNA samples from thoracic aorta and kidney 
from 5-week-old and 21-week old male SHRSP and WKY (n=3).  
 
3.2.2. Human Samples 
 
Human saphenous and varicose veins were obtained as described in section 
2.3.1. Total RNA from human heart, kidney, testes and liver were obtained 
commercially from Ambion.  
 
3.2.3. Accession of Gene Sequences 
 
3.2.3.1. Rat Gstm Sequences 
 
The GenBank accession numbers for the rGstm transcript used are BC063172.1 
(rGstm1), NM_177426.1 (rGstm2), BC059130.1 (rGstm3), NM_020540.1 
(rGstm4), NM_172038.1 (rGstm5), XM_215682.4 (rGstm6a), XM_575012.2 
(rGstm6b) and NM_001024304.1 (rGstm7). Some additional sequences obtained 
 from other known mRNA accession numbers, EST database or genomic 
sequences for the rat Gstm isoforms were added to the above accession numbers 
(Table 3.1), using the Vector NTI Suite 9. A multiple alignment of all 8 rGstm 
transcript sequences are in Appendix C. 
 
3.2.3.2. Human GSTM Sequences 
 
The GenBank accession numbers for the hGSTM mRNA transcript used for the 
design of primers are NM_000561.2 (hGSTM1), NM_000848.2 (hGSTM2), 
NM_000849.3 (hGSTM3), NM_000850.3 (hGSTM4) and NM_000851.2 
(hGSTM5). For this study, the previously reported alternate transcripts of hGSTM1 
and hGSTM4 were not explored. A multiple alignment of all 5 hGSTM transcript 
sequences are in Appendix D. 
 
3.2.4. mRNA Expression and Localisation 
 
RNA was extracted, quantified, DNase treated and reverse transcribed as 
described in section 2.5. Distribution of the rGstm family of genes in various 
tissues from 16-week-old WKY female was detected by RT-PCR. Sequencing of 
the RT-PCR amplicons was performed to confirm the specificity of the RT-PCR 
reactions. The mRNA expression levels of rGstm gene were assessed by Taqman 
Gene Expression Assays or Lightcycler (section 2.5.4). The primers and 
conditions used for detection of rGstm gene expression, real-time RT-PCR by 
Lightcycler and the sequencing of RT-PCR amplicons are as in Table 3.2. The 
primers and conditions used for detection of hGSTM gene expression are as in 
Table 3.3. The PCR products for hGSTM genes can also be digested with 
restriction enzymes (REs) for 2hr at the appropriate temperatures to confirm the 
identity of the RT-PCR sequence. 
 
The primers and conditions used for generating riboprobes used for ISH are as in 
Table 3.4. The smooth muscle alpha actin gene (ACTA2) was included as positive 
control for every experiment. The accession numbers for rat and human ACTA2 
are X06801 and NM_001613, respectively. The primers used for amplifying target 
region of the rat Acta2 are the same primers used for the human ACTA2 gene. 
 
  
 
 
 
 
 
 
 
Table 3.1: Accession numbers of sequences used to generate additional sequences 
for rat Gstm mRNA transcripts 
 
Genes Accession Numbers 
rGstm1 Contig of BC063172.1 + M28241.1 
rGstm2 Contig of NM_177426.1, J02592.1 + EST sequence CB313254 
rGstm3 Contig of BC059130.1, EST sequences CB313357 + CB315738 
rGstm4 NM_020540.1 modified* 
rGstm5 NM_172038.1 + EST sequence BM422714 
rGstm6a XM_215682.4 
rGstm6b XM_575012.2 
rGstm7 NM_001024304.1 
 
*Additional sequences for both the 5’ and 3’ ends of the mRNA transcript sequences were 
added by compiling a contig of the reference sequence with genomic sequence and then 
used for design of primers. 
  
 
 
 
Table 3.2: The primers and conditions for detection of rat Gstm gene expression 
 
Gene Primers Sequences (5' – 3') AT PCR size 
WM1F TCAAACTGGGCCTGGACTTCC rGstm1 WM1R AGTAGAGCTTCATCTTCTCAG 58°C 264bp 
     
rGSTM1-S CAAATTGAGAAGACCACAGC 53°C 120bp rGstm1 rGSTM1-AS TTCTCCTCATAGCTTGAGTC   
     
WM2F TATGAGGACAAGAAGTACAGC rGstm2 WM2R TAAACAAGAAAATCCACATAC 52°C 401bp 
     
WM3F ATGGTGCTGGCGAGACTTTGC rGstm3 WM3R TGGTTCCTCTCAAGAACATCG 59°C 180bp 
     
WM4F CCCGCATACATCTCATGATAG rGstm4 WM4R GCACTCGGGCTCAAACATACG 59°C 203bp 
     
rM4F2 CTGCGGTATCTTAGTAAACAC rGstm4 rM4R2 CTGCGGTATCTTAGTAAACAC 57°C 621bp 
     
WM5F TGAAGAGAAACAGTACACGTG rGstm5 WM5R CTTGTTCTTCCCGTCCATAAG 56°C 124bp 
     
rMNOV1F2 AGCCCTGAGTTTGAGAAACG rGstm6a rMNOV1R2 TGTCTTCAAATACACAGGGCC 56°C 289bp 
     
WMNOV1F TTGGGTCACGCCATCCGGCTG rGstm6b WMNOV1R CTTCAAGAACTCAGGCTTCCG 62°C 351bp 
     
WMNOVF ATGCTATTCGATTACTCCTGG rGstm7 WMNOVR GCTGATTGGAGACATCCATAG 56°C 288bp 
 
AT = annealing temperature 
 
  
 
Table 3.3: The primers and conditions for detection of human GSTM genes expression 
 
Gene Primer Sequence (5’ – 3’) AT PCR size RE 
hGSTM1F AGA CCA TGG ACA ACC ATA TGC A hGSTM1 hGSTM1R AGC ACT TGG GCT CAA ATA TAC G 59°C 218bp Mwo I 
      
hGSTM2F AGT TTA TGG ACA GCC GTA TGC A hGSTM2 hGSTM2R AGG CAG CTG GGC TCA AAT ACT T 62°C 217bp Pst I 
      
hGSTMF ACA AGA TCA CCC AGA GCA A hGSTM3 hGSTM3R CAG GCT TGT TGC CCC ACT GG 51°C 456bp Eco RV 
      
hGSTM4F AGG CTA TGG ACG TCT CCA AT hGSTM4 hGSTM4R ATT ACT TGT TGC CCC AGA CA 55°C 351bp Msp I 
      
hGSTMF ACA AGA TCA CCC AGA GCA A hGSTM5 hGSTM5R GCC CTA TTT GCT GTT CCA TGT A 51°C 458bp Mwo I 
     
P1 CGCCATCTTGTGCTACATTGCCCG 
P2 ATCTTCTCCTCTTCTGTCTC hGSMT1*0 
P3 TTCTGGATTGTAGCAGATCA 
52°C GSTM1 & GSTM4: 230bp (P1 + P2) GSTM1: 157bp (P1 + P3) 
 
AT = annealing temperature 
 
  
 
Table 3.4: Primers used for generating probe templates for in situ hybridisation 
 
Gene Primers Sequences (5' -- 3') AT PCR size Target size 
hACTA2-IS-F1 CACCAACTGGGACGACATGG 62°C 392bp  
hACTA2-IS-R1 CACGCTCAGCAGTAGTAACG 90 min   
     
hACTA2-IS-F2 TCTAGATTAACCCTCACTAAAGGGACCCTGCTCACGGAGG 55°C 310bp 259bp 
ACTA2 
hACTA2-IS-R2 GGATCCTAATACGACTCACTATAGGGAGGTAGTCAGTGAGATCTC 90 min   
      
hM4IS-F1 GGACCTTGCTCCCTGAACACTC 62°C 250bp  
hM4IS-R1 CCTCAGCTGGGCTGAACTGC 90 min   
      
hM4IS-F2 TCTAGATTAACCCTCACTAAAGGGATGGATCTTACTCCTTCCAGC 55°C 251bp 200bp 
hGSTM4 
hM4IS-R2 GGATCCTAATACGACTCACTATAGGGCTGCGACCTCCTCTGG 90 min   
      
rM1IS-F1 TTTGTCCGGCCCACGTTTCTCTG 62°C 761bp  
rM1IS-R1 CAAGGGCCTACTTGTTACTCCATTGG 90 min   
     
rM1IS-F2 TCTAGATTAACCCTCACTAAAGGGATTTGTCCGGCCCACG 55°C 130bp 89bp 
rGstm1 
rM1IS-R2 GGATCCTAATACGACTCACTATAGGGCGCTGTGGTCTTCTCAATTTG 90 min   
 
The underlined sequences are the binding site for T3 and T7 RNA polymerases. 
 
 3.2.5. Protein Expression and Localisation 
 
The antisera used to assess the protein expression and localisation of the rGstm1, 
rGstm2, rGstm5 and hGSTM3 by immunohistochemistry were gifts from Prof. John 
D. Hayes. The hGSTM4-specific antiserum was a gift from Prof. Irving Listowsky. 
The hGSTM1-specific monoclonal antibody was from Abnova (Taiwan), 
hGSTM1/2 polyclonal antibody was from Abcam. Assessment of the localisation of 
rGstm proteins were analysed by Dr. Barbara Young, a consultant histopathologist 
at the Western Infirmary Glasgow. 
 
3.2.6. hGSTM1*0 Genotyping of Human Vascular Tissues 
 
Due to high homology between hGSTM1 and hGSTM2, there are no specific 
antibodies available for these two isoenzymes. Specific detection of hGSTM2 can 
be carried out by IHC on samples from hGSTM1*0 patients therefore all human 
vascular samples were genotyped for the hGSTM1*0 allele. DNA was extracted 
from approximately 0.5cm section of each biological sample as described in 
section 2.4.1, purified as described in section 2.4.2 and quantified as described in 
section 2.4.3. The samples were then diluted to 5ng/μl working concentration. 
 
A 20μl PCR reaction was set up containing a final concentration of 1.5mM MgCl2, 
1X buffer, 0.2mM dNTPs, 0.5μM of primer P1, 0.25μM of primers P2 and P3, 
0.01u/μl of Qiagen HotStar Taq polymerase and 25ng of DNA. The PCR reaction 
was set at 95°C for 15min followed by 35 cycles of 95°C for 1min, appropriate 
annealing temperature for 1min, 72°C for 1min and finally 60°C for 30min. The 
primers used for detection of hGSTM1*0 genotype are as in Table 3.3. 
 
3.2.7. Statistical Analysis 
 
Results are shown as mean ± SEM. 2-sample t-test was used to test for 
significance in expression level between the males and females of each strain. 
One-way ANOVA with Tukey’s comparison was used to test for significance 
between the SHRSP and WKY or SP.WKYGla2c* (2c*) strain, in either males or 
females only. For the effect of age on rGstm gene expression, 2-sample t-test was 
used to test for significance between WKY and SHRSP at each time points. 
 3.3. Results  
 
3.3.1. Systolic Blood Pressure of the Rat Strains 
 
The SBP of SHRSP males was significantly higher than WKY males (p = 0.006; 
confidence interval (CI) = –44.12, –7.52) and congenic SP.WKYGla2c* males (CI = 
8.64, 49.56) (Figure 3.1). The SBP of SHRSP females was non-significantly higher 
than WKY females (p = 0.200; CI = 8.52, –41.69). There was no difference in SBP 
between SHRSP and SP.WKYGla2c* females (p = 0.200; CI = 27.57, –25.09). 
There was also a gender-specific difference in WKY (p = 0.007; CI = 8.23, 38.30) 
and SHRSP (p = 0.016; CI = 8.44, 56.56) but not SP.WKYGla2c* (p = 0.631; CI = –
18.66, 27.94) 
 
3.3.2. Characterisation of Rat Gstms 
 
3.3.2.1. Rat Gstm Sequences 
 
Multiple alignment of the mRNA transcript sequences from the databases NCBI 
and Ensembl shows that this family of genes are highly homologous both in mRNA 
and peptide sequences (Appendix C). The rGstm1 gene shares between 71% to 
89% homology for coding sequences and 64% to 82% for peptide sequences with 
other members of rGstm family (Table 3.5). The least homologous isoform is 
rGstm5 ranging from 70% to 74% for coding sequences and 59% to 68% for 
peptide sequences. The untranslated region (UTR) of the mRNA transcripts at 
both 5’ and 3’ ends of the genes also share high homology. 
 
3.3.2.2. Expression of Rat Gstm Isoforms in Various Tissues 
 
Semi-quantitation of rGstm genes in various tissues, from 16-week-old WKY 
female rats (due to lack of male), based on intensities of RT-PCR product bands 
are given in Table 3.6. Expression of rGstm1 gene was highest in liver and brain, 
followed by kidney, heart and least in thoracic aorta. The rGstm2 gene was 
expressed most in liver followed by kidney, and least in heart and thoracic aorta. 
The rGstm3 gene was expressed highly in the brain, to a lesser extent in thoracic 
aorta and little in heart, kidney and liver. Expression of rGstm5 was highest in 
  
Figure 3.1: Systolic blood pressure by tail cuff plethysmography 
Systolic blood pressures (SBP) from 16-week old rats were measured using tail cuff 
plethysmography. 2c* = SP.WKYGla2c* 
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Table 3.5: (A) Percentage homology in coding sequences between rGstm isoforms 
 
 rGstm1 rGstm2 rGstm3 rGstm4 rGstm5 rGstm6a rGstm6b rGstm7
rGstm1         
rGstm2 84%        
rGstm3 85% 85%       
rGstm4 89% 84% 82%      
rGstm5 71% 72% 74% 70%     
rGstm6a 83% 88% 83% 83% 72%    
rGstm6b 86% 86% 83% 86% 74% 84%   
rGstm7 82% 84% 83% 80% 74% 83% 83%  
 
(B) Percentage homology in protein sequences between rGstm isoforms 
 
 rGstm1 rGstm2 rGstm3 rGstm4 rGstm5 rGstm6a rGstm6b rGstm7
rGstm1         
rGstm2 78%        
rGstm3 77% 80%       
rGstm4 82% 76% 76%      
rGstm5 64% 67% 68% 59%     
rGstm6a 75% 83% 77% 75% 66%    
rGstm6b 75% 79% 76% 75% 66% 80%   
rGstm7 74% 80% 81% 71% 68% 78% 80%  
 
 
  
Table 3.6: Expression of rGstm isoforms in various tissues 
 
Gene Thoracic A. Brain Heart Kidney Liver 
rGstm1 ++ +++++ +++ ++++ +++++ 
rGstm2 + – + ++ +++ 
rGstm3 ++ +++ + + + 
rGstm4 – – – – – 
rGstm5 ++ +++ ++ +++ + 
rGstm6a – – – – – 
rGstm6b – ++ – – – 
rGstm7 ++ ++++ + +++ +++ 
 
The rGstm genes are expressed at varying levels in different tissues from WKY female 
rat, with (+) being present to high levels (++++), and the scale being compared across 
tissue for each gene. The grading of the expression was based on the intensities of the 
RT-PCR product band. (–) denotes that the gene was not expressed in the tissue in 
question. 
 
 
Table 3.7: Gene expression levels of rGstm isoforms in selected tissues  
 
Gene Aorta Kidney Liver 
rGstm1 1.000 ± 0.333 6.548 ± 0.416 891.509 ± 375.360 
    
rGstm2 1.000 ± 0.164 1.731 ± 0.162 160.975 ± 25.260 
    
rGstm3 1.000 ± 0.081 0.343 ± 0.049 2.529 ± 0.521 
    
rGstm5 1.000 ± 0.183 0.256 ± 0.016 0.142 ± 0.040 
    
rGstm7 1.000 ± 0.070 1.008 ± 0.026 4.063 ± 0.826 
 
Each gene is expressed as fold-change, relative to vascular expression levels for 
consistency. 
 
 heart and kidney, followed by thoracic aorta and heart, least in liver. The rGstm6b 
gene expression was detected only in the brain. Expression of rGstm7 gene was 
highest in brain, slightly less in kidney and liver, to a lesser extent in thoracic aorta 
and least in heart. Expression of rGstm4 and rGstm6a was not detected in any of 
the tissues examined. 
 
Real-time relative quantitation of the rGstm genes in thoracic aorta, kidney and 
liver from 16-week-old WKY male rats are shown in Table 3.7. Liver expressed up 
to nearly 900-fold more rGstm1 while kidney expressed 6-7 fold more than aorta. 
Liver expressed nearly 200-fold more rGstm2, whereas kidney expressed nearly 
2-fold more than aorta. Liver expressed 2-3 fold more rGstm3 than aorta. In 
contrast, kidney expressed only 0.343-fold the rGstm3 expression in aorta. 
Expression of rGstm5 was highest in aorta, with kidney expressing only 0.256-fold 
and liver expressing only 0.142-fold the level of expression in aorta. Aorta and 
kidney expressed equivalent levels of rGstm7 but liver expressed approximately 4-
fold higher. 
 
3.3.2.3. Vascular Localisation and Expression of Rat Gstm Isoforms  
 
Due to lack of rGstm isoform-specific antibodies, localisation of rGstm subunits 
were available only for rGstm1, rGstm2 and rGstm5. Localisation of rGstm1, 
rGstm2 and rGstm5 in carotid arteries from 16-week-old rats were done by IHC 
using isoform-specific antisera. Expression of rGstm1 protein by IHC was detected 
in all of the vascular cell types (Figure 3.2A). Expression of rGstm2 protein was 
localised to the endothelium (Figure 3.2C) while rGstm5 expression was detected 
only in the VSMCs (Figure 3.2E). Figures 3.2 (B), (D) and (F) were the respective 
negative control IHC.  
 
Real-time absolute quantitation of rGstm isoforms measured in 16-week-old WKY 
male rats were expressed as a percentage of β-actin expression level. There was 
no predominant isoform in aorta, with rGstm1 (0.554% ± 0.062%), rGstm2 
(0.690% ± 0.023%), rGstm3 (0.501% ± 0.057%) and rGstm5 (0.763% ± 0.041%) 
expressed at similar levels but the least expressed isoform was rGstm7 (0.080% ± 
0.006%).  
 
  
Figure 3.2: Localisation of rGstm isoforms in vasculature 
(A), (C) and (E) represent the localisation of rGstm1, rGstm2 and rGstm5 in carotid artery 
from WKY male rat by immunohistochemistry, respectively. (B), (D) and (F) are the 
appropriate negative (-ve) controls. Magnification = x400.  
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 Real-time relative quantitation of rGstm mRNA expression levels in 16-week-old 
rats, relative to rGstm7 in SHRSP male as fold-changes are shown in Figure 3.3. 
There were no significant differences in rGstm1 expression between the SHRSP 
and WKY or SP.WKYGla2c* strains in either male or female rats. However, there 
was a trend towards reduced rGstm1 in SHRSP compared to WKY or 
SP.WKYGla2c* in both male and female rats. IHC of rGstm1 in carotid arteries from 
WKY, SHRSP and SP.WKYGla2c* male rats showed reduced rGstm1 expression in 
SHRSP compared to WKY and congenic SP.WKYGla2c* strains (Figure 3.4). There 
was no significant difference in rGstm1 mRNA expression between male and 
female rats in all three strains (Figure 3.3).  
 
There were no significant differences in rGstm2 mRNA expression between the 
SHRSP and WKY or SP.WKYGla2c* strains in either male or female rats (Figure 
3.3). There was a trend towards reduced rGstm2 in SHRSP compared to WKY 
and SP.WKYGla2c*, in males only. There was no significant difference in rGstm2 
expression between male and female rats in all three strains. IHC of rGstm2 in 
carotid arteries from WKY, SHRSP and SP.WKYGla2c* male rats showed reduced 
rGstm2 expression in SHRSP compared to WKY and congenic SP.WKYGla2c* 
strains across the vessel wall (Figure 3.5). However, rGstm2 was shown to be 
localised to endothelium (Figure 3.2). In order to investigate the specificity of the 
anti-rGstm2 serum, a dot blot was performed on recombinant rGstm1 and rGstm2 
proteins. The antiserum detected both rGstm1 and rGstm2 recombinant proteins.  
 
SHRSP male rats expressed non-significantly lower rGstm3 than WKY male (p = 
0.414; CI = –0.46, 1.04) and significantly lower rGstm3 than SP.WKYGla2c* males 
(p = 0.018; CI = –2.10, –0.29) (Figure 3.3). The rGstm3 expression in SHRSP 
female rats was significantly higher than WKY females (p = 0.003; CI = –2.51, –
0.60) but not the SP.WKYGla2c* female rats (p = 0.998; CI = –1.01, 1.01). 
Expression of rGstm3 gene showed gender-specific difference in the SHRSP rats 
(p = 0.005; CI = 0.71, 2.59) but not in the WKY (p = 0.359; CI = –0.68, 0.28) or 
SP.WKYGla2c* (p = 0.293; CI = –0.68, 1.59). 
 
There was no significant difference in rGstm5 expression levels between strains 
(Figure 3.3). In males only, there was a trend towards lower rGstm5 expression in 
the SHRSP compared to WKY or SP.WKYGla2c*. There was no significant 
  
Figure 3.3: Vascular expression levels of rGstm isoforms in male and female rats 
RQ = relative quantitation; 2c* = SP.WKYGla2c*;  
‡ SHRSP males vs. 2c* males, p < 0.02; # SHRSP females vs. WKY females, p = 0.003; * male vs. female, p < 0.05 
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Figure 3.4: IHC of rGstm1 in male WKY, SHRSP and SP.WKYGla2c* carotid arteries  
IHC of rGstm1 protein in carotid arteries from WKY, SHRSP and SP.WKYGla2c* (2c*) male 
rats. Magnification = x200; –ve = negative controls. 
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Figure 3.5: IHC of rGstm2 in male WKY, SHRSP and SP.WKYGla2c* carotid arteries  
IHC of rGstm1 protein in carotid arteries from WKY, SHRSP and SP.WKYGla2c* (2c*) male 
rats. Magnification = x200; –ve = negative controls. 
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 difference in rGstm5 expression levels between males and females, though there 
was a trend towards lower expression in male compared to female rats. 
 
The slightly lower rGstm7 expression level in SHRSP males compared to WKY 
males was not significant (p = 0.148; CI = –0.16, 0.99) but reached statistical 
significance when compared to SP.WKYGla2c* male (p = 0.008; CI = –1.67, –0.40) 
(Figure 3.3). This strain effect was not observed in the female rats. There were 
gender-specific differences in rGstm7 expression levels between SHRSP (p = 
0.02; CI = 0.20, 1.52) and SP.WKYGla2c* (p = 0.043; CI = –1.22, –0.03) rats but 
not the WKY rats. 
 
The effect of age on real-time relative quantitation of vascular rGstm expression 
levels in 5-week-old, 16-week-old and 20-week-old rats, relative to 5-week-old 
SHRSP males following normalisation to β-actin expression for each gene are 
shown in Figure 3.6. The expression of rGstm1, rGstm2, rGstm5 increased 
gradually with age, while rGstm7 increased after 16 weeks of age in both SHRSP 
and WKY rats. Expression of rGstm3 gene increased gradually in WKY rats but 
increased more sharply after 16 weeks of age in SHRSP, resulting in significantly 
higher rGstm3 expression in SHRSP rats at 20 weeks of age (p = 0.003; CI = 0.43, 
1.52).  
 
3.3.2.4. Renal Localisation and Expression of Rat Gstm Isoforms  
 
Previous work from our laboratory demonstrated co-localisation of rGstm1 protein 
with aquaporin-2, which localised specifically to the principal cells of collecting 
ducts (67). In this study, multiple antigen IHC for aquaporin-2 and rGstm1 on 
kidney sections from WKY rat co-localised rGstm1 expression to the principal cells 
of collecting ducts (Figure 3.7). In addition, rGstm1 expression was also detected 
in the distal convoluted epithelial cells (personal communications with Dr. Barbara 
Young). The proximal convoluted tubules (PCTs) can be identified in the renal 
cortex by their lining of a single layer of cuboidal epithelial cells with a prominent 
brush border composed of microvilli [(222) &  personal communications with Dr. 
Barbara Young]. The cytoplasm of these cells is eosinophilic and granular due to 
their high content of mitochondria. In contrast, the distal convoluted tubules 
(DCTs) are lined by cuboidal epithelial cells of fewer microvilli and therefore no 
  
Figure 3.6: Effect of age on expression levels of vascular rGstm isoforms  
The values are represented by mean ± SEM. Quantitation of each gene is expressed as 
fold-change relative to 5-week-old SHRSP expression. p-value denotes significance 
between WKY and SHRSP at time point indicated.  
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Figure 3.7: Localisation of rGstm1 in kidney 
Aquaporin-2 stains grey-black, rGstm1 stains brown and nucleus counterstains blue. The 
sections were analysed at magnification as indicated on the left of the pictures. The 
rectangle in the positively-stained pictures were magnified and shown immediately below. 
–ve = negative controls. 
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 brush border which leaves the lumen more open. There are also fewer 
mitochondria so that the cytoplasm is less eosinophilic. The thick ascending lumb, 
which makes up the majority of thick loop of Henle in the renal medulla can be 
identified as simple cuboidal cells, often round in cross-section. The thick loop of 
Henle can be differentiated from the larger diameter of collecting tubules and 
collecting ducts. Similarly, expression of rGstm2 and rGstm5 protein co-localised 
with aquaporin-2, to the principal cells of collecting ducts (Figure 3.8 and 3.9, 
respectively). In addition, rGstm2 expression was detected in DCTs and rGstm5 
expression was detected in PCTs and DCTs  (personal communications with Dr. 
Barbara Young). 
 
Real-time absolute quantitation of rGstm isoforms in 16-week-old WKY male rats, 
expressed as a percentage of β-actin expression level, showed that the 
predominant isoform in kidney was rGstm1 (1.468% ± 0.034%) and the least 
expressed isoform was rGstm7 (0.007% ± 0.001%). The rGstm2 (0.199% ± 
0.015%), rGstm3 (0.034% ± 0.004%) and rGstm5 (0.024% ± 0.002%) isoforms 
were expressed at approximately one-tenth the expression level of rGstm1.  
 
Real-time relative quantitation of rGstm expression levels in 16-week-old rats, 
relative to rGstm7 in SHRSP male as fold-changes are shown in Figure 3.10. 
Expression of rGstm1 gene in SHRSP was significantly reduced compared to 
WKY and SP.WKYGla2c*, in both male (p ≤ 0.008; CI = 2.04, 3.64 and –3.78, –
2.17, respectively) and female rats (p < 0.001; CI = 1.78, 2.69 and –2.72, –1.77, 
respectively). In addition, there was also a significantly lower rGstm1 gene 
expression in the WKY females (p = 0.002; CI = –1.05, –0.36) than WKY males. 
There was also a trend towards lower rGstm1 expression in the SP.WKYGla2c* 
females (p = 0.057; CI = –1.73, 0.06) compared to SP.WKYGla2c* males. This 
gender-specific effect was not observed in the SHRSP rats. There was no 
significant difference in rGstm1 expression between SHRSP and WKY males or 
SP.WKYGla2c* males; or SHRSP and WKY females. IHC of whole kidney sections 
from WKY, SHRSP and SP.WKYGla2c* showed reduced rGstm1 expression in 
SHRSP compared to WKY and congenic SP.WKYGla2c* strains (Figure 3.11A). 
The reduced rGstm1 expression was observed in cortex, outer and inner medulla 
(Figure 3.11B), especially in the principal cells of collecting ducts. 
 
  
Figure 3.8: Localisation of rGstm2 in kidney 
Localisation of rGstm2 in kidney. Aquaporin-2 stains grey-black, rGstm2 stains brown and 
nucleus counterstains blue. The sections were analysed at magnification as indicated on 
the left of the pictures. The rectangle in the positively-stained pictures were magnified and 
shown immediately below. –ve = negative controls. 
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Figure 3.9: Localisation of rGstm5 in kidney 
Localisation of rGstm5 in kidney. Aquaporin-2 stains grey-black, rGstm5 stains brown and 
nucleus counterstains blue. The sections were analysed at magnification as indicated on 
the left of the pictures. The rectangle in the positively-stained pictures were magnified and 
shown immediately below. –ve = negative controls. 
 
Cortex Medulla 
-ve rGstm5 
x40 
 
 
 
x100 
 
 
x200 
 
 
x400 
  
Figure 3.10: Renal expression levels of rGstm isoforms in male and female rats 
RQ = relative quantitation; 2c* = SP.WKYGla2c*;  
† SHRSP male vs. WKY male, p < 0.05; ‡ SHRSP male vs. 2c* male, p < 0.05; # SHRSP female vs. WKY female, p < 0.05; § SHRSP female vs. 2c* 
female, p < 0.05; * male vs. female, p < 0.05 
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Figure 3.11: IHC of rGstm1 on male WKY, SHRSP and SP.WKYGla2c* kidney 
(A) IHC of rGstm1 protein on whole kidney sections from WKY, SHRSP and 
SP.WKYGla2c* (2c*) male rats and (B) magnified x100.  
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 There was no significant difference in rGstm2 expression between SHRSP and 
WKY or SP.WKYGla2c* in males (Figure 3.10). SHRSP female expressed 
significantly lower rGstm2 mRNA than SP.WKYGla2c* females (p = 0.024; CI = –
0.70, –0.07) and non-significantly lower rGstm2 than WKY females (p = 0.169; CI 
= –0.61, 0.12). There was no gender-specific difference in rGstm2 expression in 
any of the three strains. 
 
SHRSP rats expressed lower rGstm3 than WKY and SP.WKYGla2c* in both male 
and female rats but the difference between SHRSP males and WKY males did not 
reach statistical significance (Figure 3.10). There was no gender-specific 
difference in rGstm3 expression in any of the three strains. 
 
The rGstm5 expression pattern was similar to rGstm1, where SHRSP expressed 
significantly lower rGstm5 than WKY or SP.WKYGla2c* in both male (p ≤ 0.031; CI 
= –1.17, –0.11 and 0.21, 1.49, respectively) and female rats (p ≤ 0.032; CI = –
0.60, –0.08 and 0.08, 1.12, respectively) (Figure 3.10). There were significantly 
lower rGstm5 expression in WKY females compared to males (p = 0.005; CI = –
0.96, –0.32). There was also a trend towards lower rGstm5 expression in 
SP.WKYGla2c* females (p = 0.053; CI = –1.18, 0.01) compared to SP.WKYGla2c* 
males but this gender-specific difference was not observed in the SHRSP rats.  
 
The pattern of rGstm7 expression was similar to rGstm1 and rGstm5 but at much 
lower levels (Figure 3.10). However, the difference in rGstm7 expression levels 
between SHRSP and WKY males (p = 0.070; CI = –0.12, 1.29) or SP.WKYGla2c* 
males (p = 0.164; CI = –0.30, 1.11) did not reach statistical significance. The 
difference in rGstm7 expression between SHRSP and WKY females or 
SP.WKYGla2c* females were statistically significant (p < 0.001; CI = 0.32, 1.05 and 
–1.00, –0.23, respectively). The gender-specific difference in rGstm7 expression 
levels was statistically significant only in WKY rats (p = 0.006; CI = –0.63, –0.16) 
but not in SHRSP (p = 0.099; CI = –1.23, 0.23) or SP.WKYGla2c* (p = 0.237; CI = –
0.86, 0.27) rats.  
 
The effect of age on real-time relative quantitation of renal rGstm expression levels 
in 5-week-old, 16-week-old and 20-week-old rats, relative to 5-week-old SHRSP 
males following normalisation to β-actin expression for each gene are shown in 
 Figure 3.12. The SHRSP rats expressed significantly lower rGstm1 than WKY rats 
at 5-weeks of age (p = 0.002; CI = –2.78, –1.55), remaining significantly lower at 
16-weeks of age (p = 0.008; CI = 2.04, 3.64) and 21-weeks of age (p = 0.009; CI = 
–3.89, –1.67). The rGstm1 expression in WKY rats increased gradually with age 
but not in SHRSP rats. There were no significant differences in rGstm2 expression 
between SHRSP and WKY at all time points studied and remained constant with 
age. The rGstm3 expression in SHRSP rats remained constant with age while the 
expression in WKY rats increased after 16-weeks of age to a significantly higher 
rGstm3 expression in WKY than SHRSP at 21-weeks of age (p = 0.023; CI = –
3.16, –0.48). The expression of rGstm5 increased in both SHRSP and WKY rats 
after 5-weeks of age and plateau after 16-weeks of age. However, the increase of 
rGstm5 mRNA expression in WKY was more pronounced resulting in a 
significantly higher rGstm5 expression than SHRSP at 16-weeks of age (p = 
0.031; CI = –1.17, –0.11) and 21-weeks of age (p = 0.009; CI = –1.00, –0.26). 
There was no change in rGstm7 expression in the SHRSP with increasing age but 
there was an increase in rGstm7 expression in WKY rats after 5 weeks of age, 
reaching a plateau between 16 weeks and 21 weeks of age. This resulted in 
higher rGstm7 expression in the WKY than SHRSP at 16-weeks of age (p = 0.056; 
CI = –1.54, 0.059) and 21-weeks of age (p = 0.001; CI = –1.35, –0.65). 
 
3.3.3. Characterisation of Human GSTM Genes 
 
3.3.3.1. Human GSTM Sequences 
 
Multiple alignment of the mRNA transcript sequences from NCBI and Ensembl 
databases showed that hGSTM1 shares between 77% to 92% homology for 
coding sequences and 73% to 87% for peptide sequences with other members of 
GSTM family (Table 3.8). The least homologous isoforms was hGSTM3 ranging 
from 70% to 74% for coding sequences and 59% to 68% for peptide sequences. 
The untranslated region (UTR) of the mRNA transcripts at both 5’ and 3’ ends of 
the genes also share high homology.  
 
  
Figure 3.12: Effect of age on expression levels of renal rGstm isoforms  
The values are represented by mean ± SEM. Quantitation of each gene is expressed as 
fold-change relative to 5-week-old SHRSP expression. 2-sample t-test was used to test 
for significance between WKY and SHRSP at each time points. p-value denotes 
significance between WKY and SHRSP at time point indicated.  
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Table 3.8: (A) Percentage homology in coding sequences between hGSTM isoforms 
 
 hGSTM1 hGSTM2 hGSTM3 hGSTM4 hGSTM5 
hGSTM1      
hGSTM2 89%     
hGSTM3 77% 74%    
hGSTM4 92% 89% 77%   
hGSTM5 92% 89% 77% 90%  
 
(B) Percentage homology in protein sequences between hGSTM isoforms 
 
 hGSTM1 hGSTM2 hGSTM3 hGSTM4 hGSTM5 
hGSTM1      
hGSTM2 84%     
hGSTM3 73% 68%    
hGSTM4 86% 83% 72%   
hGSTM5 87% 81% 72% 83%  
 
 3.3.3.2. Expression of Human GSTM Isoforms in Various Tissues 
 
The hGSTM1 was expressed in kidney, testes and saphenous vein (SV) but 
expression data was inconclusive in heart and liver (Table 3.9) as the RNA for 
these tissues were commercial RNA and may have come from individuals who 
were hGSTM1*0. The hGSTM1 was expressed at higher level in testes than 
kidney or SV. The hGSTM2 was expressed most in heart, followed by testes, 
kidney and least in SV and was not in the liver. The hGSTM3 was expressed most 
in testes, followed by heart, kidney or liver, and least in the SV. The hGSTM4 was 
expressed in roughly equivalent levels in kidney, testes and SV and less in heart 
and liver. The hGSTM5 was expressed only in the testes and vascular tissues.  
 
3.3.3.3. Vascular Localisation of Human GSTM Isoforms 
 
As there was no specific antibody for hGSTM2 protein, the localisation of the 
protein was detected using an antibody that recognises both hGSTM1 and 
hGSTM2 on sections from subjects with the hGSTM1*0 polymorphism. Since 
subjects with hGSTM1*0 polymorphism do not have the hGSTM1 gene, the 
antibody will only bind to hGSTM2 protein. The specificity of the antibodies and 
antisera were also confirmed by dot blot analysis with recombinant hGSTM 
proteins. Figure 3.13 shows that expression of hGSTM1 (A), hGSTM2 (C) and 
hGSTM4 (G) were detected in all the vascular cell types while hGSTM3 was 
expressed only in VSMCs (E). Figures 3.13 (B), (D), (F) and (H) show the 
respective negative control IHC. 
 
3.3.4. Optimisation of In Situ Hybridisation on Vascular Tissue 
 
As part of the characterisation of the rGstm in vascular and renal tissues, as well 
as hGSTM genes in vascular tissues, in situ hybridisation was chosen as the 
technique of choice to localise the expression of each of the Gstm isoforms. This 
was due to the high homology of the sequences both at coding and protein levels, 
and lack of readily available isoform-specific antibodies. Even though Prof. I. 
Listowsky’s group have previously published work using hGSTM isoform-specific 
antisera, most of their subsequent work have used reverse-phase high 
performance liquid chromatography (HPLC) (223). There were also other isoforms 
  
 
 
 
 
 
 
 
 
Table 3.9: Expression of hGSTM isoforms in various tissues 
 
Gene Heart Kidney Liver Testes SV 
hGSTM1 ? + ? ++ + 
hGSTM2 ++++ ++ – +++ + 
hGSTM3 +++ ++ ++ ++++ + 
hGSTM4 + ++ + ++ ++ 
hGSTM5 – – – ++ + 
 
The hGSTM genes are expressed at varying levels in different tissues, with (+) being 
present to high levels (++++), and the scale being compared across tissue for each gene. 
The grading of the expression was based on the intensities of the RT-PCR product band. 
It is unclear (?) if these tissues expressed hGSTM1. (–) denotes that the gene was not 
expressed in the tissue in question. SV = saphenous vein 
 
  
Figure 3.13: Localisation of hGSTM isoforms in vasculature 
(A), (C), (E) and (G) represent the localisation of hGSTM1, hGSTM2, hGSTM3 and 
hGSTM4 in saphenous veins by IHC. (B), (D), (F) and (H) are the appropriate negative 
controls. Magnification = x100; SV = saphenous vein; -ve = negative control.  
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 that could not be localised using immunohistochemistry, due to lack of available 
GSTM-specific antisera in both rat and human. In addition, the later described 
rGstm6a, rGstm6b and rGstm7 meant that the specificity of the available antisera 
was in question. Thus, a more specific method was required to localise the 
expression of these genes. 
 
Riboprobes were used for hybridisation to mRNA transcripts in 10μm frozen 
sections of thoracic aorta (TA) and kidney from rats and varicose veins from 
human subjects. Preliminary ISH experiments to detect hGSTM4 in varicose vein 
yielded unsuccessful results due to high background signals in the negative 
control sections (Figure 3.14A) while rGstm1 in thoracic aorta and kidney yielded 
very low detectable signal (Figure 3.14B). The smooth muscle α-actin (ACTA2) 
used as a positive control gene in the rat and human vascular tissues confirmed 
the high background signal (Figure 3.14C). The use of ACTA2 probes on kidney 
sections suggested that the protocol was adequate for the kidney sections (Figure 
3.14D) and so the lack of rGstm1 signal in kidney was probably due to unsuitable 
target sequence or yet-to-be identified problem of in situ detection of rGstm1 gene.  
 
Variations in a number of steps were introduced in an attempt to improve the Gstm 
signals while reducing the background signals. The results of the variations 
compared to the initial protocol are shown in Figure 3.15. The changes compared 
to the (A) initial protocol were (B) reducing the paraformaldehyde fixing time from 
10min to 5min to reduce cross-linking of proteins to allow more access by 
riboprobes to target mRNA; (C) increase acetylation with acetic anhydride from 
10min to 15min to reduce non-specific binding of probes to the highly positively 
charged vascular tissue; (D) introduction of antigen retrieval using 10mM citrate 
buffer, pH 6.0 after PBS washes following formaldehyde fixing to break some of 
the bonds between proteins formed during cross-linking; (E) introduction of second 
RNase incubation following the first wash at 60°C after the first RNase digestion to 
digest any non-specifically bound or trapped riboprobes that might be more 
accessible following washing at 60°C; (F) combination of increased acetylation 
with additional RNase digestion; and (G) combination of decreased fixation with 
increased acetylation. Increased acetylation of the sections increased the 
positive/antisense signal while two RNase digestions reduced the non-
specific/sense signal. Decreased fixation did not improve the signal to background 
  
Figure 3.14: Preliminary in situ hybridisation experiments 
In situ hybridisation for (A) hGSTM4 in human varicose vein (VV); (B) rGstm1 in rat 
thoracic aorta (TA) and kidney (K); (C) smooth muscle α-actin (ACTA2) in human varicose 
vein and rat thoracic aorta; and (D) Acta2 in rat kidney. AS = antisense, S = sense. 
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Figure 3.15: Variations in pre-treatment of rat aorta for ISH  
Changes to the ISH protocol are (B) reducing the fixing of tissue sections in 4% 
paraformaldehyde from 10min to 5min; (C) increase acetylation of tissue sections with 
acetic anhydride from 10min to 15min; (D) introducing antigen retrieval with citrate buffer 
following acetylation; (E) an additional RNase step following first wash at 60°C; (F) a 
combination of variations C and E; and (G) a combination of variations B and C. AS = 
antisense; S = sense 
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 ratio. In contrast, antigen retrieval reduced both specific and non-specific signals. 
A combination of reduced fixation and increased acetylation did not improve the 
signal:background ratio more than increased acetylation alone. A combination of 
increased acetylation and additional RNase digestion appeared to improve the 
antisense signal while reducing the sense signal. 
 
Due to time and practicality constraints optimisation of ISH method was not 
investigated further. Consequently localisations of rGstm and hGSTM genes by 
ISH are not available. 
 
3.3.5. Lower Smooth Muscle α-Actin in Female Rats 
 
While comparing the protein expression levels of rGstm isoforms in the vascular 
tissues using IHC, control IHC using smooth muscle α-actin (Acta2) was also 
carried out on carotid artery sections from male and female rats of SHRSP, WKY 
and congenic SP.WKYGla2c* strains (Figure 3.16). Surprisingly, there was a lower 
Acta2 protein expression in the smooth muscle layer in the carotid arteries from 
female rats than their male counterparts, regardless of strains. This gender effect 
is an important observation, which should be taken into account when using Acta2 
as a house-keeping protein (control) in studies using both males and females. 
 
3.4. Discussion 
 
Previous work in our group has shown that SBP and DBP of the congenic 
SP.WKYGla2c* strain was significantly lower than SHRSP but higher than WKY 
(61). In that study, BP was measured by radiotelemetry only in male rats. In this 
project, SBP of the congenic strain was significantly lower than SHRSP but not 
higher than WKY. This discrepancy could be due to the different methods of SBP 
measurement. Results generated by tail cuff plethysmography may be subject to 
stress artifacts due to warming and handling and therefore cannot be directly 
compared with telemetry. In addition, there were significant gender-specific 
difference in WKY and SHRSP but not the congenic strain. 
 
Analysis of rGstm sequences at transcriptional and protein level showed that there 
was high homology between the family members. The expression of rGstm1, 
  
Figure 3.16: IHC of smooth muscle α-actin (Acta2) in carotid arteries 
(A), (C), (E) are IHC of Acta2 gene in male WKY, SHRSP and SP.WKYGla2c* (2c*), while 
(B), (D), (F) are the female counterparts and (G) is a representative negative (-ve) control. 
Magnification = x200 
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 rGstm2, rGstm3, rGstm5 and rGstm7 were detected in thoracic aorta, brain, heart, 
kidney and liver. In addition to the five rGstm genes, expression of rGstm6b was 
also detected in brain. However, the expression of rGstm4 and rGstm6a were not 
detected in all the tissues examined. The original paper that first characterised rat 
Gstm4 gene from a genomic DNA clone did not detect any mRNA transcripts 
(224). A study that attempted to characterise expression of the rGstm gene family 
in various tissues also failed to detect any mRNA transcripts or corresponding 
protein (225). A search through the EST databases did not provide any “hits” for 
either rGstm4 or rGstm6a, suggesting that these two genes may be pseudogenes. 
It is also possible that these genes are expressed in tissues yet to be looked at or 
in certain developmental stages only. The latter explanation seems likely as a 
recombinant rat Gstm4 (rGstm4) protein expressed in Escherichia coli showed the 
S-glutathiolated form of the enzyme was catalytically active (226). Antibodies 
raised against unique C-terminal undecapeptide or tridecapeptide of rGSTM4 
reacted with rat and mouse liver GSTs revealing an orthologous mouse GSTM4 
(mGSTM4). The mGSTM4 was present at low basal levels but was inducible in 
mouse liver. It is likely that rGSTM4 is also present at very low levels in rat liver 
and is inducible. However, in the major cardiovascular tissues (e.g. kidney and 
vasculature) the expression of rGSTM4 was not detected in either the WKY or 
SHRSP rat. 
 
Generally, vascular rGstm gene expressions were lower in SHRSP compared to 
WKY and/or SP.WKYGla2c*. There were also gender-specific differential 
expression of rGstm3 and rGstm7. Despite the significant differential expression, 
the differences were less than 1-fold and the variations within groups were high. A 
search through the literature revealed that no known studies have attempted to 
characterise the entire rGstm gene family. This study is the most comprehensive 
study of rGstm gene family expression in vascular tissues. The data from this 
study provides a reference guide for future vascular rGstm studies. 
 
Differences in mRNA expression levels may not be translated equally to protein 
levels and so it was necessary to investigate vascular rGstm protein expression. 
The expression of rGstm1 protein was detected in all the vascular cell types. The 
SHRSP vascular rGstm1 protein expression was lower than WKY and 
SP.WKYGla2c*.  
  
The rGstm2 protein was initially localised to endothelium. Unexpectedly, attempts 
to compare rGstm2 protein expression in thoracic aortas from the three strains by 
IHC revealed rGstm2 expression in all vascular cell types. Subsequent dot blot of 
anti-rGstm2 serum showed that the antiserum is non-specific, detecting both 
rGstm1 and rGstm2 recombinant proteins, suggesting that the observed difference 
in rGstm2 expression was probably a consequence of the difference in rGstm1 
protein expression. The rGstm5 protein was localised to VSMCs.  
 
As there were no available recombinant proteins or peptides available for the 
entire rGstm gene family that could be used to confirm the specificity of the 
antisera, an alternative localisation method for rGstm expression would be 
required to confirm the current findings. Even though ISH detects mRNA 
expression, it provides the opportunity for specific localisation of rGstm isoforms. 
Optimisation experiments for ISH gave promising results. However, the length of 
time required for an experiment is extremely long (e.g. approximately 7 weeks for 
hGSTM4 in SV), when using radioactive detection method. Thus the opportunity 
for repeated experiments and optimisation steps is limited. It would be beneficial 
for further optimisation of ISH and, perhaps, using a more rapid detection method 
such as enzymatic colour change or fluorochrome detection system (227). In situ 
RT-PCR is another option for detecting transcripts present at very low amounts, 
below detection limit of the usual IHC or ISH (228). 
 
IHC co-localised rGstm1, rGstm2 and rGstm5 expression with aquaporin-2 in the 
principal cells of collecting duct. Expression of rGstm1, rGstm2 and rGstm5 protein 
were also detected in other cell types within the kidney. To further determine the 
localisation of these rGstm proteins in the kidney, co-localisation with other genes 
expressed specifically in different regions of nephron would be required. An 
example is aquaporin-1, which was localised to renal proximal tubule and 
descending limb of the loop of Henle (Figure 3.17) (229). However, since the non-
specificity of the anti-rGstm2 antiserum and possibly the other antisera remains to 
be clarified, an alternative localisation method would be required to confirm the 
current findings. 
 
  
 
 
 
Figure 3.17: Schematic diagram of a juxtamedullary nephron. 
Taken from Ref. (237) 
 
 Previous microarray analysis of gene expression in kidney homogenates from 16-
week old rats showed reduction in rGstm1 mRNA and protein expression (61;67). 
It is likely that decreased expression of one isoform may be compensated by 
increasing expression of another isoforms. This is highly likely since the enzymes 
consist of homo- and hetero-dimeric subunits, which can be formed between 
members of the same class of GSTs (184). In this project, renal expression of 
rGstm1 was highest, followed by rGstm2, rGstm3, rGstm5 and rGstm7. 
Expression of rGstm1 mRNA was approximately 7.5 times higher than rGstm2 
mRNA. In this project, the differential rGstm1 expression at mRNA and protein 
levels identified in previous studies were confirmed. IHC of rGstm1 protein in 
kidneys from male rats showed reduced cortical and medullary expression by 
SHRSP, compared to WKY and SP.WKYGla2c*. The mRNA expression of other 
members of rGstm gene family were also reduced in SHRSP compared to WKY 
and SP.WKYGla2c*, except for rGstm2. However, the differences between SHRSP 
and WKY or SP.WKYGla2c* were small compared to rGstm1. From these data, we 
can conclude that there is no compensatory increase in other rGstm isoforms and 
there is a general reduction in expression of rGstm family members with the 
greatest effect in rGstm1. 
 
In addition to strain-specific differences, gender-specific differences were also 
observed in this project. WKY and SP.WKYGla2c* female expressed significantly 
lower rGstm1 expression than their male counterparts. This gender-specific 
difference was not observed in SHRSP. This was probably because the extent of 
the reduction in SHRSP eliminated the gender effect observed in the WKY and 
SP.WKYGla2c*. Expression of rGstm5 in WKY female and SP.WKYGla2c* female; 
and rGstm7 in WKY female were also lower than their male counterparts. This 
effect may be the result of hormonal regulation of rGstm gene expression as 
gender-specific difference was also previously reported in rat liver (230). Several α 
and μ class GSTs were expressed in a sex-dependent fashion in adult rat liver, 
where they were regulated by multiple pituitary-dependent hormones through pre-
translational mechanisms.  
 
The expression of rGstm1 was reduced in SHRSP even at 5 weeks of age. This 
difference in rGstm1 mRNA expression became larger with age. The expression of 
rGstm3, rGstm5 and rGstm7 increased with age in WKY but less so in SHRSP. 
 Reduced expression of rGstm1 exists before the onset of hypertension indicating a 
primary cause rather than secondary effect of BP. There is evidence for renal 
oxidative stress in hypertensive rat models (67;231). Superoxide levels in the 
kidney medulla and cortex, measured by lucigenin chemiluminescence, were 
significantly higher in SHRSP compared to WKY, with that of SP.WKYGla2c* being 
intermediate. Overall, the results point to rGstm as important enzymes in 
hypertension, especially rGstm1 in the kidney. It is likely that rGstm enzymes are 
important for reducing renal oxidative stress. 
 
Analysis of hGSTM sequences at transcriptional and protein level showed that the 
homology between the gene family members are high. Distribution of hGSTM 
genes and localisation of hGSTM1-hGSTM4 did not provide any further indication 
as to which of the hGSTM genes is the orthologue of rGstm1. Analysis of Gstm 
gene sequences from rat, mouse and human suggested that the hGSTM gene 
family evolved independently of rodent Gstm genes, except for hGSTM3. (Figure 
3.18). Despite this, the hGSTM enzymes could still play important roles in 
protection against vascular oxidative stress in hypertension.  
 
Obtaining good quality vascular tissues from human subjects was problematic. In 
this study, tissues were obtained from two sources, SV from CAD patients 
undergoing CABG surgery and VV from patients undergoing varicose vein 
removal. In both cases, removal and maintenance of vessels before receiving 
them in the laboratory was not optimal for RNA extraction procedures. Samples 
from CAD patients were kept in sterile saline for a long period of time before they 
could be snap frozen for further processing. The method of removal of VV often 
results in inversion of the vessel potentially causing loss of the endothelial layer. 
This mechanical stress could also prompt inflammatory responses which could 
render the results unreliable. The expression data generated in the human 
subjects may be less reliable than those obtained for the rats. 
 
It has been shown that approximately 50% of Caucasians have a deletion of the 
entire hGSTM1 gene (232). This results in the lack of the relevant protein 
expression. There is no known rGstm gene deletion in the rats, which also have 
more members in the gene family. The hGSTM1 was associated with altered 
expression of hGSTM3 (204). The Medical Research Council BRItish Genetics of 
  
Figure 3.18: Phylogenetic tree of Gstm gene family from human, rat and mouse  
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 HyperTension (BRIGHT) study aimed to identify genes that confer susceptibility to 
essential hypertension, consisted of 1599 severely hypertensive families (233). 
Sequencing and genotyping of DNA samples from the BRIGHT study implicated 
hGSTM5 as an important candidate gene in hypertension (234). 
 
As an aside to the GSTM results presented in this study, an interesting 
observation was also made regarding Acta2 protein expression. Surprisingly, 
Acta2 protein expression in thoracic aorta was lower in female compared to male, 
regardless of strain. A search through the literature did not provide any previous 
report of differential Acta2 expression between males and females. To my 
knowledge, this is the first report of gender-specific differential Acta2 expression in 
VSMC from rats. Acta2, more commonly known as smooth muscle α-actin, is one 
of the contractile proteins important for the differentiated function of VSMCs (235). 
There is a higher ratio of α-actin to γ-actin in aortic tissues than venous tissues, 
emphasising the importance of α-actin in contractile function. Acta2 knock-out 
mice demonstrated lower SBP than wild-type mice (236). Despite the importance 
of Acta2 protein, it is not required for the development of the cardiovascular 
system. The observed gender-specific difference in Acta2 expression could 
possibly account, in part, for the observed difference in SBP between male and 
female rats.  
 
The majority of studies investigating GSTMs have focussed on biochemical 
properties and role in cancer, since GSTs are phase II drug-metabolising 
enzymes. In contrast, this study provided a detailed characterisation of the GSTM 
gene family in terms of cardiovascular tissue expression. These data provide an 
important basis for further functional investigation of the role of GSTM in the 
development of hypertension in both rat models and humans. 
 
 CHAPTER 4:  EFFECTS OF ANTIHYPERTENSIVE DRUGS ON THE 
EXPRESSION LEVELS OF RAT GLUTATHIONE S-TRANSFERASE μ 
ISOFORMS 
 
4.1. Introduction 
 
In the previous chapter, characterisation of the rGstm family confirmed differential 
expression of rGstm1 at both mRNA and protein levels in SHRSP. Furthermore, 
rGstm3, rGstm5 and rGstm7 were also shown to be significantly reduced in the 
SHRSP compared to WKY. It is unknown whether the observed differences in 
rGstm gene expression are secondary effects due to changes in 
pathophysiological mechanisms involved in the development of hypertension or 
whether rGstm expression can be manipulated by preventing or reversing elevated 
BP. 
 
The SHRSP is an excellent model for investigating the functional role of the rGstm 
family. Previous studies in our laboratory have identified increased levels of 
vascular O2- and reduced NO bioavailability in SHRSP (121;238;239). We have 
also shown that significant improvements in NO bioavailability in SHRSP can be 
achieved using AT1R antagonists (240;241). 
 
The aims of this study were to carry out pharmacological intervention studies to 
investigate the role of rGstm enzymes in oxidative stress and determine whether 
reduced rGstm expression in SHRSP can be improved with antihypertensive 
treatment. Two different classes of antihypertensive drugs were used for 
mechanistic assessment of the role of the rGstm family in oxidative stress and 
hypertension. We compared the effects of AT1R antagonist (olmesartan) (242) with 
a vasodilator and diuretic combination (hydralazine and hydrochlorothiazide, H + 
H) on SBP, O2- and H2O2 production and expression levels of rGstm genes. AT1R 
blockers (ARBs) reduce oxidative stress in models of hypertension and 
atherosclerosis by inhibiting Ang II stimulated O2- production through Ang II 
receptor blockade (240;243;244), whereas H + H act through different 
mechanisms by causing direct vasodilation and diuresis (47;245;246). As Ang II is 
a potent stimulator of O2- production by NADPH oxidase, measurement of the 
gene expression of CYBA (which encodes for p22phox subunit of NAD(P)H 
 oxidase), Ncf1 (which encodes for p47phox subunit of NAD(P)H oxidase) and Rac1 
(which encodes for GTP-binding protein rac1) were also carried out. The 
expression of p22phox and p47phox subunits have both been detected in all the 
vascular cell layers (247). The p22phox subunit represents membrane component 
of the NAD(P)H oxidase while p47phox subunit represents the cytoplasmic 
component of the NAD(P)H oxidase. The rac1 protein is the ubiquitously 
expressed regulator required for the activation of non-phagocytic NAD(P)H 
oxidases (247). Furthermore, to ensure that any observed effects of olmesartan 
were not due to the amount of AT1R present, the expression of Agtr1a gene, which 
encodes for α subtype of AT1R was also measured. 
 
Two study protocols were undertaken (prevention and reversal) to allow 
investigation of different aspects of BP control and development of hypertension 
on gene expression. The reversal study allows identification of non-reversible 
changes occurring due to hypertension and the prevention study allows 
investigation of functional effects in rGstm expression when hypertension is 
prevented from developing. 
 
4.2. Materials & Methods 
 
The details for all the equipments, chemicals, reagents and consumables used in 
this study are listed in Appendix B. 
 
4.2.1. Animal Strains and Antihypertensive Therapy 
 
In the reversal drug study, 16-week-old male SHRSP were treated orally with 
olmesartan (20 mg/kg per day; n = 8) or hydralazine plus hydrochlorothiazide (H + 
H) (16 mg/kg per day; n = 8) or vehicle (n = 9) for 4 weeks. In the prevention drug 
study, 8-week-old male SHRSP were treated orally with olmesartan (20 
mg/kg/day; n = 7) or H + H (16 mg/kg/day; n = 7) or vehicle (n = 7) for 8 weeks. 
The WKY strain (n=6) was also treated with vehicle in parallel. Olmesartan 
(courtesy of Sankyo Pharma GmBH, marketed as olmesartan medoxomil), first 
described as CS-866, is a pro-drug that de-esterifies to its active form (242). As 
olmesartan is poorly water soluble, a suspension of the drug was prepared daily in 
a commercially available preparation of custard baby food, which was eaten by the 
 rats immediately. For consistency, the other drugs were administered in the same 
manner. Control animals received custard but no drugs. Drug doses were chosen 
to achieve equipotent blood pressure-lowering effects as determined in preliminary 
experiments in males. The animals were weighed weekly to adjust the drugs 
accordingly. SBP was measured weekly by tail-cuff plethysmography as described 
in section 2.1.2. 
 
At sacrifice, thoracic aorta and kidney were removed and snap-frozen in liquid 
nitrogen for total RNA and protein extraction. Abdominal arteries and a quarter of 
kidney dissected into cortex and medulla were removed for measurement of 
superoxide production by lucigenin. One half of a kidney from each animal was 
embedded into frozen blocks, as described in section 2.2.1., and one half formalin-
fixed and embedded into paraffin blocks, as described in section 2.2.2. The carotid 
arteries were also formalin-fixed and embedded into paraffin blocks. A schematic 
diagram of the drug studies are shown in Figure 4.1. 
 
4.2.2. Superoxide Production Measurement 
 
Abdominal aortas were cleaned, cut into segments of approximately 5mm, 
weighed and placed in a scintillation vial containing 2ml of Krebs buffer. Quartered 
sections of kidney which had been dissected into renal cortex and medulla were 
homogenised separately in 0.05M phosphate buffer pH7.8 (20mls buffer/0.1g 
tissue) containing protease inhibitors. The samples were centrifuged at 1000g for 
5min and the supernatant stored in aliquots at –70°C. For the lucigenin assays, 
0.2 – 0.5μl of renal samples, depending on protein concentrations, was added to 
2ml of Krebs buffer in a scintillation vial. 
 
Lucigenin was added and the samples counted immediately in liquid scintillation 
analyzer TRI-CARB 2100TR. Readings were taken every 10 seconds for 3min. A 
standard curve was prepared with every assay by addition of 20μl of xanthine 
oxidase (0.1U/ml), 20μl of lucigenin (25μM for vessels; 5μM for kidney 
homogenates) and increasing volume of 20nM xanthine into a scintillation vial 
containing 2ml of Krebs buffer. 
 
  
Figure 4.1: Schematic protocol for the reversal and prevention drug study 
WKY rats of the same age given vehicle control were ran in parallel in both studies. SBP = 
systolic blood pressure. 
 
Control Olmesartan Hydralazine + 
 (20mg/kg/day) Hydrochlorothiazide 
  (16mg/kg/day) 
4 weeks, (Reversal) 
8 weeks, (Prevention) 
Sacrifice 
16-week SHRSP male (Reversal) 
8-week SHRSP male (Prevention) 
• SBP was measured weekly by tail-cuff plethysmography.  
• O2- production was measured by lucigenin chemiluminescence.  
• H2O2 production was measured by Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit 
• Gene expression was measured by relative quantitative RT-PCR. 
 4.2.3. Hydrogen Peroxide Production Measurement 
 
Hydrogen peroxide production was measured using the Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit [Molecular Probes] according to the manufacturer’s 
instructions. The plate was read using the Wallac 1420 Victor plate reader.  
 
4.2.4. Gene Expression 
 
The gene expression levels were measured as described in section 2.5.4.2. In 
addition to rGstm genes, we also measured the gene expression of AT1R, NADPH 
subunit p22phox, p47phox and regulator rac1. 
 
4.2.5. Statistical Analysis 
 
Results are shown as mean ± SEM. SBP of WKY or either drug-treated groups 
were all compared to the SHRSP control group using repeated measures ANOVA, 
general linear model. The superoxide production, hydrogen peroxide production 
and gene expression measurements of WKY or drug-treated groups were all 
compared to the untreated SHRSP control group using one-way ANOVA with 
Dunnett’s comparison for 95% confidence interval. The statistically significant p-
values compared to untreated SHRSP control group are shown, when available. 
Non-significant p-values are not shown. 
 
4.3. Results 
 
4.3.1. Olmesartan Reversal Study 
 
At 16 weeks of age, all the SHRSP rats had fully developed hypertension with 
SBP of 173mmHg ± 20mmHg compared to SBP of normotensive WKY (122mmHg 
± 13mmHg). After 1 week of treatment, both olmesartan (green line) and H + H 
(red line) treatments significantly reduced the SBP of the SHRSP to levels 
equivalent as the WKY (p < 0.001) (Figure 4.2). This reduction in SBP was 
maintained at levels equivalent to the WKY for the course of the study. The SBP of 
the SHRSP control (yellow line) remained high (>170mmHg) for the course of the 
study. 
  
Figure 4.2: Reversal study systolic blood pressure 
16-week-old SHRSP males were treated with either drug at for 4 weeks. WKY rats of the 
same age were included in parallel. H + H = Hydralazine + hydrochlorothiazide; Olme = 
olmesartan. 
 
 
Figure 4.3: Reversal study vascular superoxide production 
Basal and NADH-stimulated O2- production in abdominal aorta from WKY and SHRSP 
rats treated with vehicle, hydralazine + hydrochlorothiazide (H + H) or olmesartan (Olme).  
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 4.3.1.1. Effect of Drugs on Vascular Function and Gene Expression 
 
The vascular basal and NADH-stimulated O2- production were measured as a 
marker of oxidative stress (Figure 4.3). Abdominal aorta from SHRSP control 
demonstrated significantly higher levels of basal (p = 0.015; CI = –4.06, –0.54) and 
NADH-stimulated (p < 0.001; CI = –10.07, –3.51) O2- production than WKY rats. 
Neither drug treatments affected O2- production in SHRSP rats at basal or with 
NADH stimulation.  
 
In order to determine if the difference in O2- production between SHRSP and WKY 
was due to differential expression of vascular NAD(P)H oxidase subunits or Ang II 
stimulation, the gene expression of p22phox, p47phox, rac1 and AT1R were 
measured (Figure 4.4).There were no significant differences in the vascular gene 
expression levels for p22phox, p47phox, rac1 or AT1R mRNA between untreated 
SHRSP controls and WKY rats. Neither of the drug treatments significantly 
affected the gene expression of p22phox, p47phox, rac1 or AT1R. The apparent 
increased in p47phox gene expression by H + H treatment was not statistically 
significant (p = 0.088; CI = –1.77, 0.13), probably due to the large variability within 
the group.  
 
SHRSP rats expressed significantly higher levels of vascular rGstm3 than WKY 
but there were no significant differences in rGstm1, rGstm2, rGstm5 and rGstm7 
expression (Figure 4.5). Neither of the drug treatments affected the vascular gene 
expression of rGstm1, rGstm2, rGstm3, rGstm5 or rGstm7.  
 
4.3.1.2. Effect of Drugs on Renal Function and Gene Expression  
 
Basal, NADH- and NADPH-stimulated O2- production was significantly higher in 
the SHRSP renal cortex (p < 0.05; CI = –0.14, –0.02; –2.89, –1.52 and –1.43, –
0.13, respectively) and medulla than WKY (p < 0.05; CI = –0.14, 0.02; –3.29, –
0.76 and –1.62, –0.11, respectively) with the exception of basal O2- production in 
renal medulla (Figure 4.6A). Neither of the drug treatments significantly affected 
the levels of O2- production but there was a trend for reduced NADH-stimulated 
O2- production in renal cortex from olmesartan-treated rats. H2O2 production 
following NADH or NADPH stimulation were measured to see if the similar trends 
  
Figure 4.4: Effect of drugs on vascular gene expression in reversal study 
Gene expression of p22phox, p47phox, rac1 and AT1R relative to SHRSP expression levels. 
RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; Olme = 
olmesartan. 
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Figure 4.5: Effect of drugs on vascular rGstm gene expression in reversal study 
Gene expression of rGstm1, rGstm2, rGstm3, rGstm5 and rGstm7 relative to SHRSP 
expression levels. RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; 
Olme = olmesartan. 
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Figure 4.6: Reversal study – Superoxide and hydrogen peroxide production in renal cortex and medulla 
(A) Basal, NADH- and NADPH-stimulated O2- production in renal cortex and medulla.  
(B) H2O2 production stimulated with NADH or NADPH in renal cortex or medulla. H + H = Hydralazine + hydrochlorothiazide; Olme = olmesartan; 
SHRSP = stroke-prone spontaneously hypertensive rat; WKY = Wistar Kyoto; ns = non-significant. 
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 could be observed. SHRSP rats produced significantly higher levels of H2O2 in 
renal cortex with both NADH and NADH stimulation compared to WKY. There was 
also a non-significant trend towards higher levels of H2O2 production in renal 
medulla from SHRSP compared to WKY (Figure 4.6B). A small reduction in 
NADH-stimulated H2O2 production in renal cortex was obtained by both drug 
treatments but these effects did not reach statistical significance. 
 
As with vascular tissues, gene expression levels of renal NAD(P)H oxidase 
subunits, regulatory protein rac1 and AT1R gene expression were measured to 
determine if the difference in ROS production between SHRSP and WKY was due 
to differences in gene expression levels (Figure 4.7). SHRSP expressed 
significantly higher level of p47phox mRNA than WKY (p = 0.032; CI = 0.12, 1.07) 
but there were no significant differences in gene expression of p22phox, rac1 or 
AT1R. The expression levels of AT1R, p22phox, p47phox or rac1 were not affected by 
either drug treatments. 
 
SHRSP expressed significantly lower rGstm1 than WKY in renal tissue by 
approximately 5-fold (p < 0.001; CI = –2.69, –2.02), rGstm3 by approximately 1-
fold (p = 0.002; CI = –1.45, –0.25) and rGstm7 by approximately 0.5-fold (p < 
0.001; CI = –0.90, –0.27) (Figure 4.8). There were no significant difference in 
rGstm2 or rGstm5 expression between SHRSP and WKY. Neither drug treatments 
affected the expression levels of the rGstm isoforms.  
 
4.3.2. Olmesartan Prevention Study 
 
At 8 weeks of age, the SBP of prehypertensive SHRSP rats was 130mmHG ± 
10mmHg, similar to WKY SBP of 129mmHg ± 13mmHg (Figure 4.9). The SHRSP 
rats SBP began to rise, reaching 188mmHg ± 21mmHg by 11 weeks of age and 
remained at this level for the rest of the duration of the study. The WKY SBP 
remained between 125mmHg and 137mmHg for the course of the study. 
Olmesartan and H + H significantly prevented the rise in SBP observed in control 
SHRSP over the course of the 8-week treatment period (p < 0.001). SBP of 
olmesartan and H + H treated rats were maintained at equivalent levels to that of 
WKY rats. 
 
  
Figure 4.7: Effect of drugs on renal gene expression in reversal study 
Gene expression of p22phox, p47phox, rac1 and AT1R relative to SHRSP expression levels. 
RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; Olme = 
olmesartan.  
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Figure 4.8: Effect of drugs on renal rGstm gene expression in reversal study 
Gene expression of rGstm1, rGstm2, rGstm3, rGstm5 and rGstm7 relative to SHRSP 
expression levels. RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; 
Olme = olmesartan.  
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Figure 4.9: Prevention study systolic blood pressure 
Prehypertensive 8-week-old SHRSP males were treated with either drug for 8 weeks. 
WKY rats of the same age were included in parallel. H + H = Hydralazine + 
hydrochlorothiazide; Olme = olmesartan. 
 
 
Figure 4.10: Prevention study vascular superoxide production 
Basal and NADH-stimulated O2- production in aorta from WKY and SHRSP rats treated 
with vehicle, hydralazine + hydrochlorothiazide (H + H) or olmesartan (Olme).  
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 4.3.2.1. Effect of Drugs on Vascular Function and Gene Expression  
 
As with the reversal study, basal and NADH-stimulated O2- productions were 
measured as a marker of oxidative stress (Figure 4.10). There was no significant 
difference in basal O2- production between the SHRSP and WKY rats. There was 
a trend towards higher levels of NADH-stimulated O2- production in SHRSP but 
this did not reach statistical significance. Olmesartan appeared to reduce NADH-
stimulated O2- production to the WKY levels but this reduction was not statistically 
significant. H + H did not affect the basal or NADH-stimulated O2- production.  
 
Again, in order to determine if the difference in O2- production between SHRSP 
and WKY was due to differences in expression levels of vascular NAD(P)H 
oxidase subunits or Ang II stimulation, the gene expression of p22phox, p47phox, 
rac1 and AT1R were measured (Figure 4.11). There were no significant differences 
in p22phox, p47phox, rac1 or AT1R gene expression levels between the SHRSP 
control and WKY. Neither of the drug treatments significantly affected the gene 
expression of p22phox, p47phox, rac1 or AT1R.  
 
SHRSP expressed significantly lower rGstm1 than WKY by approximately 0.6-fold 
(p < 0.001) and rGstm5 by approximately 0.8-fold (p = 0.005; CI = –1.09, –0.37) 
(Figure 4.12). There were no significant differences in rGstm2, rGstm3 and rGstm7 
between SHRSP control and WKY. Olmesartan significantly increased rGstm3 
expression in SHRSP by approximately 0.5-fold (p = 0.003; CI = –1.21, –0.06) and 
rGstm7 by approximately 0.4-fold (p = 0.045; CI = –1.04, –0.07). Both H + H and 
olmesartan significantly increased rGstm5 expression by approximately 0.6-fold (p 
= 0.018; CI = –1.15, –0.13) and 0.7-fold (p = 0.010; CI = –1.26, –0.24), 
respectively. Although H + H increased rGstm3 and rGstm7 expression, these 
were not statistically significant. Neither drug treatments significantly affected the 
expression levels of rGstm1 and rGstm2 
 
4.3.2.2. Effect of Drugs on Renal Function and Gene Expression  
 
SHRSP controls demonstrated significantly higher NADH-stimulated O2- 
production in renal cortex and medulla than WKY (Figure 4.13A). The higher 
NADPH-stimulated O2- production in renal cortex and medulla from SHRSP 
  
Figure 4.11: Effect of drugs on vascular gene expression in prevention study 
Gene expression of p22phox, p47phox, rac1 and AT1R relative to SHRSP expression levels. 
RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; Olme = 
olmesartan. 
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Figure 4.12: Effect of drugs on vascular rGstm gene expression in prevention study 
Gene expression of rGstm1, rGstm2, rGstm3, rGstm5 and rGstm7 relative to SHRSP 
expression levels. RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; 
Olme = olmesartan. 
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Figure 4.13: Prevention study – Superoxide and hydrogen peroxide production in renal cortex and medulla 
(A) Basal, NADH- and NADPH-stimulated O2- production in renal cortex and medulla.  
(B) H2O2 production stimulated with NADH or NADPH in renal cortex or medulla. H + H = Hydralazine + hydrochlorothiazide; Olme = olmesartan; 
SHRSP = stroke-prone spontaneously hypertensive rat; WKY = Wistar Kyoto; ns = non-significant. 
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 compared to WKY was not significant. There were no significant differences in 
basal O2- production in either cortical or medullary tissues between SHRSP and 
WKY. Both treatments did not affect the levels of O2- production but there was a 
trend for reduced NADH-stimulated O2- production in renal cortex from 
olmesartan-treated rats. SHRSP control also demonstrated a non-significant trend 
towards higher H2O2 production with NADH-stimulation in renal cortex and 
medulla, as well as NADPH-stimulation in renal medulla than WKY (Figure 4.13B). 
As with reversal study, both treatments reduced NADH-stimulated H2O2 production 
in renal cortex but these effects did not reach statistical significance. Both 
treatments did not affect NADH-stimulated H2O2 production in renal medulla or 
NADH-stimulated H2O2 production. 
 
SHRSP untreated controls demonstrated a small (approximately 0.3-fold) but 
significantly lower p22phox mRNA expression than WKY (p = 0.023; CI = –0.67, –
0.08) (Figure 4.14). Both H + H and olmesartan significantly increased p22phox 
gene expression (p = 0.010; CI = –0.65, –0.08 and p = 0.012; CI = –0.62, –0.06, 
respectively). There were no significant differences in p47phox, rac1 and AT1R gene 
expression between SHRSP control and WKY. Olmesartan significantly increased 
AT1R gene expression by approximately 0.4-fold (p = 0.012; CI = –0.82, –0.14) 
while H + H did not affect AT1R gene expression. Both drug treatments did not 
affect p47phox and rac1 gene expression. 
 
SHRSP controls expressed significantly lower rGstm1 than WKY in renal tissue by 
approximately 5-fold (p < 0.001; CI = –2.97, –2.22), rGstm3 and rGstm5 by 
approximately 1-fold (p < 0.001; CI = –1.33, –0.57 and p < 0.01; CI = –1.35, –0.60, 
respectively), and rGstm7 by approximately 0.8-fold (p < 0.001; CI = –1.23, –0.51) 
(Figure 4.15). There was no significant difference in rGstm2 expression level 
between SHRSP control and WKY groups. Olmesartan treatment significantly 
increased renal rGstm5 expression by approximately 0.4-fold (p < 0.005; CI = –
0.83, –0.10) but was not affected by H + H treatment. Both drug treatments did not 
affect the renal rGstm1, rGstm2, rGstm3 and rGstm7 expression. 
 
  
Figure 4.14: Effect of drugs on renal gene expression in prevention study 
Gene expression of p22phox, p47phox, rac1 and AT1R relative to SHRSP expression levels. 
RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; Olme = 
olmesartan. 
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Figure 4.15: Effect of drugs on renal rGstm gene expression in prevention study 
Gene expression of rGstm1, rGstm2, rGstm3, rGstm5 and rGstm7 relative to SHRSP 
expression levels. RQ = relative quantitation; H + H = Hydralazine + hydrochlorothiazide; 
Olme = olmesartan. 
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 4.4. Discussion 
 
Despite significant reductions in SBP by both olmesartan and H + H to equivalent 
normotensive levels and some improvements in O2- levels,  this study was unable 
to show major effects on rGstm expression levels, particularly rGstm1. This 
inability to improve rGstm expression indicate that the rGstm gene defect cannot 
be modulated by changes in BP. 
 
4.4.1. Vascular Effects of Antihypertensive Treatment 
 
Vascular O2- production was significantly higher in SHRSP when compared to 
WKY in the reversal study. However, vascular O2- production was not different 
between SHRSP and WKY in the prevention study. This observation was 
unexpected since a previous study from our group has shown higher O2- 
production in abdominal aorta from SHRSP compared to WKY (248). Neither 
hydralazine plus hydrochlorothizide or olmesartan treatments significantly affect 
the vascular O2- despite lowering BP to normotensive levels. This was unexpected 
as previous studies have shown reduction in vascular O2- production with AT1R 
blockade (240;244). However, there was a trend towards reduction in O2- in 
vascular tissue of rats treated with AT1R blocker. 
 
There was no significant difference in vascular AT1R, p22phox, p47phox and rac1 
expression levels between SHRSP and WKY. Neither treatment affected vascular 
AT1R, p22phox, p47phox and rac1 expression levels. These results confirm data from 
a previous study in male apolipoprotein E knockout mice, where olmesartan did 
not affect vascular AT1R, p47phox and rac1 expression nor reduce superoxide 
production or NAD(P)H oxidase activity (243).  
 
Untreated SHRSP expressed significantly higher vascular rGstm3 than WKY in the 
reversal study. This is not surprising since in the previous characterisation chapter, 
rGstm3 was shown to increase with age in the SHRSP to a significantly higher 
level than WKY. There were no differences in vascular rGstm1, rGstm2, rGstm5 
and rGstm7 expression in the reversal study. In the prevention study, rGstm1 and 
rGstm5 were significantly higher in WKY thoracic aorta than SHRSP. In contrast to 
the previous characterisation chapter, the higher vascular rGstm1 and rGstm5 
 expression in WKY rats of the same age did not reach statistical significance. Both 
drug treatments significantly increased vascular rGstm5 expression but only 
olmesartan treatment significantly increased rGstm3 and rGstm7 expression. 
These results suggest that different control mechanisms may regulate or influence 
the expression of different vascular rGstm isoforms. RAS may influence 
expression of some of the rGstm genes via Ang II. As the improvements in rGstm 
expression were observed in the prevention but not the reversal study, this 
suggests that once mature levels of BP have been achieved the changes in rGstm 
expression cannot be reversed.  
 
4.4.2. Renal Effects of Antihypertensive Treatment 
 
Generally, data from the current reversal and prevention studies, demonstrated 
that SHRSP produces higher levels of renal ROS than WKY rats. The levels of 
ROS production in renal cortex and renal medulla were similar in 16-week-old rats 
but were higher in renal medulla than renal cortex in 20-week-old rats. This is in 
agreement with the study by Zou et.al. 2001, in which they showed that renal outer 
medulla exhibited the greatest enzymatic activities for O2- production (249). 
Increased superoxide concentration within the renal medulla selectively reduced 
medullary blood flow resulting in chronic hypertension (250), possibly involving 
other ROS such as H2O2 (251). There were trends towards decreased ROS 
production in renal cortex by both drug treatments when stimulated with NADH 
and NADPH, the largest effect occurring with olmesartan treatment. The 
reductions in ROS production were greater in reversal study compared to 
prevention study. This suggests that some of the renal oxidative stress in 
hypertension was a consequence of increased BP. 
 
Results from the reversal study showed that SHRSP expressed small but 
significantly higher levels of p47phox mRNA than WKY. In contrast, SHRSP 
expressed significantly less p22phox mRNA than WKY in the prevention study. 
Prevention of BP increase with both drug treatments increased p22phox expression 
significantly, and olmesartan treatment increased AT1R expression. These results 
were surprising as SHRSP was expected to express higher levels of p22phox, 
p47phox and rac1, which would be decreased with AT1R blockers. Despite this, the 
differences were less than 0.5-fold and may consequently have little biological 
 importance. Zou et. al. 2001 previously determined that NADPH oxidase and 
mitochondrial enzymatic sources were responsible for O2- production in outer 
medulla (249). It is also likely that the expected differences in gene expression 
were more pronounced in the medulla. However, for the current study, whole 
kidney was homogenised for gene expression measurements therefore the 
important differences might have been missed. 
 
SHRSP expressed significantly lower renal rGstm1, rGstm3 and rGstm7 than 
WKY in both reversal and prevention study. SHRSP also expressed significantly 
lower rGstm5 than WKY in the prevention study. This confirms the differential 
expression of rGstm genes observed in the previous chapter. Preventing BP 
increase with olmesartan increased rGstm5 expression significantly but only 
slightly and had no effect on the other rGstm family members. This suggests that 
the differential rGstm gene expression ws not a secondary effect of high blood 
pressure. This is further supported by the observation that rGstm1 gene 
expression was reduced in SHRSP prior to development of hypertension as 
reported in the previous chapter and by McBride et. al. 2005 (67). Both drug 
treatments did not have a great impact on the rGstm gene expression, despite 
improvements in SBP in the reversal study. Okuda et. al. 2002 also previously 
identified rGstm1 as a positional and physiological candidate gene for blood 
pressure regulation (65;66). In one of their studies, short-term treatment with the 
antihypertensive drugs enalapril or hydralazine decreased the blood pressure of 
the SHR but did not modify the expression levels of renal rGstm1 (65). Taken 
together, these results demonstrated that improvement in BP does not improve 
rGstm1 gene expression. The rGstm gene family is less consistently influenced by 
pharmacological interventions due to strain-dependent genetic abnormalities.  
 
 CHAPTER 5:  GENE – PHENOTYPE INTERACTIONS IN THE OXIDATIVE 
STRESS PATHWAY  
 
5.1. Introduction 
 
We hypothesise that polymorphisms in enzymes responsible for the balance 
between ROS species and NO bioavailability influence the risk of developing 
hypertension and thus coronary artery disease. The aim of this study was to look 
for association between three polymorphisms in CYBA and NOS3 genes with 
coronary artery disease and arterial stiffness. CYBA and NOS3 genes are 
selected as a representative gene on each side of the balance. CYBA encodes for 
p22phox subunit of NAD(P)H oxidase, which produces superoxide anion (the first 
reactive oxygen species of the reactive oxygen radical cascade) while NOS3 
encodes for eNOS enzyme, which produces NO required for vasodilation. Three 
arterial stiffness indices were selected for investigating the association between 
CYBA and NOS3 polymorphisms and arterial stiffness. 
 
5.1.1. CYBA Polymorphisms 
 
In recent years, polymorphisms within the 8.5kB long genomic CYBA gene 
localised to chromosome 16q24, encoding the p22phox subunit of NAD(P)H 
oxidase, have been associated with higher risk of CAD (252). Four types of allelic 
polymorphisms in the CYBA gene were reported by Dinauer et. al. 1990 (253). In 
addition, there are three other SNPs within the CYBA gene (254). Of these, the 
C242T polymorphism in exon 4 of CYBA results in a change from histidine at 
residue 72 to tyrosine (His72Tyr), in the potential haem-binding site  (253). The 
SNP A640G in the 3’ untranslated region (3’UTR) of the mRNA transcript had 
been suggested to be related to mRNA processing and stability, which may 
influence p22phox protein biosynthesis (255). The C242T, but not the A640G 
polymorphism, was first associated with CAD in a Japanese population (256). The 
authors speculated that the C242T polymorphism might modulate the activity and 
regulation of NAD(P)H oxidase, which leads to decrease in oxidative stress and 
thus reduce susceptibility to CAD. In contrast, the A640G, but not the C242T 
polymorphism, was found to be associated with CAD in the Caucasian population 
(255). Since then, there have been contrasting results as to whether there was an 
 association of either of these two SNPs with CAD (257-259). A new polymorphism 
in the promoter region (A-930G) of the human CYBA gene was found to be 
associated with essential hypertension in the Caucasian population (260). 
Transfection experiments on rat vascular smooth muscle cells (VSMCs) showed 
that the G allele produced increased reporter gene expression by 30% in cells 
from hypertensive rats (260;261). In this study, investigation of polymorphisms A-
930G, C242T and A640G as individual SNP as well as haplotype in the West of 
Scotland population and to determine if there was an association with CAD as 
single locus polymorphism and as three-SNP haplotype. C242T was reported to 
be in linkage disequilibrium with A640G in Caucasians (255) but there was no 
information regarding the linkage disequilibrium score between either C242T or 
A640G with A-930G. Hence, analysis of linkage disequilibrium between the three 
SNPs was also undertaken. 
 
5.1.2. NOS3 Polymorphisms 
 
Endothelial nitric oxide synthase (eNOS) is encoded by 21kB NOS3 gene 
localised to chromosome 7q36 (262;263). To date, the two most studied 
polymorphisms due to their transcriptional and functional effects are T-786C in the 
promoter region and G894T in exon 7. Three linked mutations (T-786C, A-922G 
and T-1468A) in the 5’-flanking region of NOS3 gene were associated with 
coronary spasm in a Japanese population (264). Reporter assays of constructs of 
the mutations showed that T-786C reduced promoter activity by 52%. The G894T 
polymorphism results in the production of glutamate or aspartate at position 298 
respectively (265;266). The 894T allele produces a protein that is more 
susceptible to proteolytic cleavage. These polymorphisms had been associated 
with CAD, acute myocardial infarction, atherosclerosis and hypertension (264;267-
275). A third polymorphism consists of either four or five tandem repeats of 27bp 
in intron 4, known as 4A or 4B respectively, and has been associated with 
expression levels of eNOS (276). The association between this polymorphism and 
CAD is less consistent (269;272;277). In this project, associations between these 
three polymorphisms and CAD as single locus polymorphisms and haplotype was 
investigated. In addition, it was determined whether different expression levels 
observed with 4A/4B might be the effect of linkage disequilibrium with T-786C or 
G894T.  
 5.1.3. Arterial Stiffness and Vascular Compliance 
 
Arterial stiffness is an intermediate phenotype and can be assessed non-
invasively. Arterial stiffness describes rigidity of arterial walls, often expressed as 
indices such as large (C1) and small artery compliance (C2) and augmentation 
index (AIx) (Table 5.1) (278;279). C1 describes the relationship between pressure 
change and volume change in the arteries during the exponential component of 
diastolic pressure decay. C2 describes the relationship between oscillating 
pressure change and oscillating volume change around the exponential pressure 
decay during diastole. AIx is the difference between the second and first systolic 
peaks as a percentage of pulse pressure. Arterial stiffness increases both with age 
and BP, and is elevated in subjects with other risk factors for CVD (278;280). 
Arterial stiffness is also related to endothelial function in large and small arteries 
(281;282). Changes in arterial stiffness can be detected before the appearance of 
clinically apparent vascular disease (278). AIx is also highly predictive of CV 
mortality (283).  
 
The first aim of this study was to look for association between the three 
polymorphisms in CYBA and NOS3 genes with CAD as single locus 
polymorphisms and haplotypes consisting of 3 polymorphisms. The second aim of 
this study was to look for association between CYBA and NOS polymorphisms 
with arterial stiffness indices C1, C2 and AIx as single locus polymorphisms and 3-
polymorphisms haplotypes. 
 
5.2. Materials & Methods 
 
The vascular compliance measurements were carried out by Dr. Christian Delles, 
Dr. Lukas Zimmerli, Dr. David McGrane and Dr. Russell Drummond. The details 
for the equipments, chemicals, reagents and consumables used in this study are 
listed in Appendix B. 
 
5.2.1. Subjects 
 
Full ethical approval was attained from the West Ethics Committee, Glasgow and 
all the subjects had given informed consent for the use of their DNA for 
  
Table 5.1: Indices of arterial stiffness 
 
Terms Definitions Formula 
Pulse wave velocity (PWV) Velocity of travel of the pulse along a length of artery with the equation  
Distance (cm) 
∆t (s) 
Capacitative or “large” artery compliance (C1) 
 
(Windkessel Model) 
Change in volume (ΔV)/ change in pressure (ΔP) during diastolic decay 
(ml/mm Hg)  
∆V (cm3) 
∆P (mmHg) 
Oscillatory or “small” artery compliance (C2) ΔV/ΔP during oscillations around diastolic decay (ml/mmHg)  
∆V (cm3) 
∆P (mmHg) 
Augmentation index (AIx) 
 
Difference in pressure between first and second peaks (ΔP) of the central 
pressure waveform, expressed as a percentage of PP.  
∆P x 100% 
PP 
 
R = systemic vascular resistance; L = inertia of the blood; P1 = proximal pressure; P2 = distal pressure. Adapted from Ref. (278;279;284;292)  
 cardiovascular research. The coronary artery disease (CAD) cohort consisted of 
patients with angiographically proven obstructive CAD, who were about to undergo 
coronary artery bypass graft surgery. Patients with evidence of secondary 
hypertension or hormonal, renal and hepatic abnormalities were excluded form 
this study. Patients who did not have regular sinus rhythm were also excluded as 
arrythmias including atrial fibrillation change the pressure shape. The control 
subjects were recruited from local universities and a local health club. Control 
subjects underwent clinical assessment and did not have evidence of CAD or 
other CVD including hypertension. Each subject had their baseline demographic 
measurements recorded.  
 
5.2.2. Pulse Wave Analysis 
 
The subjects were placed in the supine position and right radial artery waveforms 
were acquired with the use of a calibrated proprietary tonometer (model CR-2000 
Hypertension Diagnostics Inc.) after a 30min resting period. The subject’s arm was 
stabilised in an angulated wrist support and radial artery waveforms analysed for a 
20sec period. The CR-2000 device then utilises the 4 element modified 
Windkessel model to generate large (C1) and small artery elasticity index (C2) 
(284;285). For both C1 and C2, the average of four independent readings was 
calculated. The SphygmoCor device (PWV Medical, Sydney, Australia) was used 
for estimation of the central augmentation index (AIx) corrected for heart rate, 
expressed as a percentage of pulse pressure. 
 
5.2.3. DNA samples 
 
Whole blood samples in ethylenediaminetetraacetic acid (EDTA) tubes collected 
were stored at 4°C for DNA extraction. DNA samples were extracted routinely 
within a fortnight in batches using the Promega Wizard genomic DNA kit according 
to the manufacturer’s instructions. The DNA samples were re-solubilised in 400μl 
of 1x Tris borate EDTA (TBE) buffer and quantified as described in section 2.4.3. 
 
 5.2.4. PCR 
 
An optimisation PCR with annealing temperature set as a gradient from 50°C to 
65°C were run prior to any experimental PCR of the DNA samples to determine 
the optimal PCR conditions for every polymorphism. The PCR reactions were run 
on the Peltier Thermal Cycler (PTC-225). The primers for each of the genotype, 
the sizes of their PCR products and the annealing temperature used are as in 
Table 5.2.  
 
For the CYBA A-930G, C242T, NOS3 T-786C and intron 4 VNTR, a 20μl PCR 
reaction was set up containing a final concentration of 1.5mM MgCl2, 1X buffer, 
0.2mM dNTPs, 0.5μM of each primer, 0.01u/μl of Qiagen HotStar Taq polymerase  
and 25ng of DNA. The forward primer used for genotyping of the eNOS intron 4 
alleles was tagged with 6-FAM at the 5’-end. For the CYBA A640G and NOS3 
G984T, a 20μl PCR reaction was set up containing a final concentration of 1.5mM 
MgCl2, 1X buffer, 1X Q-solution, 0.2mM dNTPs, 0.5μM of each primer, 0.01u/μl of 
Qiagen HotStar Taq polymerase and 25ng of DNA.  
 
5.2.5. Genotyping 
 
5.2.5.1. Genotyping by Sequencing 
 
The CYBA A-930G and A640G; and NOS3 T-786C and G894T were genotyped 
by direct sequencing as described in section 2.4.6. 
 
5.2.5.2. Genotyping of by RFLP 
 
The PCR products for C242T polymorphism of 348bp were digested with 
restriction enzyme (RE) RsaI at 37°C for 2hr. A 20μl reaction was set up with 10μl 
PCR products, 1u/μl RE and 1X RE buffer. There is no RsaI restriction site in the 
C242 allele of p22phox while T242 mutation introduces a RsaI site digesting the 
PCR product into 2 fragments of 160bp and 188bp. The digested fragments were 
resolved in a 2% agarose gel. 14 random samples were amplified and genotypes 
determined by sequencing. As these were shown to match completely with the 
  
Table 5.2: Genotyping primers for CYBA and NOS3 
 
Gene SNPs Primers Sequences (5'---3') AT PCR size 
CYBA A-930G For CCACCAAGTGCCTCGGATGG 
(p22phox) Promoter Rev TGGACTCCCTGACAGGTGCC 
59°C 255bp 
      
CYBA C242T For TGCTTGTGGGTAAACCAAGG 
(p22phox) Tyr72His Rev GGAAAAACACTGAGGTAAGTG 55°C 348bp 
      
CYBA A640G For AGCAGTGGACGCCCATGGAGCCCAA 
(p22phox) 3'UTR Rev CGCTGCGTTTATTGCAGGTGGGTGC 61°C 258bp 
      
NOS3 T-786C For TGGAGAGTGCTGGTGTACCCCA 
(eNOS) Promoter Rev GCCTCCACCCCCACCCTGTC 62°C 180bp 
      
NOS3 VNTR (27bp) For *AGGCCCTATGGTAGTGCCTTT  4A: 393bp 
(eNOS) Intron 4 Rev TCTCTTAGTGCTGTGGTCAC 57°C 4B: 420bp 
      
NOS3 G894T For AAGGCAGGAGACAGTGGATGGA 
(eNOS) Asp298Glu Rev CCCAGTCAATCCCTTTGGTGCTCA 58°C 248bp 
 
*6-FAM dye was tagged to 5'-end of primer 
 
 results from RFLP, further analysis of C242T polymorphism were done using 
RFLP. 
 
5.2.5.3. Genotyping by PAGE Resolution 
 
2μl of the PCR products were diluted 1/20, of which 1μl were added into 10μl of 
formamide with DNA ladder GeneScanTM 500 LizTM size standard in a barcoded 
plate and analysed on the 3730 DNA analyser and GeneMapper v2.0 software. 
The rest of the un-diluted PCR products were kept at -20°C. When necessary, 
different dilutions of the PCR products were prepared for analysis on the 3730 
DNA analyser. 
 
5.2.6. Statistical Analysis 
 
The linkage disequilibrium (LD) tests were performed using the EMLD software 
(Author: Qiqing Huang; https://epi.mdanderson.org/~qhuang/Software/pub.htm), 
where the pair-wise haplotype reconstruction and frequencies were estimated 
based on the expectation-maximisation algorithm. The genotype analyses were 
performed using the software PHASE version 2.1 
(http://www.stat.washington.edu/stephens/software.html) (286;287). The genotype 
analyses for both genes were run with 200 iterations, 5 thinning intervals and burn-
in of 200, with the algorithm run repeated ten times. All 153 samples, including 
both cases and controls, were used to estimate recombination rates. The 
likelihood ratio statistical test (not affected by HWE) was used to test for 
differences among the cases and controls. The 2-proportions test was used to test 
for significance between the two groups for each haplotype combination. ANOVA 
was used to test for association between each polymorphism and phenotypic traits 
of CAD. 
 
The haplotype association analysis was carried out using the large artery 
compliance, small artery compliance and AIx as the phenotypic traits of interest in 
both genes. This was done using the software whap (Author: Shaun Purcell and 
Pak Sham; http://pngu.mgh.harvard.edu/purcell/whap/). This programme used the 
likelihood ratio test to determine if any of the haplotypes were significantly 
associated with the phenotypic traits of interest. The haplotype frequencies 
 generated by whap programme was similar to the haplotype frequencies 
generated by PHASE. The whap programme also gives an overall p-value for 
association between haplotype frequencies and clinical phenotypes, comparing 
the two groups. 
 
5.3. Results 
 
A significantly higher proportion of the CAD subjects were males and older than 
the control subjects (Table 5.3). The pulse pressure (PP) and AIx were 
significantly higher in the CAD group. The C2 was significantly lower in the CAD 
group. There were no statistical difference in SBP, DBP C1 and heart rate 
obetween the CAD and control groups. The CAD subjects had significantly higher 
levels of plasma triglycerides and very low density lipoprotein (VLDL) cholesterol 
but significantly lower levels of total cholesterol, high density lipoprotein (HDL) 
cholesterol and low density lipoprotein (LDL) cholesterol. 
 
5.3.1. Genotype and Haplotype Analysis of CYBA Polymorphisms 
 
Odds ratios (OR) were estimated from logistic regression analysis for the 
genotypes without making any assumptions and with the assumptions for 
recessive and dominant models. The Hardy-Weinberg equilibrium (HWE) tests 
(Table 5.4) showed that the C242T and A640G polymorphisms were not deviant 
from HWE, while the A-930G SNP deviated from HWE in both groups (p ≤ 0.05).  
 
The most common genotypes are -930G/G, 242C/T and 640A/G (Table 5.4). The 
logistic regression analyses found that the -930A/A frequencies were significantly 
different between the patients and controls (p = 0.042) but no evidence of 
association was found for the C242T and A640G SNPs with CAD. The frequencies 
of the -930A/A genotype between the two groups were significantly different in the 
recessive model (p = 0.011) but not the dominant model (p = 0.535). The T allele 
at position 242 was previously shown to have a dominant effect (288) but there 
was no significant difference in genotype frequencies of C242T between the two 
groups from the current study, even when the dominant model was applied. There 
was no significant difference in the A640G genotype frequencies between the two 
groups, even when the recessive or dominant models were employed.  
  
 
 
 
Table 5.3: Baseline characteristics of the study subjects 
 
Characteristics Control (n=156) CAD (n=209) p-value 
Gender (M/F) 81/75 161/48 <0.001* 
Age (year) 53 ± 11 62 ± 9 <0.001* 
Systolic BP (mmHg) 130.4 ± 16.5 132.8 ± 18.4 0.228 
Diastolic BP (mmHg) 73.9 ± 9.2 71.9 ± 9.8 0.064 
Pulse pressure (mmHg) 56.6 ± 11.1 60.1 ± 12.4 0.011* 
C1 (ml/mmHg x 10) 13.88 ± 4.17 14.71 ± 4.80 0.107 
C2 (ml/mmHg x 100) 5.58 ± 3.22 4.60 ± 2.70 0.005* 
Augmentation Index (%) 22.8 ± 12.2 26.5 ± 11.1 0.009* 
Heart Rate (beats/min) 62 ± 10 61 ± 11 0.206 
Total cholesterol (mmol/L) 5.15 ± 1.08 4.09 ± 0.91 <0.001* 
Triglycerides (mmol/L) 1.33 ± 0.78 1.91 ± 1.08 <0.001* 
HDL cholesterol (mmol/L) 1.44 ± 0.37 1.06 ± 0.35 <0.001* 
LDL cholesterol (mmol/L) 3.11 ± 1.00 2.16 ± 0.76 <0.001* 
VLDL cholesterol (mmol/L) 0.69 ± 0.38 0.87 ± 0.49 0.001* 
 
All data are expressed as mean ± SD. Augmentation index (AIx) has been corrected for 
the heart rate. The gender distributions in the two groups were compared using the χ2 
test. The other comparisons were made using the 2-sample t-test for normally distributed 
data and Mann-Whitney U-test for data not following normal distribution. * denotes 
characteristics that are significantly different between the control and coronary artery 
disease (CAD) groups. BP = blood pressure; C1 = large artery compliance; C2 = small 
artery compliance; HDL = high density lipoprotein; LDL = low density lipoprotein; VLDL = 
very low density lipoprotein 
  
 
Table 5.4: Single SNP genotype distribution of CYBA gene 
 
 Control CAD OR (95% CI) p-value
A-930G (n = 136) (n = 204)  
GG 64 (47.06%) 103 (50.49%) 1.00   
AG 28 (20.59%) 60 (29.41%) 1.33 (0.77 - 2.30) 1.696 
AA 44 (32.35%) 41 (20.10%) 0.58 (0.34 – 0.98) 0.042* 
HWE χ2 = 17.570 χ2 = 13.318    
Recessive Model 
GG or AG 92 (67.65%) 163 (79.90%) 1.00   
AA 44 (32.35%) 41 (20.10%) 0.53 (0.32 - 0.86) 0.011* 
Dominant Model 
GG 64 (47.06%) 103 (50.49%) 1.00   
AG or AA 72 (52.94%) 101 (49.51%) 0.87 (0.56 - 1.35) 0.535 
 
C242T (n = 138) (n = 203)    
CC 56 (40.58%) 88 (43.35%) 1.00   
CT 64 (46.38%) 96 (47.29%) 0.95 (0.60 - 1.51) 0.843 
TT 18 (13.04%) 19 (9.36%) 0.67 (0.32 - 1.39) 0.283 
HWE χ2 = 0.000 χ2 = 0.844    
Recessive Model 
CC or CT 120 (86.96%) 184 (90.64%) 1.00   
TT 18 (13.04%) 19 (9.36%) 0.69 (0.35 - 1.36) 0.285 
Dominant Model 
CC 56 (40.58%) 88 (43.35%) 1.00   
CT or TT 82 (59.42%) 115 (56.65%) 0.89 (0.58 - 1.38) 0.611 
 
A640G (n = 136) (n = 206)    
AA 37 (27.21%) 43 (20.87%) 1.00   
AG 64 (47.06%) 105 (50.97%) 0.99 (0.59 – 1.67) 0.970 
GG 35 (25.74%) 58 (28.16%) 0.70 (0.38 – 1.29) 0.252 
HWE χ2 = 0.192 χ2 = 0.027    
Recessive Model 
GG or AG 99 (72.79%) 163 (79.13%) 1.00   
AA 37 (27.21%) 43 (20.87%) 0.71 (0.43 - 1.17) 0.088 
Dominant Model 
GG 35 (25.74%) 58 (28.16%) 1.00   
AG or AA 101 (74.26%) 148 (71.84%) 0.88 (0.54 - 1.44) 0.311 
 
The odds ratio (OR) was estimated from logistic regression analysis. * denotes 
significantly different frequency between the two groups. CAD = coronary artery disease; 
CI = confidence interval; HWE = Hardy Weinberg equilibrium. 
 
  
As all the three SNPs studied occur at different allele frequencies. Pair-wise LD 
score by r2 makes the assumption of equal allele frequencies (289;290) so only the 
pair-wise LD score by |D’| is relevant. LD analysis by |D’| showed that C242T and 
A640G were in relatively low LD in control (0.482) and CAD (0.374) groups. A-
930G and C242T or A-930G and A640G were not linked in control (0.034, 0.188 
respectively) or CAD (0.018, 0.068 respectively) groups. 
 
The frequencies of three-SNP haplotypes of the CYBA gene in the CAD and 
healthy groups are summarised in Table 5.5. The most commonly observed 
haplotype in both groups is -930G/242C/640G and the least common haplotype was 
-930G/242T/640G. The frequencies of the other six haplotypes differed slightly 
between the CAD and control groups in the order of how common or uncommon 
they were. The comparison of the haplotype frequencies in both groups by the 
software PHASE gave an overall p-value of borderline significance (p = 0.06). 2-
proportions test was used to look for significantly different frequencies of each of 
the haplotype combinations. The most different haplotype between the two groups 
is the -930G/242C/640G but this did not reach statistical significance. 
 
5.3.2. CYBA Gene – Phenotype Interactions 
 
The significance of the influence of CYBA polymorphisms as single locus on 
clinical phenotypes are summarised in Table 5.6. A-930G was significantly 
associated with heart rate in both CAD and control groups. In the control group, 
the heart rate in subjects with -930A/A was 65 ± 11 beats/min, 61 ± 9 beats/min in 
subjects with -930G/G and 59 ± 10 beats/min in subjects with -930A/G. In the CAD 
population, the heart rate in subjects with -930A/A was 62 ± 12 beats/min, 63 ± 10 
beats/min in subjects with -930G/G and 56 ± 10 beats/min in subjects with -930A/G. 
The C242T and A640G polymorphisms were not associated with any of the clinical 
phenotypes examined. There were also no significant associations between any of 
the haplotypes with vascular compliance indices C1 (p = 0.385), C2 (p = 0.742) 
and AIx (p = 0.188). 
 
 Table 5.5: Frequency of three-polymorphism haplotypes of the CYBA gene  
 
Haplotype Control (n=138) 
CAD 
(n=206) p-value 
-930 242 640    
A C A 0.088 0.090 0.897 
A C G 0.176 0.149 0.308 
A T A 0.089 0.067 0.287 
A T G 0.067 0.055 0.615 
G C A 0.159 0.162 0.911 
G C G 0.214 0.270 0.092 
G T A 0.173 0.157 0.578 
G T G 0.033 0.050 0.228 
      
Global permutation test (PAC-likelihood ratio test) for case control 
comparison 0.06 
 
2-proportions test was used to test for significance between the two groups for each 
haplotype combination. The overall significance between the two groups was tested using 
likelihood ratio test that was not based on Hardy-Weinberg equilibrium. CAD = coronary 
artery disease 
 
 
Table 5.6: Significance of the association between CYBA polymorphisms and 
clinical phenotypes as single polymorphisms 
 
 Control (n=139) CAD (n=246) 
 A-930G C242T A640G A-930G C242T A640G 
Systolic BP (mmHg) 0.800 0.375 0.484 0.316 0.062 0.447 
Diastolic BP (mmHg) 0.605 0.582 0.814 0.093 0.307 0.746 
Pulse Pressure (mmHg) 0.519 0.199 0.361 0.939 0.247 0.169 
C1 (ml/mmHg x 10) 0.189 0.917 0.682 0.304 0.153 0.168 
C2 (ml/mmHg x 100) 0.364 0.135 0.209 0.463 0.448 0.451 
Augmentation Index (%) 0.736 0.742 0.938 0.092 0.610 0.242 
Heart Rate (beats/min) 0.028* 0.776 0.710 0.005* 0.444 0.665 
 
One-way ANOVA analysis was used to test for association between each polymorphism 
and phenotypic traits in both groups. CAD = coronary artery disease  
 5.3.3. Genotype and Haplotype Analysis of NOS3 Polymorphisms  
 
Similar to CYBA polymorphisms, OR were estimated from logistic regression 
analysis for the genotypes without making any assumptions and with the 
assumptions for recessive and dominant models. The HWE tests (Table 5.7) 
showed that all three polymorphisms were not deviant from HWE in both groups.  
 
The most common genotypes were -786C/T, 4B/B and 894G/G (Table 5.7). The 
logistic regression analyses found that the G894T polymorphism was not 
associated with the absence or presence of CAD. However, 894T/T was 
significantly lower in the CAD group when recessive model was applied (p = 
0.030). The polymorphisms T-786C and intron 4A/4B were not associated with the 
absence or presence of CAD, even when the recessive or dominant model was 
applied.  
 
For the same reason as CYBA polymorphisms, only pair-wise LD score by |D’| is 
of relevance. LD analysis by |D’| showed that T-786C and 4A/4B or 4A/4B and 
G894T were in relatively high LD in control (0.718 and 0.756, respectively) and 
CAD (0.695 and 0.751, respectively) groups. T-786C and G894T were in relatively 
low LD for control (0.404) and CAD (0.484) groups. 
 
The frequencies of three-SNP haplotypes of the NOS3 gene in the CAD and 
healthy groups are summarised in Table 5.8. The most commonly observed 
haplotype in both groups was -786T/4B/894G while the least common haplotype 
was -786C/4A/894G. The frequencies estimated for the haplotypes -786C/4A/894G 
and -786T/4A/894T were less than 5%. There was no significant difference in 
haplotype frequencies between the two groups. The haplotype -786T/4A/894G was 
significantly more frequent in the CAD than the control groups. The frequencies of 
the other NOS3 haplotypes studied were not significantly different between the two 
groups. 
 
5.3.4. NOS3 Gene – Phenotype Interactions 
 
The significance of the influence of each NOS3 polymorphisms and clinical 
phenotypes are summarised in Table 5.9. The T-786C was significantly associated 
  
 
Table 5.7: Single SNP genotype distribution of NOS3 gene 
 
 Control CAD OR (95% CI) p-value
T-786C (n = 138) (n = 206)    
TT 48 (34.78%) 79 (38.35%) 1.00   
CT 63 (45.65%) 90 (43.69%) 0.87 (0.54 - 1.41) 0.565 
CC 27 (19.57%) 37 (17.96%) 0.83 (0.45 - 1.54) 0.558 
HWE χ2 = 0.254 χ2 = 0.346    
Recessive Model 
TT or CT 111 (80.43%) 169 (82.04%) 1.00   
CC 27 (19.57%) 37 (17.96%) 0.90 (0.52 - 1.56) 0.708 
Dominant Model 
TT 48 (34.78%) 79 (38.35%) 1.00   
CT or CC 90 (65.22%) 127 (61.65%) 0.86 (0.55 - 1.34) 0.502 
 
Intron 4A/4B (n = 139) (n = 201)    
BB 97 (69.78%) 153 (75.00%) 1.00   
AB 34 (24.46%) 39 (19.12%) 0.73 (0.43 - 1.23) 0.235 
AA 8 (5.76%) 12 (5.88%) 0.95 (0.38 - 2.41) 0.916 
HWE χ2 = 1.732 χ2 = 3.150    
Recessive Model 
BB or AB 131 (94.24%) 192 (94.12%) 1.00   
AA 8 (5.76%) 12 (5.88%) 1.02 (0.41 - 2.57) 1.039 
Dominant Model 
BB 97 (69.78%) 153 (75.00%) 1.00   
AB or AA 42 (30.22%) 51 (25.00%) 0.77 (0.48 - 1.25) 0.287 
 
G894T (n = 134) (n = 201)    
GG 62 (46.27%) 88 (43.78%) 1.00   
GT 45 (33.58%) 90 (44.78%) 1.36 (0.84 - 2.20) 1.784 
TT 27 (20.15%) 23 (11.44%) 0.59 (0.31 - 1.13) 0.109 
HWE χ2 = 3.559 χ2 = 0.000    
Recessive Model 
GG or GT 107 (79.85%) 178 (88.56%) 1.00   
TT 27 (20.15%) 23 (11.44%) 0.51 (0.27 - 0.94) 0.030* 
Dominant Model 
GG 61 (45.52%) 88 (43.78%) 1.00   
GT or TT 73 (54.48%) 113 (56.22%) 1.07 (0.69 - 1.67) 1.247 
 
The odds ratio (OR) was estimated from logistic regression analysis. * denotes 
significantly different frequency between the two groups. CAD = coronary artery disease; 
CI =confidence internal; HWE = Hardy Weinberg equilibrium 
 
 
 Table 5.8: Frequency of three-polymorphism haplotypes of the NOS3 gene  
 
Haplotype 
-786 4A/4B 894 
Control 
(n = 139) 
CAD 
(n = 206) p-value 
C A G 0.028 0.022 0.574 
C A T 0.112 0.103 0.767 
C B G 0.157 0.162 0.879 
C B T 0.127 0.113 0.572 
T A G 0.143 0.205 0.031* 
T A T 0.031 0.042 0.538 
T B G 0.302 0.291 0.759 
T B T 0.101 0.061 0.063 
      
Global permutation test (PAC-likelihood ratio test) for case control 
comparison 0.23 
 
2-proportions test was used to test for significance between the two groups for each 
haplotype combination. The overall significance between the two groups was tested using 
likelihood ratio test that was not based on Hardy-Weinberg equilibrium. CAD = coronary 
artery disease 
 
 
Table 5.9: Significance of the association between NOS3 polymorphisms and 
clinical phenotypes as single polymorphisms 
 
 Control (n=139) CAD (n=206) 
 T-786C 4A/4B G894T T-786C 4A/4B G894T 
Systolic BP (mmHg) 0.066 0.453 0.615 0.343 0.354 0.470 
Diastolic BP (mmHg) 0.823 0.681 0.969 0.395 0.355 0.887 
Pulse Pressure (mmHg) 0.018* 0.499 0.433 0.367 0.321 0.388 
C1 (ml/mmHg x 10) 0.191 0.174 0.247 0.283 0.779 0.104 
C2 (ml/mmHg x 100) 0.037* 0.118 0.838 0.024* 0.792 0.157 
Augmentation index (%) 0.514 0.407 0.545 0.474 0.116 0.914 
Heart Rate (beats/min) 0.827 0.699 0.130 0.209 0.656 0.593 
 
One-way ANOVA analysis was used to test for association between each polymorphism 
and phenotypic traits in both groups. BP = blood pressure; CAD = coronary artery disease  
 
 
 with PP in the control group but not the CAD group. In the control group, PP in -
786C/C subjects is 53 ± 9 mmHg, 61 ± 14 mmHg in subjects with -786T/T and 55 ± 
10 mmHg in subjects with -786C/T. In the CAD group, PP in -786C/C subjects was 
58 ± 11 mmHg, 59 ± 12 mmHg in subjects with -786T/T and 61 ± 13 mmHg in 
subjects with -786C/T.  
 
The T-786C was also significantly associated with small artery compliance index 
C2 in both control and CAD group. In the control group, C2 in -786C/C subjects was 
6.4 ± 2.7 ml/mmHg, 4.5 ± 2.6 ml/mmHg in subjects with -786T/T and 5.5 ± 3.3 
ml/mmHg in subjects with -786C/T. In the CAD group, C2 in -786C/C subjects was 
4.2 ± 1.6 ml/mmHg, 5.4 ± 3.3 ml/mmHg in subjects with -786T/T and 4.2 ± 2.4 
ml/mmHg in subjects with -786C/T. 
 
The intron 4A/4B and G894T were not associated with any of the clinical 
phenotypes examined. None of the haplotype combinations of the three NOS3 
polymorphisms were significantly associated with C1 (p = 0.857), C2 (p = 0.626) 
and AIx (p = 0.197). 
 
5.4. Discussion 
 
As expected, CAD patients were mostly males, older and had higher PP. The 
small artery compliance in CAD patients was lower but not the large artery 
compliance. The AIx and heart rate was higher in CAD patients than control 
subjects. The significantly higher levels of triglycerides and VLDL, along with lower 
levels of HDL in CAD group were expected while the significantly lower levels of 
total cholesterol and LDL were the result of lipid-lowering drugs used by the CAD 
patients. 
 
In this study, the frequency of -930A/A genotype was significantly lower in the CAD 
group without any assumption for dominance and with assumption for recessive 
model. This result correlated with the transfection experiments reported by Moreno 
et. al. (260). Although the A-930G was significantly associated with heart rate, the 
results could be influenced by the β-blockers administered to the CAD patients. 
The A-930G was not associated with any of the clinical phenotypes investigated. 
Since the LD score by |D’| between A-930G and C242T or A640G was very low, 
 any effect of A-930G was probably independent of C242T or A640G. The C242T 
and A640G polymorphism were not associated with CAD, even in recessive and 
dominant models. Neither C242T nor A640G was associated with any of the 
clinical phenotypes investigated. The difference in haplotype frequencies between 
the control and CAD groups was only of borderline significance. None of the 
haplotype combinations were associated with vascular compliance indices C1, C2 
or AIx. 
 
The results showed that T-786C and intron 4A/4B polymorphisms were not 
associated with CAD, with and without assumptions of allele dominance. The T-
786C was associated with pulse pressure and small artery compliance. Studies 
showed increased susceptibility of the 894T allele to proteolytic cleavage (265) 
and decreased eNOS activity (266), and appeared to have dominant effect (275). 
In contrast, logistic regression analysis in the current study found the 894G allele 
to be dominant and was associated with CAD. However, there was no association 
between G894T and any of the clinical phenotypes investigated. The rare 4A allele 
of intron 4 was strongly linked to the 894G allele of exon 7 and the -786C allele in 
the promoter polymorphism. The intron 4 and G894T polymorphisms were in 
complete linkage disequilibrium in both control and CAD subjects, suggesting that 
previously associated functional effect of the intron 4 polymorphisms (276) may be 
attributed to T-786C or G894T. There was no significant difference in the 
haplotype frequencies between the control and CAD groups. There was no 
association between any of the haplotype combinations with vascular compliance 
indices C1, C2 or AIx. 
 
In the present study, the comparisons between the control and CAD groups were 
not adjusted for confounders, most notably the cholesterol levels, gender and age. 
The lower cholesterol levels in CAD patients were the consequence of lipid-
lowering drugs. Adjustments for cholesterol levels would effectively be adjusting 
for medications. The correlation between gender and age, where the majority of 
control group are mostly young females while the CAD patients are mostly old 
men, meant that adjustment for one factor would effectively be adjusting for the 
other factor as well. Since the patients are on medications, any adjustment for age 
would also be an adjustment for the cholesterol levels. As most of the data are not 
significant, adjustments for the confounders would not provide any additional 
 information. In addition, there is also a risk of over-adjustments in this relatively 
small study cohort.  
 
Another limitation of the present study is the age difference between patients and 
controls. At this stage, it cannot be excluded that some of the controls willl develop 
CAD over the next 10years and therefore would be cases rather than controls. In 
the group of CAD patients we examined a selected group of elderly but clinically 
stable patients whereas we did not have access to more critically ill patients who 
had to undergo emergency operation or indeed died. This may lead to survival 
bias and data have to be interpreted with caution. 
 
This exploratory study was also not corrected the genetic analysis for repeated 
measures. Clearly, the association between A-930G of CYBA gene or G894T of 
NOS3 gene would become non significant. However, the observed associations 
suggest that further investigation of these two SNPs are required and justified in 
an adequately powered cohort of patients with CAD or other functional assays. 
 
This is a medium-size collection of patients who are very well phenotyped and 
have advanced three vessel CAD. However, as we are studying multiple 
polymorphisms with subtle effects, large numbers are necessary to have adequate 
power to confirm or refute the stated hypothesis. A major drawback of this study 
was the number of subjects. The current study was powered for stiffness analysis 
but more patients and control subjects need to be recruited for genomic analysis. 
In addition to the three polymorphisms in each gene studied, there were also other 
polymorphisms within these genes (254;291). Due to the large number of 
variations in human genome, the net effects of polymorphisms within the same 
gene or between genes could be cancelled out. CYBA and NOS3 were only two of 
the many genes that code for proteins involved in maintaining the balance 
between NO and O2-. All the genes of the oxidative stress pathway should be 
investigated for functional polymorphisms and association with CAD.  
 CHAPTER 6:  CONCLUSIONS 
 
In conclusion, this thesis provides the most detailed characterisation of the Gstm 
gene family in terms of CVD to date. It has confirmed the previously identified 
reduction in rGstm1 expression in SHRSP, which could not be improved by 
antihypertensive treatment despite significant reductions in BP and oxidative 
stress levels. Previous work from our group identified thirteen polymorphisms in 
the promoter correlating to reduced rGstm1 expression (67). Subsequent 
investigation using luciferase activities of plasmid constructs in our laboratory has 
recently implicated five of these variants with consistently significant reduction in 
luciferase activities (293). However, it is still not clear as to how the reduction in 
renal rGstm1 gene expression may influence BP regulation in the SHRSP. There 
are a number of strategies currently being carried out within our group to 
investigate this further. One of the strategies is transgenic rescue as previously 
described for Cd36 (58), with replacement of the rGstm1 gene in the SHRSP from 
a normotensive strain, such as WKY or the Brown Norway (BN), followed by full 
phenotypic analysis. Another strategy extensively used in our group is gene 
transfer, in which viral vectors may be used to overexpress rGstm1 gene in the 
SHRSP (91). A reciprocal study using RNA interference (RNAi) to inhibit normal 
rGstm1 activity in the WKY is an additional strategy currently being undertaken by 
our group (125). Subsequent measurements of BP and markers of oxidative stress 
will enable us to understand the role of rGstm1 in the development of 
hypertension. The results from this project have also shown reduced expression of 
several members of the rGstm gene family in SHRSP. Further investigation should 
include sequencing of these rGstm members in the SHRSP and WKY to ascertain 
the presence of any functional polymorphisms for further studies. 
 
There is evidence for renal oxidative stress in hypertensive rat models (67;231). 
Our group have previously also shown significantly higher levels of O2– levels in 
the SHRSP renal medulla and cortex when compared to WKY (67). Similarly, 
Meng et.al. have shown increased renal cortical and medullary O2– production in 
Dahl-salt sensitive rats (231). In the study by Meng et.al., they have also shown 
reductions in Mn-SOD and Cu/Zn-SOD in renal cortex and medulla. We suggest 
that reduced rGstm gene family, in particular rGstm1, expression is contributing to 
diminished protection against renal oxidative stress during the development of 
 hypertension in the SHRSP. This could be further investigated by inducing 
oxidative stress with NOS inhibition (294), in a normotensive strain such as the 
WKY. This provides the opportunity to observe effects of renal oxidative stress on 
rGstm gene family. Markers of oxidative stress (such as oxidised lipids), 
antioxidant capacity (such as [GSH]:[GSSH] ratio) and gene expresssion levels of 
other pro-oxidative and anti-oxidative enzymes can also be measured. 
 
In the present study, despite careful characterisation, there are still four hGSTM 
genes as potential orthologues for rGstm1. Further investigation for differential 
expression in vascular or renal tissues from hypertensive patients will therefore be 
required. The difficulties in obtaining good quality mRNA from surgically 
manipulated vascular tissues indicates that pre-treatment of tissues will be 
required to overcome this problem. Culture of endothelial cells (295), VSMCs 
(296) and adventitial fibroblasts (297) from CAD and control vascular tissues may 
provide the opportunity to obtain sufficient good quality mRNA and protein for 
gene expression or oxidative stress measurements for further investigations. 
 
In addition, a relatively small association study identified significant association 
between CAD and polymorphisms in two key enzymes involved in NO and O2- 
balance. In addition to NAD(P)H oxidase and eNOS, there are other important 
enzymes (such as SODs) involved in maintaining the balance between NO and 
O2-. Polymorphisms in ecSOD (Arg760Gly) and catalase (C-262T) have been 
associated with CAD and hypertension (298;299). Various studies have also 
implicated the hGSTM1*0 allele as a genetic risk factor for cigarette smoking 
related CAD risk (201;202). Since it is not possible for RNAi, gene transfer or 
transgenic strategies to be investigated in the human, the hGSTM gene family 
needs to be investigated in a large scale association study. A large scale 
population with well-phenotyped CAD and control subjects will be required. The 
large number of polymorphisms, each imparting small effects can be scored 
according to pro-oxidative or anti-oxidative effects. With a sufficiently large 
population study, a range of scores can be assigned and pharmacogenomic 
therapies can then be designed for individual patients. 
 
Finally, this thesis presents data supporting the GSTM family of enzymes as an 
important target for further investigation. Moreover future investigations of the 
 GSTM gene family in rat models and human studies should take into consideration 
contributions of polymorphisms within the gene family, as well as other genes. 
 REFERENCES 
 
1) World Health Report 2003: Shaping the Future. 2003. 
http://www.who.int/whr/2003/en/index.html 
2) Coronary Heart Disease Statistics 2006. 2006. 
http://www.heartstats.org/datapage.asp?id=5739 
3) Economic costs of CVD and CHD. 2006. 
http://www.heartstats.org/datapage.asp?id=101 
4) The Atlas of Heart Disease and Stroke. 2006. 
http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html 
5) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular 
disease in clinical practice. Heart 2005 Dec;91 Suppl 5:v1-52. 
6) Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. 
Lancet 2003 May 10;361(9369):1629-41. 
7) Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. 
Am J Cardiol 2000 Jan 15;85(2):251-5. 
8) World Health Report 2002 - Reducing Risks, Promoting Healthy Life. 2002. 
http://www.who.int/whr/2002/en/index.html 
9) Turnbull F. Effects of different blood-pressure-lowering regimens on major 
cardiovascular events: results of prospectively-designed overviews of 
randomised trials. Lancet 2003 Nov 8;362(9395):1527-35. 
10) Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human 
hypertension. Cell 2001 Feb 23;104(4):545-56. 
11) Cowley AW, Jr. The genetic dissection of essential hypertension. Nat Rev 
Genet 2006 Nov;7(11):829-40. 
12) Unger T. The role of the renin-angiotensin system in the development of 
cardiovascular disease. Am J Cardiol 2002 Jan 24;89(2A):3A-9A. 
13) Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin 
system--an endocrine and paracrine system. Endocrinology 2003 
Jun;144(6):2179-83. 
14) Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et 
al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) 
converts angiotensin I to angiotensin 1-9. Circ Res 2000 Sep 1;87(5):E1-E9. 
15) Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. 
Angiotensin-converting enzyme 2 is an essential regulator of heart function. 
Nature 2002 Jun 20;417(6891):822-8. 
 16) Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, et al. Altered blood 
pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin 
Invest 2006 Aug;116(8):2218-25. 
17) Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II 
AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta 
of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005 
Sep;289(3):H1013-H1019. 
18) Shanmugam S, Corvol P, Gasc JM. Ontogeny of the two angiotensin II type 
1 receptor subtypes in rats. Am J Physiol 1994 Dec;267(6 Pt 1):E828-E836. 
19) Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of 
angiotensin receptor 1A and 1B in mouse. Am J Physiol 1994 Aug;267(2 Pt 
1):E260-E267. 
20) Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-
1 receptor subtype cDNAs: differential tissue expression and hormonal 
regulation. Biochem Biophys Res Commun 1992 Mar 31;183(3):1090-6. 
21) Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue-specific expression of 
type 1 angiotensin II receptor subtypes. An in situ hybridization study. 
Hypertension 1994 Nov;24(5):531-7. 
22) Marteau JB, Zaiou M, Siest G, Visvikis-Siest S. Genetic determinants of 
blood pressure regulation. J Hypertens 2005 Dec;23(12):2127-43. 
23) Feinleib M, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, et 
al. The NHLBI twin study of cardiovascular disease risk factors: methodology 
and summary of results. Am J Epidemiol 1977 Oct;106(4):284-5. 
24) Rao RM, Reddy GP, Grim CE. Relative role of genes and environment on 
BP: twin studies in Madras, India. J Hum Hypertens 1993 Oct;7(5):451-5. 
25) Longini IM, Jr., Higgins MW, Hinton PC, Moll PP, Keller JB. Environmental 
and genetic sources of familial aggregation of blood pressure in Tecumseh, 
Michigan. Am J Epidemiol 1984 Jul;120(1):131-44. 
26) Biron P, Mongeau JG, Bertrand D. Familial aggregation of blood pressure in 
558 adopted children. Can Med Assoc J 1976 Oct 23;115(8):773-4. 
27) Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Int 
Med 2003 Nov 4;139(9):761-76. 
28) Griffiths AJF, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM. Genetics and 
the Organism. In: An Introduction to Genetic Analysis, 7th Edn. New York. 
W. H. Freeman and Company Library of Congress. 1999: 1-26. 
29) Wang WY, Zee RY, Morris BJ. Association of angiotensin II type 1 receptor 
gene polymorphism with essential hypertension. Clin Genet 1997 
Jan;51(1):31-4. 
30) Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, et al. 
Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms 
 and increase in aortic stiffness with age in hypertensive subjects. J 
Hypertens 2001 Mar;19(3):407-13. 
31) Hindorff LA, Heckbert SR, Tracy R, Tang Z, Psaty BM, Edwards KL, et al. 
Angiotensin II type 1 receptor polymorphisms in the cardiovascular health 
study: relation to blood pressure, ethnicity, and cardiovascular events. Am J 
Hypertens 2002 Dec;15(12):1050-6. 
32) Reckelhoff JF. Gender differences in the regulation of blood pressure. 
Hypertension 2001 May;37(5):1199-208. 
33) Charchar FJ, Tomaszewski M, Padmanabhan S, Lacka B, Upton MN, Inglis 
GC, et al. The Y chromosome effect on blood pressure in two European 
populations. Hypertension 2002 Feb;39(2 Pt 2):353-6. 
34) Pardell H, Rodicio JL. High blood pressure, smoking and cardiovascular risk. 
J Hypertens 2005 Jan;23(1):219-21. 
35) Gordon T, Kannel WB. Drinking and its relation to smoking, BP, blood lipids, 
and uric acid. The Framingham study. Arch Intern Med 1983 
Jul;143(7):1366-74. 
36) Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly 
as large as smoking. Circulation 2005 May 24;111(20):2684-98. 
37) Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et 
al. Endothelial function and dysfunction. Part II: Association with 
cardiovascular risk factors and diseases. A statement by the Working Group 
on Endothelins and Endothelial Factors of the European Society of 
Hypertension. J Hypertens 2005 Feb;23(2):233-46. 
38) Lucas DL, Brown RA, Wassef M, Giles TD. Alcohol and the cardiovascular 
system research challenges and opportunities. J Am Coll Cardiol 2005 Jun 
21;45(12):1916-24. 
39) Aguilera MT, de la SA, Coca A, Estruch R, Fernandez-Sola J, Urbano-
Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 
24-hour ambulatory blood pressure monitoring. Hypertension 1999 
Feb;33(2):653-7. 
40) Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and 
incidence of hypertension in healthy normotensive men and women. JAMA 
1984 Jul 27;252(4):487-90. 
41) Paffenbarger RS, Jr., Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The 
association of changes in physical-activity level and other lifestyle 
characteristics with mortality among men. N Engl J Med 1993 Feb 
25;328(8):538-45. 
42) Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. 
Physical fitness as a predictor of mortality among healthy, middle-aged 
Norwegian men. N Engl J Med 1993 Feb 25;328(8):533-7. 
 43) Wenger NK. Hypertension and other cardiovascular risk factors in women. 
Am J Hypertens 1995 Dec;8(12 Pt 2):94s-9s. 
44) Hall JE. The kidney, hypertension, and obesity. Hypertension 2003 Mar;41(3 
Pt 2):625-33. 
45) Garrison RJ, Kannel WB, Stokes J, III, Castelli WP. Incidence and 
precursors of hypertension in young adults: the Framingham Offspring 
Study. Prev Med 1987 Mar;16(2):235-51. 
46) De BG, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville 
J, et al. European guidelines on cardiovascular disease prevention in clinical 
practice. Third Joint Task Force of European and other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representatives of eight societies and by invited experts). Atherosclerosis 
2004 Apr;173(2):381-91. 
47) Antihypertensive Drugs. In: Harvey RA, Champe PC, Mycek MJ., editors. 
Lippincott's Illustrated Reviews: Pharmacology 2nd Edition. Philadelphia: 
Lippincott Williams & Wilkins, 2000: 179-191. 
48) Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from 
Goldblatt to genetic engineering. Cardiovasc Res 1998 Jul;39(1):77-88. 
49) Lerman LO, Chade AR, Sica V, Napoli C. Animal models of hypertension: an 
overview. J Lab Clin Med 2005 Sep;146(3):160-73. 
50) Sun ZJ, Zhang ZE. Historic perspectives and recent advances in major 
animal models of hypertension. Acta Pharmacol Sin 2005 Mar;26(3):295-
301. 
51) Takahashi N, Smithies O. Human genetics, animal models and computer 
simulations for studying hypertension. Trends Genet 2004 Mar;20(3):136-45. 
52) Okamoto K, Yamori Y, Nagaoka A. Establishment of the Stroke-prone 
Spontanously Hypertensive Rat (SHR). Circ Res 1974 May;34/35 
Supp(Supp I):I-143-I-153. 
53) Louis WJ, Howes LG. Genealogy of the spontaneously hypertensive rat and 
Wistar-Kyoto rat strains: implications for studies of inherited hypertension. J 
Cardiovasc Pharmacol 1990;16 Suppl 7:S1-S5. 
54) Davidson AO, Schork N, Jaques BC, Kelman AW, Sutcliffe RG, Reid JL, et 
al. Blood pressure in genetically hypertensive rats. Influence of the Y 
chromosome. Hypertension 1995 Sep;26(3):452-9. 
55) Munroe PB, Caulfield MJ. Genetics of hypertension. Curr Opin Genet Dev 
2000 Jun;10(3):325-9. 
56) Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, 
et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing 
defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 
1999 Jan;21(1):76-83. 
 57) Pravenec M, Zidek V, Simakova M, Kren V, Krenova D, Horky K, et al. 
Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in 
spontaneous hypertension. J Clin Invest 1999 Jun;103(12):1651-7. 
58) Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, et al. 
Transgenic rescue of defective Cd36 ameliorates insulin resistance in 
spontaneously hypertensive rats. Nat Genet 2001 Feb;27(2):156-8. 
59) Clark JS, Jeffs B, Davidson AO, Lee WK, Anderson NH, Bihoreau MT, et al. 
Quantitative trait loci in genetically hypertensive rats. Possible sex 
specificity. Hypertension 1996 Nov;28(5):898-906. 
60) Stoll M, Kwitek-Black AE, Cowley AW, Jr., Harris EL, Harrap SB, Krieger JE, 
et al. New target regions for human hypertension via comparative genomics. 
Genome Res 2000 Apr;10(4):473-82. 
61) McBride MW, Carr FJ, Graham D, Anderson NH, Clark JS, Lee WK, et al. 
Microarray analysis of rat chromosome 2 congenic strains [erratum appears 
in Hypertension. 2003 May 5;41(6):e13]. Hypertension 2003 Mar;41(3 Pt 
2):847-53. 
62) Dutil J, Deng AY. Further chromosomal mapping of a blood pressure QTL in 
Dahl rats on chromosome 2 using congenic strains. Physiol Genomics 2001 
Jun 6;6(1):3-9. 
63) Dutil J, Deng AY. Mapping a blood pressure quantitative trait locus to a 5.7-
cM region in Dahl salt-sensitive rats. Mamm Genome 2001 May;12(5):362-5. 
64) Garrett MR, Rapp JP. Multiple blood pressure QTL on rat Chromosome 2 
defined by congenic Dahl rats. Mamm Genome 2002 Jan;13(1):41-4. 
65) Okuda T, Sumiya T, Mizutani K, Tago N, Miyata T, Tanabe T, et al. Analyses 
of differential gene expression in genetic hypertensive rats by microarray. 
Hypertens Res 2002 Mar;25(2):249-55. 
66) Okuda T, Sumiya T, Iwai N, Miyata T. Difference of gene expression profiles 
in spontaneous hypertensive rats and Wistar-Kyoto rats from two sources. 
Biochem Biophys Res Commun 2002 Aug 23;296(3):537-43. 
67) McBride MW, Brosnan MJ, Mathers J, McLellan LI, Miller WH, Graham D, et 
al. Reduction of gstm1 expression in the stroke-prone spontaneously 
hypertension rat contributes to increased oxidative stress. Hypertension 
2005 Apr;45(4):786-92. 
68) Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-
derived relaxing factor produced and released from artery and vein is nitric 
oxide. Proc Natl Acad Sci U S A 1987 Dec;84(24):9265-9. 
69) Garland CJ, Plane F, Kemp BK, Cocks TM. Endothelium-dependent 
hyperpolarization: a role in the control of vascular tone. Trends Pharmacol 
Sci 1995 Jan;16(1):23-30. 
70) Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, et 
al. The importance of the hyperpolarizing mechanism increases as the 
 vessel size decreases in endothelium-dependent relaxations in rat 
mesenteric circulation. J Cardiovasc Pharmacol 1996 Nov;28(5):703-11. 
71) Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta 
1999 May 5;1411(2-3):273-89. 
72) Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the 
vasodilator response to increased flow in vivo. Hypertension 1986 
Jan;8(1):37-44. 
73) Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and 
therapeutic potential. Cardiovasc Res 2002 Aug 1;55(2):250-60. 
74) Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, et al. 
Increased adhesion and aggregation of platelets lacking cyclic guanosine 
3',5'-monophosphate kinase I. J Exp Med 1999 Apr 19;189(8):1255-64. 
75) Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, et al. Defective 
smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 1998 
Jun 1;17(11):3045-51. 
76) Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M, et al. 
Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 2000 Oct 
27;87(9):825-30. 
77) Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the 
role of oxidant stress. Circ Res 2000 Nov 10;87(10):840-4. 
78) Irani K. Oxidant signaling in vascular cell growth, death, and survival : a 
review of the roles of reactive oxygen species in smooth muscle and 
endothelial cell mitogenic and apoptotic signaling. Circ Res 2000 Aug 
4;87(3):179-83. 
79) Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO, III, Panza JA. Role of 
nitric oxide in the vasodilator response to mental stress in normal subjects. 
Am J Cardiol 1997 Oct 15;80(8):1070-4. 
80) Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJ. Nitric 
oxide contributes to the rise in forearm blood flow during mental stress in 
humans. J Physiol 1994 Oct 15;480 ( Pt 2):361-8. 
81) Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-
derived nitric oxide in the abnormal endothelium-dependent vascular 
relaxation of patients with essential hypertension. Circulation 1993 
May;87(5):1468-74. 
82) Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in 
primary and secondary forms of human hypertension. Hypertension 1993 
Jun;21(6 Pt 2):929-33. 
83) Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-
arginine-nitric oxide pathway in offspring of essential hypertensive patients. 
Circulation 1996 Sep 15;94(6):1298-303. 
 84) Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal 
nitric oxide synthesis in essential hypertension. Lancet 1997 Mar 
22;349(9055):837-42. 
85) Cardillo C, Kilcoyne CM, Cannon RO, III, Panza JA. Racial differences in 
nitric oxide-mediated vasodilator response to mental stress in the forearm 
circulation. Hypertension 1998 Jun;31(6):1235-9. 
86) Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial 
dysfunction through regulation of eNOS and NAD(P)H oxidase activities. 
Hypertension 2003 Mar;41(3):534-9. 
87) Wigg SJ, Tare M, Forbes J, Cooper ME, Thomas MC, Coleman HA, et al. 
Early vitamin E supplementation attenuates diabetes-associated vascular 
dysfunction and the rise in protein kinase C-beta in mesenteric artery and 
ameliorates wall stiffness in femoral artery of Wistar rats. Diabetologia 2004 
Jun;47(6):1038-46. 
88) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 
20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 
2002 Jul 6;360(9326):23-33. 
89) Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E 
supplementation and cardiovascular events in high-risk patients. The Heart 
Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 
Jan 20;342(3):154-60. 
90) Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994 
May 14;343(8907):1199-206. 
91) Alexander MY, Brosnan MJ, Hamilton CA, Downie P, Devlin AM, Dowell F, 
et al. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-
dependent endothelial function in a hypertensive rat model. Cardiovasc Res 
1999 Aug 15;43(3):798-807. 
92) Alexander MY, Brosnan MJ, Hamilton CA, Fennell JP, Beattie EC, Jardine E, 
et al. Gene transfer of endothelial nitric oxide synthase but not Cu/Zn 
superoxide dismutase restores nitric oxide availability in the SHRSP. 
Cardiovasc Res 2000 Aug 18;47(3):609-17. 
93) Lerman A, Burnett JC, Jr., Higano ST, McKinley LJ, Holmes DR, Jr. Long-
term L-arginine supplementation improves small-vessel coronary endothelial 
function in humans. Circulation 1998 Jun 2;97(21):2123-8. 
94) Lund DD, Faraci FM, Miller FJ, Jr., Heistad DD. Gene transfer of endothelial 
nitric oxide synthase improves relaxation of carotid arteries from diabetic 
rabbits. Circulation 2000 Mar 7;101(9):1027-33. 
95) Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of 
protein kinase activity and gene expression by reactive oxygen species and 
their role in vascular physiology and pathophysiology. Arterioscler Thromb 
Vasc Biol 2000 Oct;20(10):2175-83. 
 96) Wolin MS, Gupte SA, Oeckler RA. Superoxide in the vascular system. J 
Vasc Res 2002 May;39(3):191-207. 
97) Li PF, Dietz R, von HR. Differential effect of hydrogen peroxide and 
superoxide anion on apoptosis and proliferation of vascular smooth muscle 
cells. Circulation 1997 Nov 18;96(10):3602-9. 
98) Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: 
Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003 
Oct 21;108(16):1912-6. 
99) Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison 
DG, et al. Expression of multiple isoforms of nitric oxide synthase in normal 
and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997 
Nov;17(11):2479-88. 
100) Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui 
H, et al. Superoxide generation by endothelial nitric oxide synthase: the 
influence of cofactors. Proc Natl Acad Sci USA 1998 Aug 4;95(16):9220-5. 
101) Schmidt HH, Nau H, Wittfoht W, Gerlach J, Prescher KE, Klein MM, et al. 
Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur 
J Pharmacol 1988 Sep 13;154(2):213-6. 
102) Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the 
physiological precursor for the formation of nitric oxide in endothelium-
dependent relaxation. Biochem Biophys Res Commun 1988 Jun 
30;153(3):1251-6. 
103) Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis 
toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. 
Circulation 1991 Feb;83(2):652-60. 
104) Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial 
nitric oxide synthase in coronary arteries. Circulation 1995 Jan 1;91(1):139-
44. 
105) Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau 
P, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in 
prehypertensive rats. J Clin Invest 1998 Apr 1;101(7):1530-7. 
106) Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide 
and vascular disease. Circ Res 2005 Apr 29;96(8):818-22. 
107) Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects 
and implications of peroxynitrite. Cardiovasc Res 1999 Oct;44(1):47-59. 
108) Pryor WA, Houk KN, Foote CS, Fukuto JM, Ignarro LJ, Squadrito GL, et al. 
Free radical biology and medicine: it's a gas, man! Am J Physiol Regul Integr 
Comp Physiol 2006 Sep;291(3):R491-R511. 
109) Kone BC. Molecular biology of natriuretic peptides and nitric oxide 
synthases. Cardiovasc Res 2001 Aug 15;51(3):429-41. 
 110) Li H, Poulos TL. Structure-function studies on nitric oxide synthases. J Inorg 
Biochem 2005 Jan;99(1):293-305. 
111) Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide 
synthases in the cardiovascular system. Cardiovasc Res 1999 Aug 
15;43(3):509-20. 
112) Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta 1999 
May 5;1411(2-3):217-30. 
113) Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, 
function and inhibition. Biochem J 2001 Aug 1;357(Pt 3):593-615. 
114) Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide 
synthase. Am J Physiol Renal Physiol 2001 Feb;280(2):F193-F206. 
115) Kanazawa K, Kawashima S, Mikami S, Miwa Y, Hirata K, Suematsu M, et al. 
Endothelial constitutive nitric oxide synthase protein and mRNA increased in 
rabbit atherosclerotic aorta despite impaired endothelium-dependent 
vascular relaxation. Am J Pathol 1996 Jun;148(6):1949-56. 
116) Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein 
decreases the expression of endothelial nitric oxide synthase. J Biol Chem 
1995 Jan 6;270(1):319-24. 
117) Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. 
Molecular regulation of the bovine endothelial cell nitric oxide synthase by 
transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995 
Aug;15(8):1255-61. 
118) Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor 
downregulates an endothelial nitric oxide synthase mRNA by shortening its 
half-life. Circ Res 1993 Jul;73(1):205-9. 
119) Wever RM, van Dam T, van Rijn HJ, de Groot F, Rabelink TJ. 
Tetrahydrobiopterin regulates superoxide and nitric oxide generation by 
recombinant endothelial nitric oxide synthase. Biochem Biophys Res 
Commun 1997 Aug 18;237(2):340-4. 
120) Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: 
implications for vascular endothelial function. Biochem Biophys Res 
Commun 1999 Oct 5;263(3):681-4. 
121) Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. 
Superoxide excess in hypertension and aging: a common cause of 
endothelial dysfunction. Hypertension 2001 Feb;37(2 Part 2):529-34. 
122) Brandes RP, Mugge A. Gender differences in the generation of superoxide 
anions in the rat aorta. Life Sci 1997;60(6):391-6. 
123) Dantas AP, Franco MC, Silva-Antonialli MM, Tostes RC, Fortes ZB, Nigro D, 
et al. Gender differences in superoxide generation in microvessels of 
hypertensive rats: role of NAD(P)H-oxidase. Cardiovasc Res 2004 Jan 
1;61(1):22-9. 
 124) Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J 2002 
Nov;4(11):1023-4. 
125) Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a 
critical component of the superoxide-generating NADH/NADPH oxidase 
system and regulates angiotensin II-induced hypertrophy in vascular smooth 
muscle cells. J Biol Chem 1996 Sep;271(38):23317-21. 
126) Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, et al. Novel 
role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial 
growth factor-induced signaling and angiogenesis. Circ Res 2002 Dec 
13;91(12):1160-7. 
127) Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci 
2005 Sep;109(3):217-26. 
128) Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, et al. 
Vascular NADH/NADPH oxidase is involved in enhanced superoxide 
production in spontaneously hypertensive rats. Hypertension 2000 
May;35(5):1055-61. 
129) Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and 
antioxidant enzyme expression and function in vascular cells. Hypertension 
2004 Oct;44(4):381-6. 
130) Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular 
disease. Arterioscler Thromb Vasc Biol 2005 Jan;25(1):29-38. 
131) Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et 
al. Angiotensin II-mediated hypertension in the rat increases vascular 
superoxide production via membrane NADH/NADPH oxidase activation. 
Contribution to alterations of vasomotor tone. J Clin Invest 1996 Apr 
15;97(8):1916-23. 
132) Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II 
stimulates NADH and NADPH oxidase activity in cultured vascular smooth 
muscle cells. Circ Res 1994 Jun;74(6):1141-8. 
133) Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, et al. 
Investigation into the sources of superoxide in human blood vessels: 
angiotensin II increases superoxide production in human internal mammary 
arteries. Circulation 2000 May 9;101(18):2206-12. 
134) Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, et al. 
Differential role of angiotensin II receptor subtypes on endothelial superoxide 
formation. Br J Pharmacol 2000 Oct;131(4):667-72. 
135) Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, et al. Role of 
p47(phox) in vascular oxidative stress and hypertension caused by 
angiotensin II. Hypertension 2002 Oct;40(4):511-5. 
136) Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects 
of angiotensin II infusion on the expression and function of NAD(P)H oxidase 
 and components of nitric oxide/cGMP signaling. Circ Res 2002 Mar 
8;90(4):E58-E65. 
137) Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK. Angiotensin II 
induces p67phox mRNA expression and NADPH oxidase superoxide 
generation in rabbit aortic adventitial fibroblasts. Hypertension 1998 
Aug;32(2):331-7. 
138) Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. 
Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. 
Circ Res 2002 Sep 6;91(5):406-13. 
139) Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a 
functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in 
smooth muscle cells from human resistance arteries: regulation by 
angiotensin II. Circ Res 2002 Jun 14;90(11):1205-13. 
140) Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. 
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical 
production in vascular smooth muscle cells: involvement of angiotensin AT1 
receptor expression and Rac1 GTPase. Mol Pharmacol 2001 Mar;59(3):646-
54. 
141) Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth 
factor-stimulated superoxide anion production modulates activation of 
transcription factor NF-kappaB and expression of monocyte chemoattractant 
protein 1 in human aortic smooth muscle cells. Circulation 1997 Oct 
7;96(7):2361-7. 
142) Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, et al. Epidermal 
growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF 
receptor-mediated tyrosine phosphorylation. J Biol Chem 1997 Jan 
3;272(1):217-21. 
143) Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, et al. 
Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. 
Evidence that p47(phox) may participate in forming this oxidase in vitro and 
in vivo. J Biol Chem 1999 Jul 9;274(28):19814-22. 
144) Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, et al. Human 
fibroblasts release reactive oxygen species in response to interleukin-1 or 
tumour necrosis factor-alpha. Biochem J 1989 Oct 15;263(2):539-45. 
145) De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling 
KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase 
in vascular smooth muscle. Biochem J 1998 Feb 1;329(Pt 3):653-7. 
146) Brandes RP, Koddenberg G, Gwinner W, Kim D, Kruse HJ, Busse R, et al. 
Role of increased production of superoxide anions by NAD(P)H oxidase and 
xanthine oxidase in prolonged endotoxemia. Hypertension 1999 
May;33(5):1243-9. 
147) Galle J, Lehmann-Bodem C, Hubner U, Heinloth A, Wanner C. CyA and 
OxLDL cause endothelial dysfunction in isolated arteries through endothelin-
 mediated stimulation of O(2)(-) formation. Nephrol Dial Transplant 2000 
Mar;15(3):339-46. 
148) Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH 
oxidase by oxidized low-density lipoprotein induces proliferation of human 
vascular endothelial cells. J Am Soc Nephrol 2000 Oct;11(10):1819-25. 
149) Li WG, Miller FJ, Jr., Zhang HJ, Spitz DR, Oberley LW, Weintraub NL. 
H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase 
causes oxidant injury. J Biol Chem 2001 Aug 3;276(31):29251-6. 
150) Li WG, Stoll LL, Rice JB, Xu SP, Miller FJ, Jr., Chatterjee P, et al. Activation 
of NAD(P)H oxidase by lipid hydroperoxides: mechanism of oxidant-
mediated smooth muscle cytotoxicity. Free Radic Biol Med 2003 Apr 
1;34(7):937-46. 
151) De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, 
Griendling KK. Oscillatory and steady laminar shear stress differentially 
affect human endothelial redox state: role of a superoxide-producing NADH 
oxidase. Circ Res 1998 Jun 1;82(10):1094-101. 
152) McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, et al. Role 
of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide 
production in response to oscillatory shear stress. Am J Physiol Heart Circ 
Physiol 2003 Dec;285(6):H2290-H2297. 
153) Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol 1998 Apr;201 ( 
Pt 8):1203-9. 
154) Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. 
Arterioscler Thromb Vasc Biol 2005 Jul;25(7):1332-40. 
155) Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes 
represent a co-ordinately regulated defence against oxidative stress. Free 
Radic Res 1999 Oct;31(4):273-300. 
156) Mates JM. Effects of antioxidant enzymes in the molecular control of reactive 
oxygen species toxicology. Toxicology 2000 Nov 16;153(1-3):83-104. 
157) Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a 
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD 
(SOD3) gene structures, evolution, and expression. Free Radic Biol Med 
2002 Aug 1;33(3):337-49. 
158) Fennell JP, Brosnan MJ, Frater AJ, Hamilton CA, Alexander MY, Nicklin SA, 
et al. Adenovirus-mediated overexpression of extracellular superoxide 
dismutase improves endothelial dysfunction in a rat model of hypertension. 
Gene Ther 2002 Jan;9(2):110-7. 
159) Zanetti M, Sato J, Katusic ZS, O'Brien T. Gene transfer of superoxide 
dismutase isoforms reverses endothelial dysfunction in diabetic rabbit aorta. 
Am J Physiol Heart Circ Physiol 2001 Jun;280(6):H2516-H2523. 
 160) Zanetti M, Sato J, Jost CJ, Gloviczki P, Katusic ZS, O'Brien T. Gene transfer 
of manganese superoxide dismutase reverses vascular dysfunction in the 
absence but not in the presence of atherosclerotic plaque. Hum Gene Ther 
2001 Jul 20;12(11):1407-16. 
161) Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, French BA. Gene therapy with 
extracellular superoxide dismutase attenuates myocardial stunning in 
conscious rabbits. Circulation 1998 Oct 6;98(14):1438-48. 
162) Chung DJ, Wright AE, Clerch LB. The 3' untranslated region of manganese 
superoxide dismutase RNA contains a translational enhancer element. 
Biochemistry 1998 Nov 17;37(46):16298-306. 
163) Kirkman HN, Gaetani GF. Catalase: a tetrameric enzyme with four tightly 
bound molecules of NADPH. Proc Natl Acad Sci U S A 1984 
Jul;81(14):4343-7. 
164) Kirkman HN, Galiano S, Gaetani GF. The function of catalase-bound 
NADPH. J Biol Chem 1987 Jan 15;262(2):660-6. 
165) Kirkman HN, Rolfo M, Ferraris AM, Gaetani GF. Mechanisms of protection of 
catalase by NADPH. Kinetics and stoichiometry. J Biol Chem 1999 May 
14;274(20):13908-14. 
166) Zamocky M, Koller F. Understanding the structure and function of catalases: 
clues from molecular evolution and in vitro mutagenesis. Prog Biophys Mol 
Biol 1999;72(1):19-66. 
167) Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular 
endothelium. J Control Release 2001 Mar 12;71(1):1-21. 
168) Durand E, Al Haj ZA, Addad F, Brasselet C, Caligiuri G, Vinchon F, et al. 
Adenovirus-mediated gene transfer of superoxide dismutase and catalase 
decreases restenosis after balloon angioplasty. J Vasc Res 2005 
May;42(3):255-65. 
169) Luo D, Rando TA. The regulation of catalase gene expression in mouse 
muscle cells is dependent on the CCAAT-binding factor NF-Y. Biochem 
Biophys Res Commun 2003 Apr 4;303(2):609-18. 
170) Nenoi M, Ichimura S, Mita K, Yukawa O, Cartwright IL. Regulation of the 
catalase gene promoter by Sp1, CCAAT-recognizing factors, and a 
WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer 
Res 2001 Aug 1;61(15):5885-94. 
171) Chen G, Kamal M, Hannon R, Warner TD. Regulation of cyclo-oxygenase 
gene expression in rat smooth muscle cells by catalase. Biochem Pharmacol 
1998 May 15;55(10):1621-31. 
172) Cotgreave IA, Gerdes RG. Recent trends in glutathione biochemistry--
glutathione-protein interactions: a molecular link between oxidative stress 
and cell proliferation? Biochem Biophys Res Commun 1998 Jan 6;242(1):1-
9. 
 173) Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism 
and its implications for health. J Nutr 2004 Mar;134(3):489-92. 
174) Richman PG, Meister A. Regulation of gamma-glutamyl-cysteine synthetase 
by nonallosteric feedback inhibition by glutathione. J Biol Chem 1975 Feb 
25;250(4):1422-6. 
175) Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000 Dec;57(13-
14):1825-35. 
176) Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 
2002 Oct;18(10):872-9. 
177) Fu Y, Porres JM, Lei XG. Comparative impacts of glutathione peroxidase-1 
gene knockout on oxidative stress induced by reactive oxygen and nitrogen 
species in mouse hepatocytes. Biochem J 2001 Nov 1;359(Pt 3):687-95. 
178) Zhang Y, Handy DE, Loscalzo J. Adenosine-dependent induction of 
glutathione peroxidase 1 in human primary endothelial cells and protection 
against oxidative stress. Circ Res 2005 Apr 29;96(8):831-7. 
179) Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Overexpression of 
cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial 
dysfunction. Proc Natl Acad Sci U S A 2001 Oct 23;98(22):12503-8. 
180) McCarver DG, Hines RN. The ontogeny of human drug-metabolizing 
enzymes: phase II conjugation enzymes and regulatory mechanisms. J 
Pharmacol Exp Ther 2002 Feb;300(2):361-6. 
181) van Bladeren PJ. Glutathione conjugation as a bioactivation reaction. Chem 
Biol Interact 2000 Dec 1;129(1-2):61-76. 
182) Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and 
evolution of glutathione transferases: implications for classification of non-
mammalian members of an ancient enzyme superfamily. Biochem J 2001 
Nov 15;360(Pt 1):1-16. 
183) Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: 
regulation of GST and the contribution of the isoenzymes to cancer 
chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 
1995;30(6):445-600. 
184) Frova C. Glutathione transferases in the genomics era: new insights and 
perspectives. Biomol Eng 2006 Sep;23(4):149-69. 
185) Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-
transferase family of enzymes. Mutat Res 2001 Oct 1;482(1-2):21-6. 
186) Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene 
family. Hum Genomics 2004 Nov;1(6):460-4. 
187) Hayes JD, Strange RC. Potential contribution of the glutathione S-
transferase supergene family to resistance to oxidative stress. Free Radic 
Res 1995 Mar;22(3):193-207. 
 188) Mannervik B, Awasthi YC, Board PG0, Hayes JD, Di Ilio C, Ketterer B, et al. 
Nomenclature for human glutathione transferases. Biochem J 1992;282:305-
6. 
189) Mannervik B, Board PG, Hayes JD, Listowsky I, Pearson WR. Nomenclature 
for mammalian soluble glutathione transferases. Methods Enzymol 
2005;401:1-8. 
190) Ross VL, Board PG, Webb GC. Chromosomal mapping of the human Mu 
class glutathione S-transferases to 1p13. Genomics 1993 Oct;18(1):87-91. 
191) DeJong JL, Chang CM, Whang-Peng J, Knutsen T, Tu CP. The human liver 
glutathione S-transferase gene superfamily: expression and chromosome 
mapping of an Hb subunit cDNA. Nucleic Acids Res 1988 Sep 
12;16(17):8541-54. 
192) Patskovsky YV, Huang MQ, Takayama T, Listowsky I, Pearson WR. 
Distinctive structure of the human GSTM3 gene-inverted orientation relative 
to the mu class glutathione transferase gene cluster. Arch Biochem Biophys 
1999 Jan 1;361(1):85-93. 
193) Board PG. Biochemical genetics of glutathione-S-transferase in man. Am J 
Hum Genet 1981 Jan;33(1):36-43. 
194) Widersten M, Pearson WR, Engstrom A, Mannervik B. Heterologous 
expression of the allelic variant mu-class glutathione transferases mu and 
psi. Biochem J 1991 Jun 1;276(Pt 2):519-24. 
195) McLellan RA, Oscarson M, Alexandrie AK, Seidegard J, Evans DA, Rannug 
A, et al. Characterization of a human glutathione S-transferase mu cluster 
containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. 
Mol Pharmacol 1997 Dec;52(6):958-65. 
196) Board PG. Gene deletion and partial deficiency of the glutathione S-
transferase (ligandin) system in man. FEBS Lett 1981 Nov 30;135(1):12-4. 
197) Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences 
in the expression of the human glutathione transferase active on trans-
stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988 
Oct;85(19):7293-7. 
198) Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz 
D, et al. Meta- and pooled analyses of the effects of glutathione S-
transferase M1 polymorphisms and smoking on lung cancer risk. 
Carcinogenesis 2002 Aug;23(8):1343-50. 
199) Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, et al. 
Pooled analysis and meta-analysis of glutathione S-transferase M1 and 
bladder cancer: a HuGE review. Am J Epidemiol 2002 Jul 15;156(2):95-109. 
200) Abu-Amero KK, Al-Boudari OM, Mohamed GH, Dzimiri N. T null and M null 
genotypes of the glutathione S-transferase gene are risk factor for CAD 
independent of smoking. BMC Med Genet 2006;7:38. 
 201) de Waart FG, Kok FJ, Smilde TJ, Hijmans A, Wollersheim H, Stalenhoef AF. 
Effect of glutathione S-transferase M1 genotype on progression of 
atherosclerosis in lifelong male smokers. Atherosclerosis 2001 
Sep;158(1):227-31. 
202) Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Glutathione S-
transferase mu1 deficiency, cigarette smoking and coronary artery disease. 
J Cardiovasc Risk 2002 Feb;9(1):25-31. 
203) Izzotti A, Cartiglia C, Lewtas J, De Flora S. Increased DNA alterations in 
atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J 
2001 Mar;15(3):752-7. 
204) Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, Campbell 
D, et al. Identification of polymorphism at the glutathione S-transferase, 
GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 1995 Dec 
15;312 ( Pt 3):713-6. 
205) Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, Smith A, et al. 
Polymorphism at the glutathione S-transferase locus GSTM3: interactions 
with cytochrome P450 and glutathione S-transferase genotypes as risk 
factors for multiple cutaneous basal cell carcinoma. Cancer Res 1996 May 
1;56(9):1974-7. 
206) Ross VL, Board PG. Molecular cloning and heterologous expression of an 
alternatively spliced human Mu class glutathione S-transferase transcript. 
Biochem J 1993 Sep 1;294(Pt 2):373-80. 
207) Tetlow N, Robinson A, Mantle T, Board P. Polymorphism of human mu class 
glutathione transferases. Pharmacogenetics 2004 Jun;14(6):359-68. 
208) Turella P, Pedersen JZ, Caccuri AM, De Maria F, Mastroberardino P, Lo BM, 
et al. Glutathione transferase superfamily behaves like storage proteins for 
dinitrosyl-diglutathionyl-iron complex in heterogeneous systems. J Biol Chem 
2003 Oct 24;278(43):42294-9. 
209) Daggett DA, Oberley TD, Nelson SA, Wright LS, Kornguth SE, Siegel FL. 
Effects of lead on rat kidney and liver: GST expression and oxidative stress. 
Toxicology 1998 Jul 17;128(3):191-206. 
210) Armstrong RN. Structure, catalytic mechanism, and evolution of the 
glutathione transferases. Chem Res Toxicol 1997 Feb;10(1):2-18. 
211) Cummings BS, Lasker JM, Lash LH. Expression of glutathione-dependent 
enzymes and cytochrome P450s in freshly isolated and primary cultures of 
proximal tubular cells from human kidney. J Pharmacol Exp Ther 2000 
May;293(2):677-85. 
212) Armstrong RN. Mechanistic imperatives for the evolution of glutathione 
transferases. Curr Opin Chem Biol 1998 Nov;2(5):618-23. 
213) Segura-Aguilar J, Baez S, Widersten M, Welch CJ, Mannervik B. Human 
class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze 
 detoxication of the dopamine metabolite aminochrome. J Biol Chem 1997 
Feb 28;272(9):5727-31. 
214) Hansson LO, Bolton-Grob R, Massoud T, Mannervik B. Evolution of 
differential substrate specificities in Mu class glutathione transferases 
probed by DNA shuffling. J Mol Biol 1999 Mar 26;287(2):265-76. 
215) Patskovsky YV, Patskovska LN, Listowsky I. The enhanced affinity for 
thiolate anion and activation of enzyme-bound glutathione is governed by an 
arginine residue of human Mu class glutathione S-transferases. J Biol Chem 
2000 Feb 4;275(5):3296-304. 
216) Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control 
of acute lung failure by the SARS receptor ACE2. J Mol Med 2006 
Oct;84(10):814-20. 
217) Luft FC, Toka O, Toka HR, Jordan J, Bahring S. Mendelian hypertension 
with brachydactyly as a molecular genetic lesson in regulatory physiology. 
Am J Physiol Regul Integr Comp Physiol 2003 Oct;285(4):R709-R714. 
218) Bahring S, Rauch A, Toka O, Schroeder C, Hesse C, Siedler H, et al. 
Autosomal-dominant hypertension with type E brachydactyly is caused by 
rearrangement on the short arm of chromosome 12. Hypertension 2004 
Feb;43(2):471-6. 
219) Jeffs B, Negrin CD, Graham D, Clark JS, Anderson NH, Gauguier D, et al. 
Applicability of a "speed" congenic strategy to dissect blood pressure 
quantitative trait loci on rat chromosome 2. Hypertension 2000 Jan;35(1 Pt 
2):179-87. 
220) Lander ES, Green P, Abrahamson J, Barlow A, Daly MJ, Lincoln SE, et al. 
MAPMAKER: an interactive computer package for constructing primary 
genetic linkage maps of experimental and natural populations. Genomics 
1987 Oct;1(2):174-81. 
221) Evans AL, Brown W, Kenyon CJ, Maxted KJ, Smith DC. Improved system 
for measuring systolic blood pressure in the conscious rat. Med Biol Eng 
Comput 1994 Jan;32(1):101-2. 
222) Young B, Lowe JS, Stevens A, Heath JW. Urinary System. In Wheater's 
Functional Histology A Text and Colour Atlas. Churchill Livingstone. 2006. 
302-327. 
223) Listowsky I, Rowe JD, Patskovsky YV, Tchaikovskaya T, Shintani N, 
Novikova E, et al. Human testicular glutathione S-transferases: insights into 
tissue-specific expression of the diverse subunit classes. Chem Biol Interact 
1998 Apr 24;111-112:103-12. 
224) Lai HC, Qian B, Grove G, Tu CP. Gene expression of rat glutathione S-
transferases. Evidence for gene conversion in the evolution of the Yb 
multigene family. J Biol Chem 1988 Aug 15;263(23):11389-95. 
225) Hsieh CH, Tsai SP, Yeh HI, Sheu TC, Tam MF. Mass spectrometric analysis 
of rat ovary and testis cytosolic glutathione S-transferases (GSTs): 
 identification of a novel class-alpha GST, rGSTA6*, in rat testis. Biochem J 
1997 Apr 15;323 ( Pt 2):503-10. 
226) Cheng H, Tchaikovskaya T, Tu YS, Chapman J, Qian B, Ching WM, et al. 
Rat glutathione S-transferase M4-4: an isoenzyme with unique structural 
features including a redox-reactive cysteine-115 residue that forms mixed 
disulphides with glutathione. Biochem J 2001 Jun 1;356(Pt 2):403-14. 
227) Bermano G, Shepherd RK, Zehner ZE, Hesketh JE. Perinuclear mRNA 
localisation by vimentin 3'-untranslated region requires a 100 nucleotide 
sequence and intermediate filaments. FEBS Lett 2001 May 25;497(2-3):77-
81. 
228) Nuovo GJ. Co-labeling using in situ PCR: a review. J Histochem Cytochem 
2001 Nov;49(11):1329-39. 
229) Chen YC, Cadnapaphornchai MA, Schrier RW. Clinical update on renal 
aquaporins. Biol Cell 2005 Jun;97(6):357-71. 
230) Srivastava PK, Waxman DJ. Sex-dependent expression and growth 
hormone regulation of class alpha and class mu glutathione S-transferase 
mRNAs in adult rat liver. Biochem J 1993 Aug 15;294(Pt 1):159-65. 
231) Meng S, Roberts LJ, Cason GW, Curry TS, Manning RD, Jr. Superoxide 
dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats. Am 
J Physiol Regul Integr Comp Physiol 2002 Sep;283(3):R732-R738. 
232) Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus AM, Hayes JD, et al. 
Expression and polymorphism of glutathione S-transferase in human lungs: 
risk factors in smoking-related lung cancer. Carcinogenesis 1995 
Apr;16(4):707-11. 
233) Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, et 
al. Genome-wide mapping of human loci for essential hypertension. Lancet 
2003 Jun 21;361(9375):2118-23. 
234) Delles C, Braga-Marcano AC, Munroe PB, Padmanabhan S, McClure JD, 
Brain NJ, et al. Variants of the human mu type glutathion-S-transferase 
(GSTM) gene family are associated with hypertension. J Hyper Supp 2006 
Jun;24(S4):S13. 
235) Gabbiani G, Schmid E, Winter S, Chaponnier C, de CC, Vandekerckhove J, 
et al. Vascular smooth muscle cells differ from other smooth muscle cells: 
predominance of vimentin filaments and a specific alpha-type actin. Proc 
Natl Acad Sci U S A 1981 Jan;78(1):298-302. 
236) Schildmeyer LA, Braun R, Taffet G, Debiasi M, Burns AE, Bradley A, et al. 
Impaired vascular contractility and blood pressure homeostasis in the 
smooth muscle alpha-actin null mouse. FASEB J 2000 Nov;14(14):2213-20. 
237) Tortora GJ. The Urinary System. In: Principles of Human Anatomy, 8th 
Edition. New York: Benjamin/Cummings Science Publishing. 1999: 747-769. 
 238) Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr 
DF, et al. Role of superoxide in the depressed nitric oxide production by the 
endothelium of genetically hypertensive rats. Hypertension 1995 Dec;26(6 Pt 
1):854-7. 
239) McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: 
the role of superoxide anion. Hypertension 1999 Oct;34(4 Pt 1):539-45. 
240) Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak 
AF. Irbesartan lowers superoxide levels and increases nitric oxide 
bioavailability in blood vessels from spontaneously hypertensive stroke-
prone rats. J Hypertens 2002 Feb;20(2):281-6. 
241) Graham D, Hamilton C, Beattie E, Spiers A, Dominiczak AF. Comparison of 
the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial 
function and cardiac hypertrophy in the stroke-prone spontaneously 
hypertensive rat: sex differences. J Hypertens 2004 Feb;22(2):329-37. 
242) Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, et al. 
Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor 
antagonist. Eur J Pharmacol 1995 Oct 16;285(2):181-8. 
243) Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, et al. Inhibitory effects of AT1 
receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-
oxidative stress. Hypertension 2005 Apr;45(4):545-51. 
244) Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, Fan Y, et al. Olmesartan 
improves endothelin-induced hypertension and oxidative stress in rats. 
Hypertens Res 2004 Jul;27(7):493-500. 
245) Ellershaw DC, Gurney AM. Mechanisms of hydralazine induced vasodilation 
in rabbit aorta and pulmonary artery. Br J Pharmacol 2001 Oct;134(3):621-
31. 
246) Wei S, Kasuya Y, Yanagisawa M, Kimura S, Masaki T, Goto K. Studies on 
endothelium-dependent vasorelaxation by hydralazine in porcine coronary 
artery. Eur J Pharmacol 1997 Mar 5;321(3):307-14. 
247) Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms 
of activation. Cardiovasc Res 2005 Jan 1;65(1):16-27. 
248) Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. 
Superoxide anion production is increased in a model of genetic 
hypertension: role of the endothelium. Hypertension 1999 Jun;33(6):1353-8. 
249) Zou AP, Li N, Cowley AW, Jr. Production and actions of superoxide in the 
renal medulla. Hypertension 2001 Feb;37(2 Part 2):547-53. 
250) Makino A, Skelton MM, Zou AP, Roman RJ, Cowley AW, Jr. Increased renal 
medullary oxidative stress produces hypertension. Hypertension 2002 
Feb;39(2 Pt 2):667-72. 
251) Makino A, Skelton MM, Zou AP, Cowley AW, Jr. Increased renal medullary 
H2O2 leads to hypertension. Hypertension 2003 Jul;42(1):25-30. 
 252) Soccio M, Toniato E, Evangelista V, Carluccio M, De CR. Oxidative stress 
and cardiovascular risk: the role of vascular NAD(P)H oxidase and its 
genetic variants. Eur J Clin Invest 2005 May;35(5):305-14. 
253) Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human 
neutrophil cytochrome b light chain (p22-phox). Gene structure, 
chromosomal location, and mutations in cytochrome-negative autosomal 
recessive chronic granulomatous disease. J Clin Invest 1990 
Nov;86(5):1729-37. 
254) Krex D, Ziegler A, Konig IR, Schackert HK, Schackert G. Polymorphisms of 
the NADPH oxidase P22PHOX gene in a Caucasian population with 
intracranial aneurysms. Cerebrovasc Dis 2003;16(4):363-8. 
255) Gardemann A, Mages P, Katz N, Tillmanns H, Haberbosch W. The p22 phox 
A640G gene polymorphism but not the C242T gene variation is associated 
with coronary heart disease in younger individuals. Atherosclerosis 1999 
Aug;145(2):315-23. 
256) Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. 
Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with 
coronary artery disease. Circulation 1998 Jan 20;97(2):135-7. 
257) Cai H, Duarte N, Wilcken DE, Wang XL. NADH/NADPH oxidase p22 phox 
C242T polymorphism and coronary artery disease in the Australian 
population. Eur J Clin Invest 1999 Sep;29(9):744-8. 
258) Ito D, Murata M, Watanabe K, Yoshida T, Saito I, Tanahashi N, et al. C242T 
polymorphism of NADPH oxidase p22 phox gene and ischemic 
cerebrovascular disease in the Japanese population. Stroke 2000 
Apr;31(4):936-9. 
259) Zafari AM, Davidoff MN, Austin H, Valppu L, Cotsonis G, Lassegue B, et al. 
The A640G and C242T p22(phox) polymorphisms in patients with coronary 
artery disease. Antioxid Redox Signal 2002 Aug;4(4):675-80. 
260) Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Diez J, et al. 
Preliminary characterisation of the promoter of the human p22(phox) gene: 
identification of a new polymorphism associated with hypertension. FEBS 
Lett 2003 May 8;542(1-3):27-31. 
261) San Jose G, Moreno MU, Olivan S, Beloqui O, Fortuno A, Diez J, et al. 
Functional effect of the p22phox -930A/G polymorphism on p22phox 
expression and NADPH oxidase activity in hypertension. Hypertension 2004 
Aug;44(2):163-9. 
262) Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. 
Structure and chromosomal localization of the human constitutive 
endothelial nitric oxide synthase gene. J Biol Chem 1993 Aug 
15;268(23):17478-88. 
263) Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and 
chromosomal localization of the human endothelial nitric oxide synthase 
(NOS3) gene. Genomics 1994 Jan 15;19(2):350-7. 
 264) Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, 
et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric 
oxide synthase gene is associated with coronary spasm. Circulation 1999 
Jun 8;99(22):2864-70. 
265) Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. 
Intracellular processing of endothelial nitric oxide synthase isoforms 
associated with differences in severity of cardiopulmonary diseases: 
cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl 
Acad Sci USA 2000 Mar 14;97(6):2832-5. 
266) Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, et al. 
Modifier effect of eNOS in autosomal dominant polycystic kidney disease. 
Hum Mol Genet 2002 Feb 1;11(3):229-41. 
267) Cai H, Wilcken DE, Wang XL. The Glu-298-->Asp (894G-->T) mutation at 
exon 7 of the endothelial nitric oxide synthase gene and coronary artery 
disease. J Mol Med 1999 Jun;77(6):511-4. 
268) Gardemann A, Lohre J, Cayci S, Katz N, Tillmanns H, Haberbosch W. The T 
allele of the missense Glu(298)Asp endothelial nitric oxide synthase gene 
polymorphism is associated with coronary heart disease in younger 
individuals with high atherosclerotic risk profile. Atherosclerosis 2002 
Jan;160(1):167-75. 
269) Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, et al. 
Endothelial nitric oxide synthase gene polymorphism and acute myocardial 
infarction. Hypertension 1998 Sep;32(3):521-6. 
270) Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A 
common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a 
major risk factor for coronary artery disease in the UK. Circulation 1999 Oct 
5;100(14):1515-20. 
271) Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, et al. 
The T-786-->C mutation in endothelial nitric oxide synthase is associated 
with hypertension. Hypertension 2002 Apr;39(4):919-22. 
272) Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, et al. A 
common variant of endothelial nitric oxide synthase (Glu298Asp) is an 
independent risk factor for carotid atherosclerosis. Stroke 2001;32(3):735-
40. 
273) Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, 
et al. Endothelial nitric oxide synthase gene is positively associated with 
essential hypertension. Hypertension 1998 Jul;32(1):3-8. 
274) Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K, 
et al. T(-786)--> C mutation in the 5'-flanking region of the endothelial nitric 
oxide synthase gene is associated with myocardial infarction, especially 
without coronary organic stenosis. Am J Cardiol 2000 Sep 15;86(6):628-34. 
275) Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, 
et al. Association of the missense Glu298Asp variant of the endothelial nitric 
 oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998 
Jun;31(7):1506-10. 
276) Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, et al. 
Evidence of association of the ecNOS gene polymorphism with plasma NO 
metabolite levels in humans. Biochem Biophys Res Commun 1998 Apr 
7;245(1):190-3. 
277) Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-
dependent risk of coronary artery disease associated with a polymorphism of 
the endothelial nitric oxide synthase gene. Nat Med 1996 Jan;2(1):41-5. 
278) Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in 
clinical practice. QJM 2002 Feb;95(2):67-74. 
279) Woodman RJ, Kingwell BA, Beilin LJ, Hamilton SE, Dart AM, Watts GF. 
Assessment of central and peripheral arterial stiffness: studies indicating the 
need to use a combination of techniques. Am J Hypertens 2005 Feb;18(2 Pt 
1):249-60. 
280) Dart AM, Kingwell BA. Pulse pressure--a review of mechanisms and clinical 
relevance. J Am Coll Cardiol 2001 Mar 15;37(4):975-84. 
281) McVeigh GE, Allen PB, Morgan DR, Hanratty CG, Silke B. Nitric oxide 
modulation of blood vessel tone identified by arterial waveform analysis. Clin 
Sci 2001 Apr;100(4):387-93. 
282) Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. 
Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002 Jan 
15;105(2):213-7. 
283) London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. 
Arterial wave reflections and survival in end-stage renal failure. Hypertension 
2001 Sep;38(3):434-8. 
284) Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, et al. 
Noninvasive pulse wave analysis for the early detection of vascular disease. 
Hypertension 1995 Sep;26(3):503-8. 
285) McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, 
et al. Reduced vascular compliance as a marker for essential hypertension. 
Am J Hypertens 1991 Mar;4(3 Pt 1):245-51. 
286) Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype 
reconstruction from population data. Am J Hum Genet 2001 Apr;68(4):978-
89. 
287) Stephens M, Donnelly P. A comparison of bayesian methods for haplotype 
reconstruction from population genotype data. Am J Hum Genet 2003 
Nov;73(5):1162-9. 
288) Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. 
Functional effect of the C242T polymorphism in the NAD(P)H oxidase 
 p22phox gene on vascular superoxide production in atherosclerosis. 
Circulation 2000 Oct 10;102(15):1744-7. 
289) Hedrick PW. Gametic disequilibrium measures: proceed with caution. 
Genetics 1987 Oct;117(2):331-41. 
290) Lewontin RC. On measures of gametic disequilibrium. Genetics 1988 
Nov;120(3):849-52. 
291) Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and 
atherogenesis: John French Lecture 2000. Atherosclerosis 2000 Feb 
15;154(3):521-7. 
292) O'Rourke MF, Adji A. An updated clinical primer on large artery mechanics: 
implications of pulse waveform analysis and arterial tonometry. Curr Opin 
Cardiol 2005 Jul;20(4):275-81. 
293) Polke JM, McBride MM, Nicklin SA, Baker AB, Graham D, Dominiczak AF. 
Interactions between multiple promoter polymorphisms are requied for 
reduced expression of Gstm1 in the SHRSP. J Hyper Supp 2006 Dec;24 
(S6)(Supp 6):284. 
294) Zhou X, Frohlich ED. Differential effects of antihypertensive drugs on renal 
and glomerular hemodynamics and injury in the chronic nitric-oxide-
suppressed rat. Am J Nephrol 2005 Mar;25(2):138-52. 
295) Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human 
endothelial cells derived from umbilical veins. Identification by morphologic 
and immunologic criteria. J Clin Invest 1973 Nov;52(11):2745-56. 
296) Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth 
muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-
cGMP. Atherosclerosis 1990 May;82(1-2):113-23. 
297) Zhang J, Lo C. Regulation of fibronectin expression by PDGF-BB and IGF-I 
in cultured rat thoracic aortic adventitial fibroblasts. Cell Biol Int 1995 
Jun;19(6):517-25. 
298) Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD. Vascular 
effects of the human extracellular superoxide dismutase R213G variant. 
Circulation 2005 Aug 16;112(7):1047-53. 
299) Forsberg L, Lyrenas L, de FU, Morgenstern R. A common functional C-T 
substitution polymorphism in the promoter region of the human catalase 
gene influences transcription factor binding, reporter gene transcription and 
is correlated to blood catalase levels. Free Radic Biol Med 2001 Mar 
1;30(5):500-5. 
 
 APPENDICES 
 
Appendix A – Recipes for Solutions 
 
DNA extraction solution (100ml) 
1M Tris pH 8.0 5ml 
0.5M EDTA pH 8.0 20ml 
5M NaCl 2ml 
10% SDS 10ml 
 
6X nucleic acid loading dye (100ml) 
Ficoll-400 15g 
Bromophenol blue 0.05g 
Xylene cyanol 0.05g 
 
10x Phosphate buffered saline(PBS), pH 7.4 (1L) 
 
 
10X Tris/EDTA (TE) Buffer, pH 8.0 (1L) 
Tris 12.1g 
EDTA 3.72g 
 
1x Tris borate EDTA (TBE) Buffer (1L) 
NaOH 0.1g 
Tris base  10.8g 
boric acid  5.5g 
EDTA  0.74g 
 
In situ hybridisation 2X prehybridisation buffer (10ml) 
DEPC-H2O 5.88 ml 
5 M NaCl 2.4 ml 
1 M Tris (pH 7.5) 200 μl 
50 X Denhardt’s  400 μl 
250 mM EDTA 80 μl 
10 mg/ml Salmon Sperm DNA 1 ml 
50 mg/ml Yeast tRNA 40 μl 
 
In situ hybridisation 2X hybridisation buffer (10ml) 
DEPC-H2O 6.68 ml 
5 M NaCl 2.4 ml 
1 M Tris (pH 7.5) 200 μl 
50 X Denhardt’s  400 μl 
250 mM EDTA 80 μl 
Salmon Sperm DNA 200 μl 
Dextran sulphate 2.0 g 
50 mg/ml Yeast tRNA 40 μl 
 
0.01M Citrate Buffer pH 6.0 (make up fresh on day of use) 
0.1M trisodium citrate 4.1ml 
0.1M citric acid 900μl 
Make up to 40ml, pH to 6.0 with 5M NaOH and make up to 50ml 
 
 Appendix B – Suppliers and Catalogue Numbers 
 
Equipments 
Applied Biosystems Taqman (ABI Prism 7900HT Sequence Detection System) 
 - Data analysis with software SDS 2.1 
Applied Biosystems 3730 DNA Analyzer Bios 
- Data Collection Software v3.0 
- Data analysis with software Seqscape v2.5 
- Data analysis with GeneMapper v2.0 
Biorad Fluor-STM Multimager (gel imaging) 
Eppendorf Centrifuge 5415C (microcentrifuge) 
Thermo IEC Centra GP8R 
Thermo electronic Cryotome 
Thermo Shandon Finesse 325 Microtome 
Packard TRI-CAR 2100TR (liquid scintillation analyser) 
Peltier Thermal Cycler PTC-225 
 
Chemicals and consumables not listed below were purchased from campus store. 
 
Abcam, UK 
 
anti-alpha smooth muscle actin; Cat. No. ab18147 
anti-aquaporin 2; Cat. No. ab15082 
anti-GAPDH; Cat. No. ab9484 
anti-β-actin; Cat. No. ab8226 
anti-hGSTM1/2; Cat. No. ab27489 
anti-goat IgG*HRP; Cat. No. ab6741 
 
ABGene, UK 
384-well PCR plate Thermo fast; Cat. No. AB-1310 
0.2ml V-PCR plate; Cat. No. AB-0800 
Absolute Q-PCR Seal; Cat. No. AB-1170 
Clear adhesive PCR Film, 100 sheets; Cat. No. AB-0558 
Nucleofast 96 plate; Cat. No. MN743100.10 
 
Abnova, Taiwan 
GSTM1 monoclonal antibody; Cat. No. H00002944-M01 
GSTM1 recombinant protein; Cat. No. H00002944-Q01 
GSTM2 recombinant protein; Cat. No. H00002946-Q01 
GSTM3 recombinant protein; Cat. No. H00002947-P01 
GSTM4 recombinant protein; Cat. No. H00002948-P01 
GSTM5 recombinant protein; Cat. No. H00002949-Q01 
 
Agar Scientific, UK 
Ilford K5 nuclear emulsion; no catalogue number required 
 
Ambion, UK 
Human Heart Total RNA, 100μg; Cat. No. 7966 
Human Kidney Total RNA, 100μg; Cat. No. 7976 
Human Liver Total RNA, 100μg; Cat. No. 7960 
Human Testes Total RNA, 100μg; Cat. No. 7972 
DNA-freeTM; Cat. No.1906 
RNAlater;Cat. No. 7021 
RNaseZap; Cat. No. 9780 
 
Amersham, UK 
35S-UTP; Cat. No SJ40383 
 ECL Western blot detection reagents; Cat. No. RPN 2106 
Hybond™-C extra (nitrocellulose membrane); Cat. No.RPN137E 
Hybond-P (PVDF membrane); Cat. No. RPN 303F 
Hyperfilm ECL; Cat. No. RPN 3103K 
illustra Nick™ columns; Cat. No. 17-0855-01 
Recombinant Protein Molecular Weight Markers (10kDa – 250kDa); Cat. No. RPN 800 
 
Anachem, UK 
Kodak NTB2 nuclear emulsion; Cat. No. 8895666 
 
Applied Biosystems, UK 
ABI Prism® Big Dye Terminator v3.1 Cycle Sequencing Kit; Cat. No. 4337455 
Taqman Universal PCR Master Mix; Cat. No. 4324018 
GeneScanTM 500 LizTM Size Standard; Cat. No. 4322682 
Rat β-Actin (VIC-MGB) Gene Expression probe; Cat. No. 4352340E 
Rat Gstm1 (5’-FAM) Gene Expression probe; Cat. No. Rn00755117_m1 
Rat Gstm2 (5’-FAM) Gene Expression probe; Cat. No. Rn00598597_m1 
Rat Gstm3 (5’-FAM) Gene Expression probe; Cat. No. Rn00579867_m1 
Rat Gstm5 (5’-FAM) Gene Expression probe; Cat. No. Rn00597012_m1 
Rat Gstm7 (5’-FAM) Gene Expression probe; customised 
 
Dakocytomation UK 
Anti-Rabbit Igs*HRP; Cat. No. P0399 
 
Fisher Scientific, UK 
Histoclear; Cat. No. H/0468/17 
 
Genetix, UK 
GenCLEAN plate (Dye Terminator Removal 96-Well plate); Cat. No. K1015 
 
Microzone UK 
microCLEAN, 5 x 1ml; Cat. No. 2MCL-5 
 
Molecular Probes, Eugene, Oregon, USA 
PicoGreen® dsDNA Quantitation Kit; Cat. No. P-7589 
RiboGreen™ RNA Quantitation Kit; Cat. No. R-11490 
 
National Diagnostic, UK 
Histomount; Cat. No. HS-103 
 
Pierce Biotechnology Inc., UK 
BCA protein assay reagent kit; Cat. No. 23227 
 
Promega UK 
100bp DNA ladders; Cat. No. G2101 
5X Transcription buffer, Cat. No. P118B 
Blue Taq, 500u; Cat. No. M1665 
dNTPs set, 40μmol each; Cat. No. U1240 
Msp I, 2000u; Cat. No. R6401 
Proteinase K; Cat. No. V3021 
rATP, 10mM; Cat. No. P1132 
rCTP, 10mM; Cat. No. P1142 
rGTP, 10mM; Cat. No. P1152 
RQ1 DNase, 1000u; Cat. No. M6101 
Rsa I, 1000u; Cat. No. R6371 
Recombinant RNasin® Ribonuclease Inhibitor, 2500u; Cat. No. N2511 
Reverse Transcription System, 100 reactions; Cat. No. A3500 
 T3 RNA polymerase; Cat. No. P2083 
T7 RNA polymerase; Cat. No. P2075 
Wizard® Genomic DNA Purification Kit; Cat. No. A1125 
 
Qiagen, UK 
HotStar Taq DNA polymerase; Cat. No. 203203 
RNeasy Mini; Cat. No. 74104 
RNeasy Midi; Cat. No. 75142 
RNeasy Maxi; Cat. No. 75162 
 
Roche UK 
DNA markers X, 0.07 - 12.2kbp; Cat. No. 90437221 
Lightcycler FastStart DNA Master SYBR Green 1; Cat. No. 2239264 
Complete EDTA-free protease inhibitors cocktail; Cat. No. 1873580 
Sex AI, 200u; Cat. No. 1497995 
 
Sigma-Aldrich, UK 
Ammonium hydroxide solution; Cat. No. 320145 
APES; Cat. No. A3648 
4',6-diamidino-2-phenylindole (DAPI), Cat. No. D9542 
DL-dithiothreitol; Cat. No. D0632 
Eosin Y solution; Cat. No. 45242 
Ethanol ACS reagent; Cat. No. 459844 
Glycerol; Cat. No. G8773 
Glycine; Cat. No. G8898 
Harris Modified Haematoxylin; Cat. No. HHS32 
Hydralazine hydrochloride; Cat. No. H1753 
Hydrochlorothiazide; Cat. No. H2910 
Hydrogen peroxide 30% (w/w) solution, Cat. No. H1009 
IgGs from goat serum; Cat. No. I5256 
IgGs from rabbit serum; Cat. No. I5006 
IgGs from mouse serum; Cat. No. I8765 
Kodak Biomax MR (7"x9.5"); Cat. No. Z353949 
Mayer's Haematoxylin solution; Cat. No. MHS-1 
Nonidet-P40, replaced by Igepal-CA630 Cat. No. I7771 
Normal goat serum; Cat. No. G9023 
Normal mouse serum; Cat. No. M5905 
Normal rabbit serum; Cat. No. R9133 
Phosphate buffered saline (PBS) tablets; Cat. No. P4417 
Phosphatase inhibitors; Cat. No.P5726-1ML 
pUC18 DNA MspI Digest, 26 - 501bp; Cat. No. D-4797 
Sodium dodecyl sulphate for Molecular Biology; Cat. No. L4390 
Tris-base; Cat. No. T87602 
TEMED; Cat. No. T9281 
 
VWR UK 
Eppendorf Phase Lock Gel Heavy, 1.5ml; Cat. No. 427356S 
Microscope slide boxes 50, pack of 10; Cat. No. 406/0286/00 
O.C.T. compound; Cat. No. 361603E 
 
Vector Laboratories, UK 
Vectashield; Cat. No. H1000 
Vectastain Elite ABC Kit (Universal); Cat. No. PK-6200 
VectaMountTM Mounting medium; Cat. No. H5000 
DAB (diaminobenzidine tetrahydrochloride) substrate kit; Cat. No. SK-4100 
 
 Section 1
1 4510 20 30(1) 
---------------------------------------------rGstm1 (1) 
---------------------------------------------rGstm2 (1) 
---------------------------------------------rGstm3 (1) 
GGGATCCTACTCCTGCCTCTCTTGGGCTGTGGGTGTGACTCTCTGrGstm4 (1) 
---------------------------------------------rGstm5 (1) 
---------------------------------------------rGstm6a (1) 
---------------------------------------------rGstm6b (1) 
---------------------------------------------rGstm7 (1) 
 Section 2
46 9060 70 80(46) 
---------------------------------------------rGstm1 (1) 
---------------------------------------------rGstm2 (1) 
---------------------------------------------rGstm3 (1) 
ATTTAGGGTTCAAAGTCTCTGAGGAAGGGAAAGGCAGTGCCCGAGrGstm4 (46) 
---------------------------------------------rGstm5 (1) 
---------------------------------------------rGstm6a (1) 
---------------------------------------------rGstm6b (1) 
---------------------------------------------rGstm7 (1) 
 Section 3
91 135100 110 120(91) 
----------------------------TTTGTCCGGCCCACGTTrGstm1 (1) 
---------------------------------------------rGstm2 (1) 
---------GGGAAAGGCGGTCTGAAGACCTGACAGAGTGAAGCCrGstm3 (1) 
TGGGGTTAGGGCTTTGAGGGCAGGACCGTGTGCAGGGCCCCACCCrGstm4 (91) 
---AGAAAGGAGGAGGCAGTTCAGTCGCGTTGACCCCGCCCACAGrGstm5 (1) 
---------------------------------------------rGstm6a (1) 
---------------------------------------------rGstm6b (1) 
----------------------------------CCAGCCCCGCCrGstm7 (1) 
 Section 4
136 180150 160 170(136) 
TCTCTGGTAATCTGTATAAAGTCGCAACACACAGGTCAATTCTGCrGstm1 (18) 
---------------------------------------------rGstm2 (1) 
AGTCTGTT--TCTGGCAGCTCTCGGAACAGTCGAGGCTAGATTGArGstm3 (37) 
ACCTTTCCCTTAGTGCCTCTTTATAATTCCCCAGCTCAACTTGTCrGstm4 (136) 
CGTCCAGTATAAAGTTAGCCGCCC--ACAGTCCATCGCGTATCCCrGstm5 (43) 
-GGCTTCTCTCCTTGTGCACCAGGATATAGTT-ACAGTTCATTTArGstm6a (1) 
---------------------------------------------rGstm6b (1) 
CAGCTACCC-GAGGGCTCTAGGATAAAGTCAAAGCTACTCACACCrGstm7 (12) 
 Section 5
181 225190 200 210(181) 
TGAAGCCAAATTGAGAAGACCACAGCGCCAGAACCATGCCTATGArGstm1 (63) 
--AGGTTTGTCTGCTCTGTACACCCTACCAGCACGATGCCTATGArGstm2 (1) 
CACAGCCTGTCCGTTCAGACC------CCAGCACCATGCCCATGArGstm3 (80) 
TGAAGCCAGTCTGAGAAGACCACAGCACCAGAGCCATGGCTATGArGstm4 (181) 
AGAAGGGGCTAAGATCTCCCAAAATGTCGTGCTCCAAGTCTATGGrGstm5 (86) 
CTTAGCTCCACAGA--AGCCAGACAGCACAGCACCATGCCTATGArGstm6a (44) 
-----------------------------------ATGCCCGTGArGstm6b (1) 
GGAGGCTAGTGGACTCAGTCTCAGGCACCAGCATCATGCCTATGArGstm7 (56) 
 Section 6
226 270240 250 260(226) 
TACTGGGATACTGGAACGTCCGCGGGCTGACACACCCGATCCGCCrGstm1 (108) 
CACTGGGTTACTGGGACATCCGTGGGCTGGCTCACGCCATTCGCCrGstm2 (44) 
CACTGGGTTACTGGGACATCCGTGGGCTAGCGCATGCCATCCGCCrGstm3 (119) 
TACTGGGATATTGGAACGTTCGCGGACTTACTCACCCCATCCGCCrGstm4 (226) 
TTCTGGGTTACTGGGATATCCGCGGGCTGGCTCATGCCATCCGTArGstm5 (131) 
CTCTGGGTTACTGGCACATCCGTGGGTTGGGTCAAGCCATCCGTCrGstm6a (87) 
CTCTTGGTTATTGGGATATCCGCGGATTGGGTCACGCCATCCGGCrGstm6b (11) 
CACTGGGTTACTGGGACATCCGTGGGCTGGCTCATGCTATTCGATrGstm7 (101) 
 Section 7
271 315280 290 300(271) 
TGCTCCTGGAATACACAGACTCAAGCTATGAGGAGAAGAGATACGrGstm1 (153) 
TGTTCCTGGAGTATACAGACACAAGCTATGAGGACAAGAAGTACArGstm2 (89) 
TGCTCCTGGAATACACAGACTCGAGCTATGAGGAGAAGAGATACArGstm3 (164) 
TGCTCCTGGAATACACAGATTCAAACTATGAGGAGAAGAGATACGrGstm4 (271) 
TGCTCCTGGAGTTTACTGATACCAGCTATGAAGAGAAACAGTACArGstm5 (176) 
TGCTCCTGGAATACACAGGTTCAAGCTATGAGGAGAAGAGATACArGstm6a (132) 
TGCTCCTGGAATACACAGAAACAAGCTATGAGGAGAAGAGATACGrGstm6b (56) 
TACTCCTGGAATACACAGACTCAAGCTATGAGGAGAAGAGATACArGstm7 (146) 
 Section 8
316 360330 340 350(316) 
CCATGGGCGACGCTCCCGACTATGACAGAAGCCAGTGGCTGAATGrGstm1 (198) 
GCATGGGGGATGCTCCCGACTATGACAGAAGCCAGTGGCTGAGTGrGstm2 (134) 
CCATGGGAGACGCTCCCGACTTTGACAGAAGCCAGTGGCTGAATGrGstm3 (209) 
TCATGGGGGATGCCCCCAACTTTGACAGAAGCCAGTGGCTGAGTGrGstm4 (316) 
CGTGTGGGGAAGCTCCTGACTATGATAGAAGCCAATGGCTGGACGrGstm5 (221) 
CCATGGGGGACGCTCCCGACTATGACAGAAGCCAGTGGCTGAGTGrGstm6a (177) 
CCATGGGCGACGCTCCCGACTATGACAGAAGCCAGTGGCTGGATGrGstm6b (101) 
CCATGGGCGACGCTCCTGACTATGACAGAAGCCAGTGGCTGAGTGrGstm7 (191) 
 Section 9
361 405370 380 390(361) 
AGAAGTTCAAACTGGGCCTGGACTTCCCCAATCTGCCCTACTTAArGstm1 (243) 
AGAAGTTCAAACTGGGCCTGGACTTCCCCAATCTGCCCTACTTAArGstm2 (179) 
AGAAGTTCAAACTGGGCCTGGACTTCCCCAATCTGCCCTACTTAArGstm3 (254) 
AGAAATTCAATCTTGGCCTGGACATTCCCAATTTGCCCTACTTAArGstm4 (361) 
TGAAATTCAAGCTAGATCTGGATTTTCCTAACCTGCCCTACCTTArGstm5 (266) 
AGAAGTTCAAACTGGGCCTGGACATTCCTAATCTGCCCTACTTAArGstm6a (222) 
ACAAATTCAAGCTGGATCTGGACTTCCCCAATCTGCCCTACTTAArGstm6b (146) 
AGAAGTTCAAACTGGGCCTGGACTTCCCCAATCTGCCCTACTTAArGstm7 (236) 
 Section 10
406 450420 430 440(406) 
TTGATGGATCGCGCAAGATTACCCAGAGCAATGCCATAATGCGCTrGstm1 (288) 
TTGATGGGTCACACAAGATCACCCAGAGCAATGCCATCCTGCGCTrGstm2 (224) 
TTGATGGGTCACACAAGATCACCCAGAGCAACGCCATCCTGCGCTrGstm3 (299) 
TTGATGGGTCACACAAGGTCACCCAGAGCAATGCCATCCTGCGCTrGstm4 (406) 
TGGACGGGAAGAACAAGATCACCCAGAGTAACGCCATCTTGCGGTrGstm5 (311) 
TCGATGGGTCACACAAGATCACCCAGAGCAATGCCATCCTGCGCTrGstm6a (267) 
TTGATGGGTCACACAAGGTCACCCAGAGCAATGCCATCCTGCGCTrGstm6b (191) 
TCGATGGGTCACACAAGATCACCCAGAGCAATGCCATCCTGCGCTrGstm7 (281) 
 Section 11
451 495460 470 480(451) 
ACCTTGCCCGCAAGCACCACCTGTGTGGAGAGACAGAGGAGGAGCrGstm1 (333) 
ACCTTGGCCGGAAGCACAACCTTTGTGGGGAGACAGAGGAGGAGArGstm2 (269) 
ATCTTGGCCGCAAGCACAACCTGTGTGGGGAGACAGAAGAGGAGArGstm3 (344) 
ACCTTGGCCGGAAGCACAACCTGTGTGGGGAGACAGAGGAGGAGArGstm4 (451) 
ACATCGCACGCAAGCACAACATGTGTGGTGACACCGAAGAAGAAArGstm5 (356) 
ACCTTGGCCGGAAGCACAACCTGTGTGGAGAGACAGAAGAAGAGArGstm6a (312) 
ACCTTGGCCGGAAGCACAACCTGTGTGGGGAGACAGAGGAGGAGArGstm6b (236) 
ATATTGCCCGAAAGCACAACCTGTGTGGGGAGACAGAAGAAGAGArGstm7 (326) 
 Section 12
496 540510 520 530(496) 
GGATTCGTGCAGACATTGTGGAGAACCAGGTCATGGACAACCGCArGstm1 (378) 
GGATTCGTGTGGACGTTTTGGAGAACCAGGCTATGGACACCCGCCrGstm2 (314) 
GGATTCGTGTGGACATTCTGGAGAATCAGCTCATGGACAACCGCArGstm3 (389) 
GGATTCGTGTGGACACTTTGGAGAACCAGGTCATGGACACCCGCArGstm4 (496) 
AGATTCGAGTGGACATCATGGAGAACCAGATAATGGACTTCCGCArGstm5 (401) 
GACTCCGTGTGGACATTTTGGAGAACCAGGCCGTGGACACTCGTArGstm6a (357) 
GGATTCGTGTGGACATTTTGGAGAAACAGGTCATGGACACCCGCArGstm6b (281) 
AGATTCGTGTGGACATTTTGGAGAACCAGGCTATGGATGTCTCCArGstm7 (371) 
 Section 13
541 585550 560 570(541) 
TGCAGCTCATCATGCTTTGTTACAACCCCGACTTTGAGAAGCAGArGstm1 (423) 
TACAGTTGGCCATGGTCTGCTACAGCCCTGACTTTGAGAGAAAGArGstm2 (359) 
TGGTGCTGGCGAGACTTTGCTATAACCCTGACTTTGAGAAGCTGArGstm3 (434) 
TACATCTCATGATAGTTTGCTGCAGTCCTGACTTTGAGAAGCAGArGstm4 (541) 
TGCAGCTGGTTCGGCTCTGCTACAATTCTAACCACGAAAGCCTGArGstm5 (446) 
GGCAGCTTTCAATGGTCTGCTACAGCCCTGAGTTTGAGAAACGGArGstm6a (402) 
TTCAGATGGGCACACTCTGCTACAGCCCTGACTTCGAGAAACGGArGstm6b (326) 
ATCAGCTGGCTAGAGTCTGTTACAGCCCAGACTTTGAGAACCTGArGstm7 (416) 
 Section 14
586 630600 610 620(586) 
AGCCAGAGTTCTTGAAGACCATCCCTGAGAAGATGAAGCTCTACTrGstm1 (468) 
AGCCAGAGTACTTAGAGGGTCTCCCTGAGAAGATGAAGCTTTACTrGstm2 (404) 
AGCCAGGGTACCTGGAGCAACTGCCTGGAATGATGCGGCTTTACTrGstm3 (479) 
AGCCAGAGTTCTTGAAGTCCATCCCGGAGAAGATGAAAATCTATTrGstm4 (586) 
AGCCTCAGTATTTGGAACAACTGCCTGCACAGCTGAAACAGTTCTrGstm5 (491) 
AGCCAGAGTACTTAGAGGGTCTCCCTGACAAGATGAAGCTCTACTrGstm6a (447) 
AGCCTGAGTTCTTGAAGGGCCTCCCAGATCAGCTGAAGCTCTACTrGstm6b (371) 
AGGCGGAATATTTGGAGCAGCTCCCTGGGATGATGGAGCTCTTCTrGstm7 (461) 
 Section 15
631 675640 650 660(631) 
CTGAGTTCCTGGGCAAGCGACCATGGTTTGCAGGGGACAAGGTCArGstm1 (513) 
CCGAATTCCTGGGCAAGCAGCCATGGTTTGCAGGGAACAAGATTArGstm2 (449) 
CCGAGTTCCTGGGCAAGCGGCCATGGTTTGCAGGGGACAAGATCArGstm3 (524) 
CAGAGTTCCTGGGCAAGCGACCATGGTTTGCAGGGGACAAGGTCArGstm4 (631) 
CGTTGTTCCTGGGGAAATTCACATGGTTTGCAGGAGAAAAGCTGArGstm5 (536) 
CTGAGTTCCTGGGCAAGCAGCTATGGTTTGCAGGGAACAAGATTArGstm6a (492) 
CCGAGTTCCTGGGGAAGCAGCCATGGTTTGCAGGGGACAAGATCArGstm6b (416) 
CACAGTTCCTGGGGAAGCAGACGTGGTTCGTTGGTGAAAAGATTArGstm7 (506) 
 Section 16
676 720690 700 710(676) 
CCTATGTGGATTTCCTTGCTTATGACATTCTTGACCAGTACCACArGstm1 (558) 
CGTATGTGGATTTTCTTGTTTACGATGTCCTTGATCAACACCGTArGstm2 (494) 
CCTTTGTGGATTTCATTGCTTACGATGTTCTTGAGAGGAACCAAGrGstm3 (569) 
CCTATGTGGATTTCCTTGCTTATGACATTCTTGACCAGTACCGTArGstm4 (676) 
CCTTCGTGGATTTTCTCACTTATGACGTCTTGGACCAGAATCGTArGstm5 (581) 
CCTATGTGGATTTCCTTGTTTATGATGTCCTCGATAAGCACCGTArGstm6a (537) 
CCTTTGCAGATTTCCTTGTCTATGATGTCCTTGACCAGCACCGAArGstm6b (461) 
CTTTTGTAGATTTCCTTGCTTATGATATCCTGGACCTGCACCTTArGstm7 (551) 
 Section 17
721 765730 740 750(721) 
TTTTTGAGCCCAAGTGCCTGGACGCCTTCCCAAACCTGAAGGACTrGstm1 (603) 
TATTTGAACCCAAGTGCCTGGACGCCTTCCCAAACCTGAAGGACTrGstm2 (539) 
TGTTTGAGGCCACGTGCCTGGACGCGTTCCCAAACCTGAAGGATTrGstm3 (614) 
TGTTTGAGCCCGAGTGCCTGGACGCCTTCCCAAACCTGAAGGACTrGstm4 (721) 
TGTTTGAGCCCAAGTGCCTGGATGAGTTCCCAAATCTGAAGGCTTrGstm5 (626) 
TGTTTGAGCTCAAGTGCCTGGACGCCTTTCCAAATCTGAAGGACTrGstm6a (582) 
TGTTTGAACCCAAGTGCCTGGACGCCTTCCCAAACCTGATGGACTrGstm6b (506) 
TATTCGAACCCAAGTGCCTGGATGCCTTCCCAAACCTGAAGGACTrGstm7 (596) 
 Section 18
766 810780 790 800(766) 
TCCTGGCCCGCTTYGAGGGCCTGAAGAAGATCTCTGCCTACATGArGstm1 (648) 
TCGTGGCTCGGTTTGAGGGCCTGAAGAAGATATCTGACTACATGArGstm2 (584) 
TCATAGCGCGCTTTGAGGGCCTGAAGAAGATCTCCGACTACATGArGstm3 (659) 
TCCTGGCCCGCTTCGAGGGCCTGAAGAAGATCTCTGCTTACATGArGstm4 (766) 
TCATGTGCCGTTTTGAGGCTTTGGAGAAGATTGCTGCATTCCTGCrGstm5 (671) 
TCATGGCTCGATTTGAGACCCTTGAGAAGATCTCTGCCTACATGArGstm6a (627) 
TCGTGGTCCACTTTGAGGGCCTGAAGAAGATCTCTGCCTATATGArGstm6b (551) 
TTGTGGCCCGCTTCGAGGGACTGAAGAAGATCTCTGTTTACATGArGstm7 (641) 
 Section 19
811 855820 830 840(811) 
AGAGCAGCCGCTACCTCTCAACACCTATATTTTCGAAGTTGGCCCrGstm1 (693) 
AGAGCGGCCGCTTCCTCTCCAAGCCAATCTTTGCAAAGATGGCCTrGstm2 (629) 
AGTCCAGCCGCTTCCTCCCAAGACCTCTGTTCACAAAGATGGCTArGstm3 (704) 
AGAGTAGCAGCTTTCTCCCAAGACCTGTGTTTACTAAGATACCGCrGstm4 (811) 
AGTCTGACCGCTGCTTCAAGATGCCAATCAACAACAAGATGGCCArGstm5 (716) 
AGTCCAGCCGCTTCCTTTCAGGCCCTGTGTATTTGAAGACAGCGCrGstm6a (672) 
AGACCAGCCGCTTCCTTCCAAGTCCTGTGTACTTAAAACAGGCCArGstm6b (596) 
AGACCAGCCGCTTCCTCCGGACACCCCTATATACAAGGGTGGCTArGstm7 (686) 
 Section 20
856 900870 880 890(856) 
AATGGAGTAACAAGTAGGCCC------TTGCTACACTGGCACTCArGstm1 (738) 
TTTGGAACCCAAAGTAGCACCACAAAGTCCAGACCTAGGGATACTrGstm2 (674) 
TTTGGGGCAGCAAGTAGGACCCTGACAGGGTGGCTTTAGGAGAAArGstm3 (749) 
AGTGGGGCACTGATTAGGCCCC------TCGCATGCTGGCACTCArGstm4 (856) 
AGTGGGGTAACAAG-AGCATA-------TGCTGAGCTGGAGCTCGrGstm5 (761) 
TGTGGGGTAACAAGTAGAGCG--------CCCGTAATACCAGGGCrGstm6a (717) 
CGTGGGGCAACAAGTAGGACCCTGCA--TGGAGGGCCGGTGATGGrGstm6b (641) 
CTTGGGGCAATAAGTAGGGCTTTGACTCGGGCAGGAAGTGGGAACrGstm7 (731) 
 Section 21
901 945910 920 930(901) 
CAGRG-----AGGACCTGTCCACATTG----GATCCTGCAGGCA-rGstm1 (777) 
CATGA-----GTGCCCTGCTGGCTGTG----GG-CCTAGAGCATGrGstm2 (719) 
GATAC-----CAAATCTCCTGGGTTTGCCAAGAGCCCTAAGGAGCrGstm3 (794) 
CAGGA-----AGGACCTGTCCACACTG----GATCCTGCAGGCCCrGstm4 (895) 
CTG-------CTGCTGAGCCATCTTTC-------CCTCAAGGGACrGstm5 (798) 
CAGGA-----GGAGATTTACCTCTATGCT--TGCGGTCCATGGTCrGstm6a (754) 
TAGGG-----AGGATCTGTCGGCGCCCCTATCGCCCTGGACACTGrGstm6b (684) 
CTGGGGTTCTGGGAACAGTTGAGATTCCCGTATCCCTGGCGCTACrGstm7 (776) 
 Section 22
946 990960 970 980(946) 
---CCCTGGC-CTTCT-----GCACTGTGGTTCTC---TCT-CCTrGstm1 (812) 
--GCTCTGGC-GCCCA-----CCACA-TGCAGCTT---TCT-CCTrGstm2 (754) 
--GGGCAGGA-TTCCTGAGCCCCAGAGCCATGTTT---TCTTCCTrGstm3 (834) 
-TGGGCAGGAACAGCACTTTTGCACTGTGGCTCCTGGTTCTCTCTrGstm4 (931) 
-------CCA--CCCT------CTGTAAGCTTCCTG--CCAGCCTrGstm5 (829) 
-TGGGGCCCATCTGCGTCCCCGGGCATCTCTGTATCAGTCTTCCCrGstm6a (792) 
-ACTGGGTCA-CGGCTAGCTTCCAGT-AACTGCTC--TACATCAGrGstm6b (724) 
CTTCTACCTATCCCCTTCCTGACTGCAGAATGTCAAGGGTCTCCTrGstm7 (821) 
 Section 23
991 10351000 1010 1020(991) 
TCCTGC---TCCCTTCTCCA-GCTTTGYYAGCCC-CATCTCCTCArGstm1 (844) 
CCTT-----TCCATTC-CCT-GTTCCTCCATCTC-CTCTTCCCAGrGstm2 (786) 
TCCTTCCATTCCAGTCCCCAAGCCTTACCAGCTCTCATTTTTTGGrGstm3 (873) 
CCTTCCCTATCCCTTCTCCA-GCTTTCTCAGCCT-CATCTCCTCGrGstm4 (975) 
TGTCCC--ATCCGATCTGGAGGGGCCCGCACTCTGTCTCCTCTGCrGstm5 (857) 
ACCTCCG-TTCTTCTCTGAAAGGTGTTAGTGACTCCGCTTTCTACrGstm6a (836) 
TCTTCCCATTTTTTTCTGTC--TTTTCATTCTTTCCCTCTACAAGrGstm6b (764) 
TTCACCCAGTCCTTGCCCCT---TCAAGCCCTCTACAGCCTAGGCrGstm7 (866) 
 Section 24
1036 10801050 1060 1070(1036) 
ACCT---------CACCCCAGTCATGCCCACATA-GTCTTCATTCrGstm1 (884) 
CCCT---------TGCCTCAGTCAAGCCTCAGT---TCCCTGGTCrGstm2 (823) 
TCATCAAATT-CCTGCCAAACACAGGCTCTTAAA-AGCCCTAGCArGstm3 (918) 
CCCT---------CACCCCAGTCAAGTCCACACA-GTCCTCATTCrGstm4 (1018) 
TCCTTCCAAT-A-AACAGCAGTTAAATTAAAAAA-AAAAAAAAAArGstm5 (900) 
CCAGCC---T-TTCTGTAAGGGGAGGTTCTCAAA-CTCAGGTCTArGstm6a (880) 
ACCTCC---T-TGTTCCCCCCTTTGACTCAAGCC-TCCAGTGTCArGstm6b (807) 
CCCTGGTTTTCTTTAGCAAAGTGCCCTTCTAGCATGACTGTGTCCrGstm7 (908) 
 Section 25
1081 11251090 1100 1110(1081) 
TCCCCACTTTCTTT-CATAGTGGTCCCCTTCTT-TATTGACACCTrGstm1 (919) 
TCTCCA-TTTCTT--CAT--TAGTCCCCTCCCT-TGTCTCTGCCCrGstm2 (856) 
ACTCCTTTCCATTAGCAAAATAGCCTTCTAAAG-TTAAAGTGCCCrGstm3 (961) 
TTCCCACTTTCTTT-CATTATGATCCCCTTCTTCTTATGGCACCCrGstm4 (1053) 
AA-------------------------------------------rGstm5 (942) 
GTTCCCTAATTGGTTCTTGATGTGTCAATAAAGAAGGCTGGGAGCrGstm6a (920) 
GCTCCCTGTCCTCAGCAAAGTCCTTTTCTCCCCTTGTTTCTTTCTrGstm6b (847) 
TGTGCCCACTTGATGGCTTTCCTGTCAGTTGCTGTGCTGCTGTGArGstm7 (953) 
 Section 26
1126 11701140 1150 1160(1126) 
TA-AC---ACAACCTCACAGTCCTTTTCTGTGATTTG-AGGTCTGrGstm1 (962) 
T-------GCATCCAACCCTTCCCTCACTGATTTTCGGAGGACTGrGstm2 (895) 
C-------GCCCCCACCCCTCGAGCTCATGTGATTGGATAGTTGGrGstm3 (1005) 
TA-AC---CCATCCTCACAGACCTTTTCTGTGATTTG-AGGTCTGrGstm4 (1097) 
---------------------------------------------rGstm5 (944) 
CA-AT---TGCTGGGCGGAAGGTATAGGTGGGACTTCCGGGTCCCrGstm6a (965) 
GTCAT---GTTTCTAACCGTTCTTTCACTGAGCTTTGAGCACCTTrGstm6b (892) 
AGAGTTGAGACTTCATCAGCGCTCAGCCTGGGACTCCCCATGCTTrGstm7 (998) 
 Section 27
1171 12151180 1190 1200(1171) 
C-CCTGAACTCAGTCTCCC--------------------------rGstm1 (1002) 
TACCAGACCCCTGAATCCC--------------------------rGstm2 (933) 
CTCCCAACATGTGATTATTTTG-----------------------rGstm3 (1043) 
C-CCTGAACTCAGGCTCCCTAGAATTAACCCAAAGGTCAATGCTGrGstm4 (1137) 
---------------------------------------------rGstm5 (944) 
AAGAGAAAAAGGAGATTCAGGGAA-------AGATAGAGGGGCTTrGstm6a (1006) 
AACCTGAAGACCCATTCTCC--------CCGGAAGGCAGGCTCGGrGstm6b (934) 
GTCTGGAGACTGGAGATGCCTGATGTATGGAGGTCCCTGCACAGCrGstm7 (1043) 
 Section 28
1216 12601230 1240 1250(1216) 
-------------------TAGACTTACCCCAAATGT--AACACTrGstm1 (1020) 
-------------------CAGCCTGGCCTGAGAGAT--TAGA-TrGstm2 (952) 
-----------GGCAGGTGCAGGCTC-CCCGGCAGAT--GGGG-TrGstm3 (1065) 
TCTCAGTGCCAGCCCTCCTTAGAATTACCCCGAAGCTC-AACACTrGstm4 (1181) 
---------------------------------------------rGstm5 (944) 
TTTCTGCTGTGCTTCGGAGTAAGAAGGTAACAGTCATG-TAAGGTrGstm6a (1044) 
CCTCCAGAGTGGGATGGCCTAGCGTTGTTTGCTCTCTAATAAAGTrGstm6b (971) 
TCTTTTGGATCTCTCCTGTAAAGCTCGAATCACACTGGCTCTGGCrGstm7 (1088) 
 Section 29
1261 13051270 1280 1290(1261) 
GTCTCAGT-GCCAGCCTGTTCCTGG-----TGGGGGAGCTGCCCCrGstm1 (1044) 
CTCACTGT-GCTGCCCTGGTCC---------CCAGGAG--GACCCrGstm2 (975) 
CTATCTGGAGACAGTAGATTGCTAGCAGCTTTGACCACCGTAGCCrGstm3 (1095) 
GTCTCAGT-GCCAGCCTGTTCT-----CC-TGGAGGAGCTTCCCTrGstm4 (1225) 
---------------------------------------------rGstm5 (944) 
CTTCCGGCAGCTAGGGCCTGTGGCCTCCGCAACAGGCGGATAGCCrGstm6a (1088) 
ATTACCCACACTT--------------------------------rGstm6b (1016) 
TTCTGCACTGCCAGCTTTTACTGCGATC---TCCAGTGCCTGCCTrGstm7 (1133) 
 Section 30
1306 13501320 1330 1340(1306) 
AGGCCTG-TCTCATCTTTAATAAAGCCTGAAACACMAAAAAAAAArGstm1 (1083) 
A-------TTTTATTTGCAATAAAGTGTGAACCACAAA-------rGstm2 (1008) 
AAGCCCC-TCTTCT-TGCTGTTTCCCGAGACTAGCTATGAGCAAGrGstm3 (1140) 
CAGCCTG-TCTCATCTCTAATAAAGCCTGAAACACACTTGCT---rGstm4 (1263) 
---------------------------------------------rGstm5 (944) 
AAGGATGTTGGCAGGGGCTGGCTGATACAAGTCACTAAGTTTAGGrGstm6a (1133) 
---------------------------------------------rGstm6b (1029) 
AGTGACCCTGGCAGACACTGTGTTCACAGGGATTTCAGTTGGATArGstm7 (1175) 
 Section 31
1351 13951360 1370 1380(1351) 
AAAAAAAAAAAAAAAAAAA--------------------------rGstm1 (1127) 
---------------------------------------------rGstm2 (1039) 
GTGTGCTGTGTCCCCAGCACTTGTCACTGCCTCTGTAACCCGCTCrGstm3 (1183) 
GTGTGTTGTGTCTTTTTCTTTTGCT----CTTTAGCCTCTCCAAGrGstm4 (1304) 
---------------------------------------------rGstm5 (944) 
GCAGAGGGAGATGGAGATAATAAACT---GGTAAGAGCACGCCTTrGstm6a (1178) 
---------------------------------------------rGstm6b (1029) 
GGCAGGGGTTTGGGACTTCCTGGCCTCACCTGAGTTTCACAGGAGrGstm7 (1220) 
 Section 32
1396 14401410 1420 1430(1396) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
CTACCGCTCTTTCTTCCTGCTGCTGTGAGCTGTACCTCCTGACCArGstm3 (1228) 
CATTCATGGCTACTTCCAAAGAGTCTGAGCTCTGAGCCTGTAGTGrGstm4 (1345) 
---------------------------------------------rGstm5 (944) 
TCCAGGCCGTTGTTATCTGAGCCCAGCAATTGTGCCTAGCAGGCArGstm6a (1220) 
---------------------------------------------rGstm6b (1029) 
GCAGCTGCAGAAGGCTCTGTGGAGCTCAAAGGGAGCTTGGATCTCrGstm7 (1265) 
 Section 33
1441 14851450 1460 1470(1441) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
CAAACCAGAATAAATCATTCTCCCCGCAAAAAAAAAAAAAAAAAArGstm3 (1273) 
CCAGGCTCTGAAATGTCTAATGGAATCAGAAGAGCTTTAACATAArGstm4 (1390) 
---------------------------------------------rGstm5 (944) 
AATTCTAAAGTAA--------------------------------rGstm6a (1265) 
---------------------------------------------rGstm6b (1029) 
TTTTATGCTAGCAGCACTGAGGTTTGTCACCCAGGTCTCAGGGTTrGstm7 (1310) 
 Section 34
1486 15301500 1510 1520(1486) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
AAAAAAAAAAAA---------------------------------rGstm3 (1318) 
CTTTGG---------------------------------------rGstm4 (1435) 
---------------------------------------------rGstm5 (944) 
---------------------------------------------rGstm6a (1278) 
---------------------------------------------rGstm6b (1029) 
GGGGATCCAGGCTGGTGGGAGTCCCCAACAGTAAGCCAGGATCCTrGstm7 (1355) 
 Section 35
1531 15751540 1550 1560(1531) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
---------------------------------------------rGstm3 (1330) 
---------------------------------------------rGstm4 (1441) 
---------------------------------------------rGstm5 (944) 
---------------------------------------------rGstm6a (1278) 
---------------------------------------------rGstm6b (1029) 
CTCTGCCAGCTGTGCTAGGGCTGCCTTATATCTGTGTCTCCAGGArGstm7 (1400) 
 Section 36
1576 16201590 1600 1610(1576) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
---------------------------------------------rGstm3 (1330) 
---------------------------------------------rGstm4 (1441) 
---------------------------------------------rGstm5 (944) 
---------------------------------------------rGstm6a (1278) 
---------------------------------------------rGstm6b (1029) 
TCCTGTCTCTGATGCCTTCAGGGTATCCTGTCTTGGTTACAAGGGrGstm7 (1445) 
 Section 37
1621 16651630 1640 1650(1621) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
---------------------------------------------rGstm3 (1330) 
---------------------------------------------rGstm4 (1441) 
---------------------------------------------rGstm5 (944) 
---------------------------------------------rGstm6a (1278) 
---------------------------------------------rGstm6b (1029) 
ATGGGGAACATCTTGGTTAATCCCTTCTCTCTGTGAGTTCCCGTGrGstm7 (1490) 
 Section 38
1666 17101680 1690 1700(1666) 
---------------------------------------------rGstm1 (1146) 
---------------------------------------------rGstm2 (1039) 
---------------------------------------------rGstm3 (1330) 
---------------------------------------------rGstm4 (1441) 
---------------------------------------------rGstm5 (944) 
---------------------------------------------rGstm6a (1278) 
---------------------------------------------rGstm6b (1029) 
AAATAAATTTCTTCATGTTCATAAAAAAAAAAAAAAAAAAAAAAArGstm7 (1535) 
 Section 39
17111714(1711) 
----rGstm1 (1146) 
----rGstm2 (1039) 
----rGstm3 (1330) 
----rGstm4 (1441) 
----rGstm5 (944) 
----rGstm6a (1278) 
----rGstm6b (1029) 
AAAArGstm7 (1580) 
 Section 1
1 4510 20 30(1) 
---------------------------------------------hGSTM1 (1) 
---------------------------------------------hGSTM2 (1) 
---------------------------------------------hGSTM3 (1) 
GGCGAGGCCGAGCCCCTCCTAGTGCTTCCGGACCTTGCTCCCTGAhGSTM4 (1) 
---------------------------------------------hGSTM5 (1) 
 Section 2
46 9060 70 80(46) 
---------------------------------------------hGSTM1 (1) 
---------------------------------------------hGSTM2 (1) 
---------------------------------------------hGSTM3 (1) 
ACACTCGGAGGTGGCGGTGGATCTTACTCCTTCCAGCCAGTGAGGhGSTM4 (46) 
---------------------------------------------hGSTM5 (1) 
 Section 3
91 135100 110 120(91) 
---------------------------------------------hGSTM1 (1) 
---------------------------------------------hGSTM2 (1) 
---------------------------------------------hGSTM3 (1) 
ATCCAGCAACCTGCTCCGTGCCTCCCGCGCCTGTTGGTTGGAAGThGSTM4 (91) 
---------------------------------------------hGSTM5 (1) 
 Section 4
136 180150 160 170(136) 
---------------------------------------------hGSTM1 (1) 
---------------------------------------------hGSTM2 (1) 
------------------------------------GGCAAGGGAhGSTM3 (1) 
GACGACCTTGAAGATCGGCCGGTTGGAAGTGACGACCTTGAAGAThGSTM4 (136) 
---------------------------------------------hGSTM5 (1) 
 Section 5
181 225190 200 210(181) 
---------------------------------------------hGSTM1 (1) 
---------------------------------------------hGSTM2 (1) 
CGGAGAACGGGGCGGAGGCGGAGTCAGGGCGCCCGCGCGTGGGCChGSTM3 (10) 
CGGCGGGCGCAGCGG-GGCCGAGGGGGCGGGTCTGGCGCTAGGTChGSTM4 (181) 
---------------------------------------------hGSTM5 (1) 
 Section 6
226 270240 250 260(226) 
-------------------------------CTCTGAGCCCTGCThGSTM1 (1) 
--------------------------------------CCCCGCChGSTM2 (1) 
CCGCCCCCTTATGTAGGGTATA-------AAGCCCCTCCCGCTCAhGSTM3 (55) 
CAGCCCCTGCGTGCCGGGAACCCCAGAGGAGGTCGCAGTTCAGCChGSTM4 (225) 
-----------TCCTGGGCCTCTCA----AAGTCTGAGCCCCGCThGSTM5 (1) 
 Section 7
271 315280 290 300(271) 
CGGTTT----AGGCCTGTCTG---CGGAATCCG--CACCAACCAGhGSTM1 (15) 
CCGCTG----AGGCCTGTCTG---CAGAATCCA--CAGCAACCAGhGSTM2 (8) 
CAGTTTCCCTAGTCCTCGAAGGCTCGGAAGCCCGTCACCATGTCGhGSTM3 (93) 
CAGCTG----AGGCCTGTCTG---CAGAATCGA--CACCAACCAGhGSTM4 (270) 
CCGCTG----ATGCCTGTCTG---CAGAATCCG--CACCAACCAGhGSTM5 (31) 
 Section 8
316 360330 340 350(316) 
CACCATGC--CCATGATACTGGGGTACTGGGACATCCGCGGGCTGhGSTM1 (51) 
CACCATGC--CCATGACACTGGGGTACTGGAACATCCGCGGGCTGhGSTM2 (44) 
TGCGAGTCGTCTATGGTTCTCGGGTACTGGGATATTCGTGGGCTGhGSTM3 (138) 
CATCATGT--CCATGACACTGGGGTACTGGGACATCCGCGGGCTGhGSTM4 (306) 
CACCATGC--CCATGACTCTGGGGTACTGGGACATCCGTGGGCTGhGSTM5 (67) 
 Section 9
361 405370 380 390(361) 
GCCCACGCCATCCGCCTGCTCCTGGAATACACAGACTCAAGCTAThGSTM1 (94) 
GCCCATTCCATCCGCCTGCTCCTGGAATACACAGACTCAAGCTAChGSTM2 (87) 
GCGCACGCCATCCGCCTGCTCCTGGAGTTCACGGATACCTCTTAThGSTM3 (183) 
GCCCACGCCATCCGCCTGCTCCTGGAATACACAGACTCAAGCTAChGSTM4 (349) 
GCCCACGCCATCCGCTTGCTCCTGGAATACACAGACTCAAGCTAThGSTM5 (110) 
 Section 10
406 450420 430 440(406) 
GAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAGAhGSTM1 (139) 
GAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAGAhGSTM2 (132) 
GAGGAGAAACGGTACACGTGCGGGGAAGCTCCTGACTATGATCGAhGSTM3 (228) 
GAGGAAAAGAAGTATACGATGGGGGACGCTCCTGACTATGACAGAhGSTM4 (394) 
GTGGAAAAGAAGTACACGCTGGGGGACGCTCCTGACTATGACAGAhGSTM5 (155) 
 Section 11
451 495460 470 480(451) 
AGCCAGTGGCTGAATGAAAAATTCAAGCTGGGCCTGGACTTTCCChGSTM1 (184) 
AGCCAGTGGCTGAATGAAAAATTCAAGCTGGGCCTGGACTTTCCChGSTM2 (177) 
AGCCAATGGCTGGATGTGAAATTCAAGCTAGACCTGGACTTTCCThGSTM3 (273) 
AGCCAGTGGCTGAATGAAAAATTCAAGCTGGGCCTGGACTTTCCChGSTM4 (439) 
AGCCAGTGGCTGAATGAAAAATTCAAGCTGGGCCTGGACTTTCCChGSTM5 (200) 
 Section 12
496 540510 520 530(496) 
AATCTGCCCTACTTGATTGATGGGGCTCACAAGATCACCCAGAGChGSTM1 (229) 
AATCTGCCCTACTTGATTGATGGGACTCACAAGATCACCCAGAGChGSTM2 (222) 
AATCTGCCCTACCTCCTGGATGGGAAGAACAAGATCACCCAGAGChGSTM3 (318) 
AATCTGCCCTACTTGATTGATGGGGCTCACAAGATCACCCAGAGChGSTM4 (484) 
AATCTGCCCTACTTGATTGATGGGGCTCACAAGATCACCCAGAGChGSTM5 (245) 
 Section 13
541 585550 560 570(541) 
AACGCCATCTTGTGCTACATTGCCCGCAAGCACAACCTGTGTGGGhGSTM1 (274) 
AACGCCATCCTGCGGTACATTGCCCGCAAGCACAACCTGTGCGGGhGSTM2 (267) 
AATGCCATCTTGCGCTACATCGCTCGCAAGCACAACATGTGTGGThGSTM3 (363) 
AACGCCATCCTGTGCTACATTGCCCGCAAGCACAACCTGTGTGGGhGSTM4 (529) 
AATGCCATCCTGCGCTACATTGCCCGCAAGCACAACCTGTGTGGGhGSTM5 (290) 
 Section 14
586 630600 610 620(586) 
GAGACAGAAGAGGAGAAGATTCGTGTGGACATTTTGGAGAACCAGhGSTM1 (319) 
GAATCAGAAAAGGAGCAGATTCGCGAAGACATTTTGGAGAACCAGhGSTM2 (312) 
GAGACTGAAGAAGAAAAGATTCGAGTGGACATCATAGAGAACCAAhGSTM3 (408) 
GAGACAGAAGAGGAGAAGATTCGTGTGGACATTTTGGAGAACCAGhGSTM4 (574) 
GAGACAGAAGAGGAGAAGATTCGTGTGGACATTTTGGAGAACCAGhGSTM5 (335) 
 Section 15
631 675640 650 660(631) 
ACCATGGACAACCATATGCAGCTGGGCATGATCTGCTACAATCCAhGSTM1 (364) 
TTTATGGACAGCCGTATGCAGCTGGCCAAACTCTGCTATGACCCAhGSTM2 (357) 
GTAATGGATTTCCGCACACAACTGATAAGGCTCTGTTACAGCTCThGSTM3 (453) 
GCTATGGACGTCTCCAATCAGCTGGCCAGAGTCTGCTACAGCCCThGSTM4 (619) 
GTTATGGATAACCACATGGAGCTGGTCAGACTGTGCTATGACCCAhGSTM5 (380) 
 Section 16
676 720690 700 710(676) 
GAATTTGAGAAACTGAAGCCAAAGTACTTGGAGGAACTCCCTGAAhGSTM1 (409) 
GATTTTGAGAAACTGAAACCAGAATACCTGCAGGCACTCCCTGAAhGSTM2 (402) 
GACCACGAAAAACTGAAGCCTCAGTACTTGGAAGAGCTACCTGGAhGSTM3 (498) 
GACTTTGAGAAACTGAAGCCAGAATACTTGGAGGAACTTCCTACAhGSTM4 (664) 
GATTTTGAGAAACTGAAGCCAAAATACTTGGAGGAACTCCCTGAAhGSTM5 (425) 
 Section 17
721 765730 740 750(721) 
AAGCTAAAGCTCTACTCAGAGTTTCTGGGGAAGCGGCCATGGTTThGSTM1 (454) 
ATGCTGAAGCTCTACTCACAGTTTCTGGGGAAGCAGCCATGGTTThGSTM2 (447) 
CAACTGAAACAATTCTCCATGTTTCTGGGGAAATTCTCATGGTTThGSTM3 (543) 
ATGATGCAGCACTTCTCACAGTTCCTGGGGAAGAGGCCATGGTTThGSTM4 (709) 
AAGCTAAAGCTCTACTCAGAGTTTCTGGGGAAGCGGCCATGGTTThGSTM5 (470) 
 Section 18
766 810780 790 800(766) 
GCAGGAAACAAGATCACTTTTGTAGATTTTCTCGTCTATGATGTChGSTM1 (499) 
CTTGGGGACAAGATCACCTTTGTGGATTTCATCGCTTATGATGTChGSTM2 (492) 
GCCGGGGAAAAGCTCACCTTTGTGGATTTTCTCACCTATGATATChGSTM3 (588) 
GTTGGAGACAAGATCACCTTTGTAGATTTCCTCGCCTATGATGTChGSTM4 (754) 
GCAGGAGACAAGATCACCTTTGTGGATTTCCTTGCCTATGATGTChGSTM5 (515) 
 Section 19
811 855820 830 840(811) 
CTTGACCTCCACCGTATATTTGAGCCCAAGTGCTTGGACGCCTTChGSTM1 (544) 
CTTGAGAGAAACCAAGTATTTGAGCCCAGCTGCCTGGATGCCTTChGSTM2 (537) 
TTGGATCAGAACCGTATATTTGACCCCAAGTGCCTGGATGAGTTChGSTM3 (633) 
CTTGACCTCCACCGTATATTTGAGCCCAACTGCTTGGACGCCTTChGSTM4 (799) 
CTTGACATGAAGCGTATATTTGAGCCCAAGTGCTTGGACGCCTTChGSTM5 (560) 
 Section 20
856 900870 880 890(856) 
CCAAATCTGAAGGACTTCATCTCCCGCTTTGAGGGCTTGGAGAAGhGSTM1 (589) 
CCAAACCTGAAGGACTTCATCTCCCGATTTGAGGGCTTGGAGAAGhGSTM2 (582) 
CCAAACCTGAAGGCTTTCATGTGCCGTTTTGAGGCTTTGGAGAAAhGSTM3 (678) 
CCAAATCTGAAGGACTTCATCTCCCGCTTTGAGGGCTTGGAGAAGhGSTM4 (844) 
CTAAACTTGAAGGACTTCATCTCCCGCTTTGAGGGTTTGAAGAAGhGSTM5 (605) 
 Section 21
901 945910 920 930(901) 
ATCTCTGCCTACATGAAGTCCAGCCGCTTCCTCCCAAGACCTGTGhGSTM1 (634) 
ATCTCTGCCTACATGAAGTCCAGCCGCTTCCTCCCAAGACCTGTGhGSTM2 (627) 
ATCGCTGCCTACTTACAGTCTGATCAGTTCTGCAAGATGCCCATChGSTM3 (723) 
ATCTCTGCCTACATGAAGTCCAGCCGCTTCCTCCCAAAACCTCTGhGSTM4 (889) 
ATCTCTGCCTACATGAAGTCCAGCCAATTCCTCCGAGGTCTTTTGhGSTM5 (650) 
 Section 22
946 990960 970 980(946) 
TTCTCAAAGATGGCTGTCTGGGGCAACAAGTAGGGCC--TTGAAGhGSTM1 (679) 
TTCACAAAGATGGCTGTCTGGGGCAACAAGTAGGGCC--TTGAAGhGSTM2 (672) 
AACAACAAGATGGCCCAGTGGGGCAACAAGCCTGT----ATGCTGhGSTM3 (768) 
TACACAAGGGTGGCTGTCTGGGGCAACAAGTAATGCC--TTGAAGhGSTM4 (934) 
TTTGGAAAGTCAGCTACATGGAACAGCAAATAGGGCCCAGTGATGhGSTM5 (695) 
 Section 23
991 10351000 1010 1020(991) 
GCCAGGAGGTGGGAGTGAGGAGCCCATACT----CAGCCTGCTGChGSTM1 (722) 
GCCAGGAGGTGGGAGTGAGGAGCCCATACT----CAGCCTGCTGChGSTM2 (715) 
AGCAGGAGGCAGACTTGCAGAGCTTGTTTTGTTTCATCCTG-TCChGSTM3 (809) 
GCCAGGAGGTGGGAGTGAGGAGCCCATACT----CAGCCTGCTGChGSTM4 (977) 
-CCAGAAGATGGGAGGGAGGAGCCAACCTTG---CTGCCTGCGAChGSTM5 (740) 
 Section 24
1036 10801050 1060 1070(1036) 
CCAGGCTGTGCAGCGCAGCTGGACTCTGCATCCCAGCACCTGCCThGSTM1 (763) 
CCAGGCTGTGCAGCGCAGCTGGACTCTGCATCCCAGCACCTGCCThGSTM2 (756) 
GTAAGGGGT-CAGCGCTCTTGCTTTGCTCTTTTCAATGAATAGCAhGSTM3 (853) 
CCAGGCTGTGCAGCGCAGCTGGACTCTGCATCCCAGCACCTGCCThGSTM4 (1018) 
CCTGGAGGA-CAGC-----------CTGACTCCCTGGACCTGCCThGSTM5 (781) 
 Section 25
1081 11251090 1100 1110(1081) 
CCTC-GTTCCTT-TCTCCTGTTTATTCCCATCTTTACTCCCAAGAhGSTM1 (808) 
CCTC-GTTCCTT-TCTCCTGTTTATTCCCATCTTTACTCCCAAGAhGSTM2 (801) 
CTTATGTTACTGGTGTCCAGCTGAGTTTC-TCTTGGGTATAAAGGhGSTM3 (897) 
CCTC-GTTCCTT-TCTCCTGTTTATTCCCATCTTTACCCCCAAGAhGSTM4 (1063) 
TCTTCCTTTTTC--CTTCTTTCTACTCTCTTCTCTTC-CCCAAGGhGSTM5 (814) 
 Section 26
1126 11701140 1150 1160(1126) 
CTTCATTGTCCCTCTTCACTCCCCCTAAACCCCTGTCCC---ATGhGSTM1 (851) 
CTTCATTGTCCCTCTTCACTCCCCCTAAACCCCTGTCCC---ATGhGSTM2 (844) 
CTAAAAGGGAAAAAGGATATGTGGAGAATCATCAAGATATGAATThGSTM3 (941) 
CTTTATTGGGCCTCTTCACTTCCCCTAAACCCCTGTCCC---ATGhGSTM4 (1106) 
CCTCATTGG-CTTCCTTTCTTCTAACA-TCATCCCTCCCCGCATChGSTM5 (856) 
 Section 27
1171 12151180 1190 1200(1171) 
CAGGCCCTTTGAAGCCT-CAGCTACCCACTATCCTTC---GTGAAhGSTM1 (893) 
CAGGCCCTTTGAAGCCT-CAGCTACCCACTATCCTTC---GTGAAhGSTM2 (886) 
GAATCGCTGCGATACTGGCATTTCCCTACTCCCCAACTGAGTTCAhGSTM3 (986) 
CAGGCCCTTTGAAGCCT-CAGCTACCCACTTTCCTTC---ATGAAhGSTM4 (1148) 
GAGGCTCTTTAAAGCTT-CAGCTCCCCACTGTCCTCC---ATCAAhGSTM5 (899) 
 Section 28
1216 12601230 1240 1250(1216) 
CATCCCC-TCCCATCA-TTACCCTTCCCTGC--------ACTAAAhGSTM1 (934) 
CATCCCC-TCCCATCA-TTACCCTTCCCTGC--------ACTAAAhGSTM2 (927) 
AGGGCTG-TAGGTTCA-TGCCCAAGCCCTGAGAGTGGGTACTAGAhGSTM3 (1031) 
CATCCCCCTCCCAACA-CTACCCTTCCCTGC--------ACTAAAhGSTM4 (1189) 
AGTCCCCCTCCTAACGTCTTCCTTTCCCTGC--------ACTAAChGSTM5 (940) 
 Section 29
1261 13051270 1280 1290(1261) 
GCCAGCCTGACCTTCC--TTCCTGTTAGTGGTTGTGTCTGCTTTAhGSTM1 (969) 
GCCAGCCTGACCTTCC--TTCCTGTTAGTGGTTGTGTCTGCTTTAhGSTM2 (962) 
AAAAACGAGATTGCACAGTTGGAGAGAGCAGGTGTGTTAAATGGGhGSTM3 (1074) 
GCCAGCCTGACCTTCC--TTCCTGTTAGTGGTTGTATCTGCTTTGhGSTM4 (1225) 
GCCAACCTGACTGCTT--TTCCTGTCAGTGCTTTTCTCTTCTTTGhGSTM5 (977) 
 Section 30
1306 13501320 1330 1340(1306) 
AAGGGCCTGCCTGGCCCCTC-GCCTGTGGAGCTCAGCCCCGAG--hGSTM1 (1012) 
AAGGGCCTGCCTGGCCCCTC-GCCTGTGGAGCTCAGCCCCGAG--hGSTM2 (1005) 
ACTGGAGTCCCTGTGAAGACTGGGTGAGGATAACACAAGTAAAA-hGSTM3 (1119) 
AAGGGCCTACCTGGCCCCTC-GCCTGTGGAGCTCAGCCCTGAG--hGSTM4 (1268) 
AGAAGCCAGACTGATCTCTG-AGCTCCCTAGCACTGTCCTCAAAGhGSTM5 (1020) 
 Section 31
1351 13951360 1370 1380(1351) 
-----CTGTC-CCCGTGTTGCA-TGAA--GG-----AG--CAGCAhGSTM1 (1054) 
-----CTGTC-CCCGTGTTGCA-TGAA--GG-----AG--CAGCAhGSTM2 (1047) 
-----CTGTG-GTACTGATGGACTTAACCGG-----AGTTCGGAAhGSTM3 (1163) 
-----CTGTC-CCCGTGTTGCA-TGA--------------CAGCAhGSTM4 (1310) 
ACCATCTGTATGCCCTGCTCCCTTTGCTGGGTCCCTACCCCAGCThGSTM5 (1064) 
 Section 32
1396 14401410 1420 1430(1396) 
TT-GACTGGTTTACA----GGCCCTGCTCCTGCA-------GCAThGSTM1 (1083) 
TT-GACTGGTTTACA----GGCCCTGCTCCTGCA-------GCAThGSTM2 (1076) 
ACCGTCCTGTGTACACATGGGAGTTTAGTGTGATA---AAGGCAGhGSTM3 (1197) 
TT-GACTGGTTTACA----GGCCCTGCTCCTGCA-------GCAThGSTM4 (1334) 
CC-GTGTGATGCCCAGTAAAGCCTGAACCATGCCTGCCATGTCTThGSTM5 (1109) 
 Section 33
1441 14851450 1460 1470(1441) 
GGTCCCTGCCTTA-GGCCTACCTGATGGAAGT-----AAAGCCTChGSTM1 (1116) 
GGTCCCTGCCTTA-GGCCTACCTGATGGAAGT-----AAAGCCTChGSTM2 (1109) 
TATTTCAGACTGGTGGGCTAGCCAATAGAGTTGGGACAATTGCTThGSTM3 (1239) 
GGCCCCTGCCTTA-GGCCTACCTGATCAAAAT-----AAAGCCTChGSTM4 (1367) 
GTCTTATTCCCTGAGGCTCCCTTGACTCAGGA----CTGTGCTCGhGSTM5 (1153) 
 Section 34
1486 15301500 1510 1520(1486) 
AACCACA--------------------------------------hGSTM1 (1155) 
AACCACAAAAAAAAAAAAA--------------------------hGSTM2 (1148) 
ACTCATTAAAAATAATAGAGCCCCACTTGACACTATTCACTAAAAhGSTM3 (1284) 
AGCCACAAAAAAAAAAAAAAAAAAAAAAAAA--------------hGSTM4 (1406) 
AATTGTGGGTGGTTTTTTGTCTTCTGTTGTCCACAGCCAGAGCTThGSTM5 (1194) 
 Section 35
1531 15751540 1550 1560(1531) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TTAATCTGGAATTTAAGGCCCAACATTAAACACAAAGCTGTTGAAhGSTM3 (1329) 
---------------------------------------------hGSTM4 (1437) 
AGTGGATGGGTGTGTGTGTGTGTGTGTTGGGGGTGGTGATCAGGChGSTM5 (1239) 
 Section 36
1576 16201590 1600 1610(1576) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ATATTGATGAAAATGTAAGAATTTTTGTGACCACGGGGTAGGAGAhGSTM3 (1374) 
---------------------------------------------hGSTM4 (1437) 
AGGTTCATAAATTTCCTTGGTCATTTCTGCCCTCTAGCCACATCChGSTM5 (1284) 
 Section 37
1621 16651630 1640 1650(1621) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AGTTTCTTTAAAGACGTAAAAAGAAAAAAACCATAGGCTGCTCTGhGSTM3 (1419) 
---------------------------------------------hGSTM4 (1437) 
CTCTGTTCCTCACTGTGGGGATTACTACAGAAAGGTGCTCTGTGChGSTM5 (1329) 
 Section 38
1666 17101680 1690 1700(1666) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CCTGTGGAGTAGCCATTCTTTATTCTTTTACTTTTTAAAATAATAhGSTM3 (1464) 
---------------------------------------------hGSTM4 (1437) 
CAAGTTCCTCACTCATTCGCGCTCCTGTAGGCCGTCTAGAACTGGhGSTM5 (1374) 
 Section 39
1711 17551720 1730 1740(1711) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACAATCACAAAGGAAAGATTTGCCAATTGAATAGGATCAAATTCThGSTM3 (1509) 
---------------------------------------------hGSTM4 (1437) 
CATGGTTCAAAGAGGGGCTAGGCTGATGGGGAAGGGGGCTGAGCAhGSTM5 (1419) 
 Section 40
1756 18001770 1780 1790(1756) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACAACTTTTCCTAAGGCACCCACAAATAAATGACAAGTGAGACAAhGSTM3 (1554) 
---------------------------------------------hGSTM4 (1437) 
GCTCCCAGGCAGACTGCCTTCTTTCACCC-TGTCCTGATAGACTThGSTM5 (1464) 
 Section 41
1801 18451810 1820 1830(1801) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAAGCACTAGTATAAAGATTATATAAAGACCTATAAATCATTAAGhGSTM3 (1599) 
---------------------------------------------hGSTM4 (1437) 
CCCTGATCTAGATATCCTTCGTCATGACACTTCTCAATAAAACGThGSTM5 (1508) 
 Section 42
1846 18901860 1870 1880(1846) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACAACTGAGTTTTTAAAAATGGACAAAATCCATGAACAATTTATAhGSTM3 (1644) 
---------------------------------------------hGSTM4 (1437) 
ATCCCACCGTATTGT------------------------------hGSTM5 (1553) 
 Section 43
1891 19351900 1910 1920(1891) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAATAGAAATATAGCCAAAAATGTCTAAAAGATGTTTATGATGTAhGSTM3 (1689) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 44
1936 19801950 1960 1970(1936) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AGGAATTATCAATTACAACAGTGAGAAACCATATTTCCTTCTATChGSTM3 (1734) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 45
1981 20251990 2000 2010(1981) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CGATGAGTAAAAAGTTTCTAAAGTGTTGGCAAGGCTTAGGAAAGThGSTM3 (1779) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 46
2026 20702040 2050 2060(2026) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GATATGCATTTCCTGCTGGTCAAGTTGTAAATTAGTATAGCTACThGSTM3 (1824) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 47
2071 21152080 2090 2100(2071) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TTGGAGGACAATTGTAAAATTTAAATCATATCCTATGACCCAGCAhGSTM3 (1869) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 48
2116 21602130 2140 2150(2116) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ATTCCATGCTATAAAAACTCATCCATGGCCGGGCTTGGTGGCTCAhGSTM3 (1914) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 49
2161 22052170 2180 2190(2161) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGCAGATCAChGSTM3 (1959) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 50
2206 22502220 2230 2240(2206) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GAGGTCAAGAGATCGAGACCATCCTGGCCAACATGATGAAACCCChGSTM3 (2004) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 51
2251 22952260 2270 2280(2251) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GTTTCTACTAAAAATACAAAAATTAGCTGGGCATGGTGGCATGTGhGSTM3 (2049) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 52
2296 23402310 2320 2330(2296) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CCTATAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTThGSTM3 (2094) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 53
2341 23852350 2360 2370(2341) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GAACCTGGGAGGCAGAGGTTGCAGTGAGCCGAGATCACGCCACTGhGSTM3 (2139) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 54
2386 24302400 2410 2420(2386) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CACTCCAGCCTGGCTACAGGGCGAGACTCTGTCTCAAAAAAAAAAhGSTM3 (2184) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 55
2431 24752440 2450 2460(2431) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAAAAAAAAAAAAAAAAACATTCAAAGAGACATATACTAAGATGThGSTM3 (2229) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 56
2476 25202490 2500 2510(2476) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TCACTGTGGCATTGTCTGTAATGACAAATAAGTGGAAACCGTGTAhGSTM3 (2274) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 57
2521 25652530 2540 2550(2521) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AATACCTGTCAATACTATGGAGTACCATGTGGCAACGGAAGAATGhGSTM3 (2319) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 58
2566 26102580 2590 2600(2566) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AGACTGAACTGTGTGAACTAACATGCAAAGATCCCCAAAACAGGChGSTM3 (2364) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 59
2611 26552620 2630 2640(2611) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CAGGTGTGGTTGCTCACAGCTGTAATAACAACACCTTCAGAGGCThGSTM3 (2409) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 60
2656 27002670 2680 2690(2656) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GAGGTGAGAGGATCAGTTGAGGCCAGGAGTTTAAGACCAGCCTGGhGSTM3 (2454) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 61
2701 27452710 2720 2730(2701) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GCAACATAGTGAGACCCCTGTCTCCCAAAAATTTTTTTTAATTAGhGSTM3 (2499) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 62
2746 27902760 2770 2780(2746) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CTGTGCGCAATTGCTCATGCATAGTCCCAGCTACCCAGGAGGCTGhGSTM3 (2544) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 63
2791 28352800 2810 2820(2791) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AGGTGGGAGGATCACTTGAGCCCAGGAATTTGAAGCTGCAGTGAGhGSTM3 (2589) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 64
2836 28802850 2860 2870(2836) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CTGTGTTCTTGCCACTGCACTCCAATCTGGGTGACTGAGCAAGAChGSTM3 (2634) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 65
2881 29252890 2900 2910(2881) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CCTGTCTCTTAAAAAAATAAAAAAGATCTCCAAGCATAGAGAAGAhGSTM3 (2679) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 66
2926 29702940 2950 2960(2926) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GTCTGGAGGGAAACACCAAACTCATAACAGTCTTACTGCAGGCAAhGSTM3 (2724) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 67
2971 30152980 2990 3000(2971) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GTGGGATAAAGGCCCAGACTCCATGGTGGAAGTTAAAGGGCATTThGSTM3 (2769) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 68
3016 30603030 3040 3050(3016) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CCAAGTTAAGGCTAAGACTTGCTTTTCTAACTAAGAGAATGTGCThGSTM3 (2814) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 69
3061 31053070 3080 3090(3061) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CATGCATTGCTTGTGTAGTAGAAACTAGTTTTTAGAAAAGAAAGChGSTM3 (2859) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 70
3106 31503120 3130 3140(3106) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAACTTAAGAAACACTGACTCCTGTGGAGATGACTTGGCACCACThGSTM3 (2904) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 71
3151 31953160 3170 3180(3151) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CTCCTTTCACAGAGCAGAGTCTGAATAGTCTTCAGAGATAGGCCThGSTM3 (2949) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 72
3196 32403210 3220 3230(3196) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GTGGGCCAGATTGCCATCCCCTATGGACCAGAAGCCAAGGATCTChGSTM3 (2994) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 73
3241 32853250 3260 3270(3241) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TCTAGTGATGGTCAGAGGGCCCAAATGGCAGGGATACCCAGTGAThGSTM3 (3039) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 74
3286 33303300 3310 3320(3286) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GTCAGGAGGAATAGTACAGACAGAAGGTGCTAAGCAGACAATTCAhGSTM3 (3084) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 75
3331 33753340 3350 3360(3331) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACTGCCATGTTTTGCCACCCCCTGTGAGCAGGGATTAGGTGTTCAhGSTM3 (3129) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 76
3376 34203390 3400 3410(3376) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GGCCAGTATCTTGGGCATGGGGGAGCCTTTGGCCAGAAGAGGTAThGSTM3 (3174) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 77
3421 34653430 3440 3450(3421) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAAGCTCAGAAGTTTTTCAGTCTGATAACTATTGATATAATTTCChGSTM3 (3219) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 78
3466 35103480 3490 3500(3466) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ATAGTGTGAGGGAGCGGTATGCTCTACCCTTGTGTATTTAAGGCAhGSTM3 (3264) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 79
3511 35553520 3530 3540(3511) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GGACAGAGAAATTGAGGATGCCCCTGGGGCTAGATCGATGATATGhGSTM3 (3309) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 80
3556 36003570 3580 3590(3556) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACCAGAAATCAAAAAGGGAATGCATTATTTATTGCTGTGTAACAChGSTM3 (3354) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 81
3601 36453610 3620 3630(3601) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TGTTAAGAGAGGAGGTAGTTAAGGGATGGATAGGCACATAGAGAGhGSTM3 (3399) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 82
3646 36903660 3670 3680(3646) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GGAAGGTCTCAGGAGAAGGGATAGAAAGGAACTATGTTCACAAGAhGSTM3 (3444) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 83
3691 37353700 3710 3720(3691) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
ACAACGGCAAGACAGTGCCTATACTGCCTCTACAGTTAATAGGAAhGSTM3 (3489) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 84
3736 37803750 3760 3770(3736) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AAACGGAAGAAGTTACCCTTAAGCTAGGATGTTGCTCAGAAGTGAhGSTM3 (3534) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 85
3781 38253790 3800 3810(3781) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CCATCCCAACTTTGGTGCGGGCACAATAAATCAGCCTAAATGTCChGSTM3 (3579) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 86
3826 38703840 3850 3860(3826) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CTAATTTAACCCAGCTCATTATAATGTCATTAAACATGACATTAGhGSTM3 (3624) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 87
3871 39153880 3890 3900(3871) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CATTGTGGTTTTAGCACCCCCATGGGTTTTGCTTAGGCACTCATGhGSTM3 (3669) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 88
3916 39603930 3940 3950(3916) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
GGTAATAACCAAGATGGAGTCCCTTTGGCAAAACTTAGGCATGCAhGSTM3 (3714) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 89
3961 40053970 3980 3990(3961) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CAGCTGTAGTACCCCAAGAAGAAAATGTTACTTCTCTCATCTGGGhGSTM3 (3759) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 90
4006 40504020 4030 4040(4006) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
CAAAACCCACAGAAGACTTCCCAGCTTCTGCCACATAAAAGACAChGSTM3 (3804) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 91
4051 40954060 4070 4080(4051) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
AGAACACAGACGCCTTACTGGCAACCTGCTTTCAAGACCCCTGTChGSTM3 (3849) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 92
4096 41404110 4120 4130(4096) 
---------------------------------------------hGSTM1 (1162) 
---------------------------------------------hGSTM2 (1167) 
TTTGCTGAGAGCTTTCCTTTTTCCCAATAAATTCTACTCTGCCCThGSTM3 (3894) 
---------------------------------------------hGSTM4 (1437) 
---------------------------------------------hGSTM5 (1568) 
 Section 93
4141 4150(4141) 
----------hGSTM1 (1162) 
----------hGSTM2 (1167) 
ACTCACTCTChGSTM3 (3939) 
----------hGSTM4 (1437) 
----------hGSTM5 (1568) 
